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 Intakes of the highly unsaturated fatty acids (HUFA, ≥20 Carbons, ≥3 double bonds) 
eicosapentaenoic acid (20:5n-3; EPA) and docosahexaenoic acid (22:6n-3, DHA) greater than 
0.25 g/d are currently recommended for health benefits.  Targets for omega-3 blood biomarkers 
have also been proposed based on associations with protection against coronary heart disease 
mortality.  The relationship between diet intakes and blood biomarkers is not well defined, 
particularly differences between men and women.  North American intakes and blood 
biomarkers of EPA and DHA are typically below recommendations and targets.  To address this 
disparity, adherence to dietary advice strategies to increase EPA + DHA intake was investigated 
over one year.  Adherence was sustained up to 12 weeks and long-term adherence was well 
characterized by the % of DHA in erythrocytes.  For women, n-3 HUFA blood biomarkers 
increased following nutraceutical or combined strategy dietary advice but not seafood or 
functional food advice.  To assist in the assessment of EPA + DHA intakes, food sources of EPA 
and DHA in Canada were incorporated into a semi-quantitative, nutrient-specific food frequency 
questionnaire (FFQ) and validated.  The FFQ is an adequate tool for estimating habitual EPA and 
DHA intake and ranking Canadian adults by their intakes.  The blood biomarker response to 
recommended intakes of 0.25, 0.5 and 1 g/d EPA + DHA was also characterized in adult men 
and women.  Blood n-3 HUFA biomarkers increased in a dose-dependent manner and aligned 
with blood targets associated with primary cardiac arrest risk reduction.  Sex differences in the 
DHA:EPA ratio in blood observed with low intakes at baseline disappeared following 0.25 g/d 
EPA + DHA.  These findings are applicable towards informing achievable dietary guidelines for 
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 The n-3 highly unsaturated fatty acids (HUFA; ≥20 carbons, ≥3 double bonds) 
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), prevalent in 
marine-based dietary sources are associated with cardio-protection.  The effects of EPA and 
DHA on secondary cardiovascular disease prevention were first examined in the Diet and 
Reinfarction Trial where advice to consume EPA and DHA from two servings of oily fish per 
week resulted in a 29% reduction in all-cause mortality in patients with a history of myocardial 
infarction (Burr et al., 1989).  The beneficial effects were further confirmed in a larger secondary 
prevention trial where fish oil supplementation at 0.85 g/d EPA + DHA was found to reduce the 
risk of sudden cardiac death by 45% in recent myocardial infarction patients (GISSI-Prevenzione 
Investigators, 1999).   
 Reduction in cardiovascular endpoints with EPA and DHA has not been replicated in 
recent trials.  The Alpha-Omega (Kromhout, Giltay, and Geleijnse, 2010), Omega (Rauch et al., 
2010) and SU.FOL.OM3 (Galan et al., 2010) trials did not demonstrate reduction in secondary 
coronary heart disease mortality following EPA + DHA doses between 0.38 and 0.85 g/d.  
Extensive use of antithrombotic, antihypertensive and statin drugs and low statistical power may 
contribute the lack of effect observed in these recent trials (Hu and Manson, 2012; Kromhout et 
al., 2012; Mozaffarian and Wu, 2011).  Background fish intake increased during the Omega trial; 
approximately 45% of control and intervention participants reported consuming fish several 
times per week (Rauch et al., 2010).  There is limited ability to discern the protective effects of 
EPA and DHA when the control group is already consuming substantial doses of n-3 HUFA 
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(Yokoyama et al., 2007).  Adherence to study protocols in long-term, large-scale trials, such as 
maintaining background diets is challenging for participants to sustain and researchers to assess.  
Intention to treat analyses were performed in the Alpha-Omega, Omega and SU.FOL.OM3 trials, 
however relating clinical outcomes to blood levels of n-3 HUFA could have better represented 
the actual relationship between EPA and DHA status and cardiovascular risk reduction.  
 In spite of recent trials, general consensus is that EPA and DHA can reduce the risk of 
coronary heart disease mortality in populations with and without established coronary heart 
disease (He et al., 2004; Leon et al., 2008; Marik and Varon, 2009; Mozaffarian and Rimm, 
2006; Musa-Veloso et al., 2011; Wang et al., 2006).  Current intake recommendations for adults 
range from 0.25 to 4g/d with guidelines <1g/d aimed at healthy individuals and those ≥1g/d 
advised for secondary cardiovascular disease prevention and triacylglycerol lowering (Food and 
Agriculture Organization of the United Nations and World Health Organization, 2008; 
International Society for the Study of Fatty Acids and Lipids, 2004; Kris-Etherton, Harris, and 
Appel, 2003; Kris-Etherton et al., 2007; United States Department of Agriculture, 2010). A 
distinct dietary reference intake recommendation for EPA and DHA does not exist.  Instead, a 
proportion of the dietary reference intake values for alpha-linolenic acid, which are based on 
median population-level intake, can be consumed as EPA and DHA (Institute of Medicine of the 
National Academies, 2005).   
 Re-evaluation of dietary reference intakes for EPA and DHA intake based on chronic 
disease endpoints has been proposed (Harris et al., 2009; Kris-Etherton, Grieger, and Etherton, 
2009).  While risk of primary cardiac arrest in relation to quartiles of blood n-3 HUFA status has 
been evaluated (Siscovick et al., 1995), the relationship between dietary intake of EPA and DHA 
and cardio-protection is often indirectly calculated (Mozaffarian and Rimm, 2006).  Some 
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studies included in such computations collected insufficient intake data to accurately determine 
EPA and DHA consumption (Musa-Veloso et al., 2011; Osler, Andreasen, and Hoidrup, 2003).  
Establishing a relationship between dietary intake and blood levels of EPA and DHA which 
could in turn be related to cardiovascular disease risk, would facilitate establishing a dietary 
reference intake value based on cardiovascular disease as an endpoint.  Dietary reference intake 
derivation for EPA and DHA has important financial and food policy implications related to 
dietary guidelines, food labeling, fortification and feeding programs.  Furthermore, blood dose-
response data for EPA and DHA are needed to better evaluate observational and clinical trials 
used to inform regulatory decisions, including product labelling and nutritional claims 
(Brownawell et al., 2009). 
 In contrast with current intake recommendations, median North American population-
level intakes of EPA and DHA of 0.11g/d by women and 0.16g/d by men fall below existing 
guidelines (Institute of Medicine of the National Academies, 2005).  As seafood provides 
appreciable amounts of EPA and DHA, it has traditionally been recommended as a whole food 
dietary source.  Several health organizations, such as Dietitians of Canada, provide specific 
dietary advice suggesting the number of servings of fish to be consumed per week to meet EPA 
and DHA recommendations for healthy individuals (Kris-Etherton et al., 2007; United States 
Department of Agriculture, 2010) but acknowledge that achieving recommendations may not be 
sustainable through whole food sources alone (Kris-Etherton, Harris, and Appel, 2003).  Novel 
functional food and nutraceutical sources provide additional options for consumers.  Functional 
foods are food-based products enriched with EPA and DHA, such as omega-3 eggs, and 
nutraceuticals consist of isolated EPA and DHA sold in medicinal form, such as fish oil capsules.  
If recommendations to consume EPA and DHA are to be issued, the practical feasibility of 
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meeting EPA and DHA intake recommendations from the diverse dietary sources requires 
consideration.   
 The ability to accurately measure EPA and DHA intake is imperative for research and 
dietary counselling purposes; these measurements are needed to develop and evaluate the impact 
of dietary guidelines, assess diet-disease relationships and screen individuals for appropriate 
targeting of dietary advice.  Specific challenges are associated with measurement of usual EPA 
and DHA intakes as these fatty acids are concentrated in sources not typically consumed daily in 
North America.  Furthermore, the prevalence of EPA and DHA in novel functional food and 
nutraceutical products presents new considerations for traditional dietary assessment strategies.  
It has been observed that dietary intake of EPA and DHA estimated by 3-d dietary record does 
not always agree with biomarker-based assessment of EPA and DHA status (Fratesi et al., 2009).  
A FFQ may provide an alternative strategy to measure intake of EPA and DHA as this type of 
survey is aimed at measuring habitual dietary intake (Gibson, 2005).   
 Biomarkers are a potential objective tool to evaluate EPA and DHA intakes.  Blood 
levels of EPA and DHA are observed to respond to dietary intake and the response is 
characterized by a logarithmic relationship (Bjerve et al., 1993; Kobayashi et al., 2001; Vidgren 
et al., 1997).  Measurement of blood fatty acid composition to assess omega-3 status has become 
increasingly feasible by recent methodological advances, but also by the breadth of information a 
complete fatty acid profile provides.  Specifically, the combination of minimally invasive finger-
tip prick blood samples (Armstrong, Metherel, and Stark, 2008; Marangoni, Colombo, and Galli, 
2004) with rapid chemical preparation through direct transesterification (Armstrong, Metherel, 
and Stark, 2008) followed by fast gas chromatography result in cost efficient high throughput 
analyses (Stark and Salem, Jr., 2005).   
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 The present thesis examines the relationship between the dietary intake of EPA and DHA 
and resulting blood levels.  Specifically, adherence to dietary advice strategies based on seafood 
intake, nutraceuticals and/or functional foods were examined with dietary assessment tools and 
omega-3 blood biomarkers.  The omega-3 blood biomarker responses to tightly controlled 
dietary intakes of 0.25, 0.5 and 1 g/d of EPA plus DHA were also examined.  A novel FFQ for 
the determination of EPA and DHA intakes was also developed and validated to assist in dietary 







Fatty Acids and Simple Lipids 
 Fatty acids play many important biological roles as energy-yielding substrates, structural 
membrane components, elements in cell signalling pathways and building blocks for lipid and 
lipid-derived compounds (Calder and Burdge, 2004).  Structurally, fatty acids consist of a 
hydrophobic carbon chain with a methyl group at one end and a hydrophilic carboxyl group at 
the opposite end.  Variation on this general structure leads to distinct fatty acids classes.  Fatty 
acids with single bonds between each of the carbon atoms of the chain belong to the saturated 
family while those with one or multiple double bonds within the carbon chain belong to the 
monounsaturated and polyunsaturated families, respectively.  To illustrate, the polyunsaturated 
fatty acid, docosahexaenoic acid (DHA; 22:6n-3) consists of a 22-carbon fatty acid chain with 
six methylene interrupted, cis-double bonds.  The first double bond is located at the third carbon 
from the methyl or “omega” carbon and accordingly, DHA is referred to as an omega-3 (n-3) 
polyunsaturated fatty acid.  Polyunsaturated fatty acids such as DHA with ≥20 carbons and ≥3 
double-bonds can be further sub-classified as highly unsaturated fatty acids (HUFA).  HUFA, 
such as DHA and eicosapentaenoic acid (EPA; 20:5n-3), have distinctive structural and 
signalling functions in pathways related to health and disease (Lands, 2005).     
 Fatty acids may be found in free, unesterified form or bound in lipid complexes.  Various 
classes of lipid complexes exist including triacylglycerols, glycerophospholipids (phospholipids) 
and cholesteryl esters.  The fatty acid composition of these lipids is influenced by dietary intake 
and the specificity of acyltransferases and transacylases involved in the initial synthesis or 
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subsequent remodelling in various tissues (Yamashita, Sugiura, and Waku, 1997; Yeo and 
Holub, 1990).  Fatty acid composition varies between classes of lipids and accordingly has a 
relationship to function (Christie, 2003).  The triacylglycerol class consists of three fatty acids 
bound to a glycerol molecule.  These simple lipids are the primary storage form of fatty acids in 
adipose tissue and the predominant form of dietary fat (Frayn, 2010).  Triacylglycerols of 
terrestrial animal origin are mainly composed of C16 and C18 fatty acids while those of marine 
origin also contain amounts of C20 and C22 fatty acids (Christie, 2003).  Consequently, the 
predominant dietary fatty acids in human triacylglycerols are 16:0, 18:0, 18:1n-9 and 18:2n-6.   
 Phospholipids are structurally distinct from triacylglycerols with a phosphate and polar 
head group, such as choline, serine, ethanolamine or inositol, in place of one of the fatty acids on 
the glycerol backbone (Ratnayake and Galli, 2009).  Functionally, these amphipathic 
phospholipids form the lipid bilayer of cell membranes, such as erythrocytes and cardiac 
myocytes.  The various phospholipids have characteristic fatty acid compositions but typically 
consist of a saturated fatty acid at the first position (sn-1), an unsaturated fatty acid at the second 
position (sn-2) and the polar head group at the third position (sn-3).  HUFA are commonly 
selectively incorporated into the sn-2 position of phospholipids by acyl transferases and are 
therefore typically low in triacylglycerols.  The localization of HUFA in the sn-2 position of 
phospholipids influences membrane fluidity, but also makes HUFA readily available for cellular 
functions through specific phospholipases, such as serving as substrates for the production of 
lipid mediators such as eicosanoids and docosanoids.  Conversely, the predominance of saturated 
fatty acids, with no double bonds and straight carbon chains in triacylglycerol structures allows 
for tighter packing in adipose tissue storage depots.   
8 
 
 Fatty acids can also be esterified to cholesterol in the liver for transport in the plasma or 
storage (Christie, 2003).  In the plasma, lecithin cholesterol acyltransferase catalyzes fatty acid 
esterification of cholesterol from the sn-2 position of the phospholipid phosphatidylcholine.  The 
substrate preference of this acyltransferase and the fatty acid composition of phosphatidylcholine 
can also dictate the fatty acid composition of cholesteryl esters, with linoleic acid (18:2n-6) 
being preferentially incorporated (Holub, Bakker, and Skeaff, 1987). 
 
Fat Digestion and Absorption 
 Following emulsification through the churning action of the stomach, dietary lipids are 
predominantly digested in the small intestine through the action of lipases.  These enzymatic 
cleavage products then diffuse into the intestinal enterocytes where they are re-assembled and 
packaged into chylomicrons.  The more non-polar triacylglycerols and cholesterol esters form 
the chylomicron core and are surrounded by apo-proteins and the more polar phospholipids and 
cholesterol molecules (Ratnayake and Galli, 2009).  Chylomicrons are then transported through 
the lymphatic system, bypassing the liver, and enter the bloodstream at the thoracic duct.  The 
chylomicrons travelling in the plasma are then directed to various tissues, such as skeletal muscle 
or adipose tissue.  In the capillaries of these tissues, lipoprotein lipase cleaves fatty acids from 
the glycerol backbone of triacylglycerols and these components enter the cell for immediate use, 
for instance as energy-yielding substrates (Ratnayake and Galli, 2009).  The chylomicron particle 
shrinks as triacylglycerols are removed and some of the phospholipids, cholesterol and proteins 
comprising the outer coat dissociate and are scavenged by other particles such as high density 
lipoprotein (Frayn, 2010).  The chylomicron remnants and any free fatty acids not taken up by 
the tissues are bound to albumin and transported to the liver.  The liver then repackages the 
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remnant components along with endogenous lipids into lipoprotein particles which are released 
back into circulation to supply tissues (Gropper, Smith, and Groff, 2009).   
 In the post-prandial period, plasma fatty acid composition is therefore largely influenced 
by the circulating chylomicrons.  Triacylglycerols account for approximately 85% of the total 
lipids by weight in chylomicrons and chylomicron fatty acid composition reflects the diet 
(Christie, 2003).  Upon clearance of chylomicrons from the plasma, the fatty acid composition of 
plasma increasingly reflects the supply of fatty acids from endogenous synthesis or adipose 
tissue release.  Indeed, in the immediate post-prandial period, measurements of plasma total, 
triacylglycerol and cholesteryl ester fatty acids reflect recent dietary intake while measurements 
of phospholipid-rich blood fractions, including erythrocytes and plasma phospholipids, remain 
unaffected by a recent meal (Burdge, Powell, and Calder, 2006; Polozova and Salem, Jr., 2007; 
Sadou et al., 1995).  The n-3 HUFA are predominantly incorporated into phospholipids and in 
the time immediately following a meal containing n-3 HUFA, corresponding blood 
measurements of these fatty acids are not altered (Metherel et al., 2012).   
 
Endogenous n-3 HUFA Synthesis 
 In addition to structural classification, fatty acids can also be categorized by origin.  
Essential fatty acids cannot be synthesized endogenously by humans to meet physiological need 
and therefore must be obtained through the diet.  Conversely, non-essential fatty acids can be 
synthesized from an essential fatty acid precursor.  Within the family of n-3 polyunsaturated 
fatty acids, α-linolenic acid (18:3n-3) serves as the parent essential fatty acid for synthesis of n-3 
HUFA.  Specifically, the n-3 HUFA are synthesized from α-linolenic acid in the liver in limited 
amounts through a pathway which involves repeated steps of fatty acid chain desaturation and 
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elongation with a final step of peroxisomal β-oxidation (Sprecher et al., 1995; Su et al., 2001).  
The n-3 HUFA can be considered conditionally essential fatty acids as there are certain 
conditions, such as an absence of dietary precursor, which would make dietary inclusion of n-3 
HUFA essential (Cunnane, 2003).  The n-3 HUFA may also be essential metabolites in pathways 
related to health and disease.  Endogenous synthesis is sufficient to prevent overt n-3 HUFA 
deficiency in the absence of dietary intake.  However, overall conversion of α-linolenic acid to n-
3 HUFA is low with conversion to EPA and n-3 docosapentaenoic acid (22:5n-3) exceeding 
conversion to DHA.  Conversion to DHA is particularly limited as delta 6 desaturase is required 
for the insertion of the 6
th
 carbon-carbon double bond, but linoleic acid and α-linolenic acid are 
also competing delta 6 desaturase substrates (Kitson, Stroud, and Stark, 2010).  A kinetic stable 
isotope study determined that 0.2%, 0.13% and 0.05% of plasma α-linolenic acid is converted to 
EPA, n-3 docosapentaenoic acid and DHA respectively in individuals consuming a beef-based 
diet (Pawlosky et al., 2003b).  At very low intakes of EPA and DHA (0.06 g/d), the rate of 
conversion of n-3 docosapentaenoic acid to DHA is higher in women than men however, when 
the diet includes moderate intakes of EPA and DHA (0.5 g/d), these sex differences in 
endogenous synthesis are not observed (Pawlosky et al., 2003a; Pawlosky et al., 2003b). 
 
n-3 HUFA Biomarkers  
 Levels of n-3 HUFA in the body reflect both endogenous synthesis and dietary intake; 
synthesis makes an important contribution at very low n-3 HUFA intakes while diet becomes a 
greater determinant as n-3 HUFA intakes increase.  Measurement of n-3 HUFA status can be 
determined by collecting a tissue or blood sample and determining the fatty acid composition.  
Blood is often selected as a marker of fatty acid status as it is minimally invasive to collect and 
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can reflect tissue status (Stark, 2008b).  The blood dose-response curves for EPA and DHA in 
response to dietary intake demonstrate a logarithmic relationship; blood levels rise with intake 
before reaching a plateau as saturation occurs (Vidgren et al., 1997).  This curve does not begin 
at a zero value due to background endogenous HUFA synthesis.  Various blood fractions, 
including whole blood, erythrocytes, plasma and serum, have all been employed as markers of 
fatty acid status.  These pools can be further subdivided into the various lipid classes including 
phospholipids, triacylglycerols, cholesteryl esters and non-esterified fatty acids.  Additional 
analytical steps can be performed to further examine these specific lipid classes, for example 
specific phospholipids including phosphatidyl choline, ethanolamine, serine and inositol can be 
isolated.  Selection of a blood fraction for fatty acid analysis is influenced by the unique 
information it provides and analytical and other practical considerations.  
 The incorporation of fatty acids into erythrocytes reflects the cell lifespan, remodelling 
during the cell lifespan, and partitioning of particular fatty acids into specific classes of 
phospholipids within the inner and outer cell membrane. Erythrocytes have generally been 
regarded as the preferred blood marker of n-3 HUFA intake over the preceding months, 
reflecting the cell lifespan of roughly 120 days (Ebaugh, Jr., Emerson, and Ross, 1953).  
However, erythrocyte fatty acid composition will also respond to dietary change within days as 
the outer bilayer of erythrocyte membranes is in direct contact with the plasma for fatty acid 
exchange (Skeaff, Hodson, and McKenzie, 2006).   On a gram-per gram basis of dietary intake, 
EPA and DHA incorporate by the same magnitude into erythrocytes however; the rate of DHA 
incorporation and washout is slower (Katan et al., 1997).  Various transport mechanisms result in 
an asymmetric distribution of phospholipid classes across the erythrocyte membrane; 
phosphatidyl choline largely remains in the outer membrane and phosphatidyl ethanolamine and 
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serine are predominantly moved to the inner membrane (Connor et al., 1992; Seigneuret and 
Devaux, 1984).  DHA preferentially accumulates in phosphatidyl ethanolamine over 
phosphatidyl choline (Lemaitre-Delaunay et al., 1999).  As a result, DHA accumulates in the 
inner erythrocyte membrane which accounts for its slower response to dietary change relative to 
EPA.  In general, the erythrocyte phosphatidyl choline pool equilibrates to dietary change within 
weeks (Skeaff, Hodson, and McKenzie, 2006) while complete equilibration of the fatty acid 
composition of phospholipids on the interior erythrocyte membrane occurs within months, but 
specific times may depend on the dietary dose of n-3 HUFA (Von Schacky C., Fischer, and 
Weber, 1985).   
 Plasma and serum fatty acid composition is largely influenced by lipoproteins with fatty 
acids incorporated into triacylglycerols (49%), phospholipids, specifically phosphatidyl choline 
(24%), and cholesteryl esters (16%) (Christie, 1985).  As HUFA are most preferentially 
esterified into the sn-2 position of phospholipids, this pool is often selected to examine EPA and 
DHA.  Overall, the fatty acid composition of plasma responds to dietary change within days and 
reaches an equilibrium state within weeks (Metherel et al., 2009; Skeaff, Hodson, and McKenzie, 
2006).   
 Whole blood fatty acid composition has been examined to a greater extent in recent 
years.  Incorporating both plasma and erythrocytes, whole blood has been observed to respond to 
changes in dietary intake in a manner intermediate between these two pools (Metherel et al., 
2009).  Whole blood measurements of EPA and DHA have also been inversely associated with 
risk of sudden cardiac death (Albert et al., 2002).  A whole blood sample can easily be collected 
through finger-tip prick sampling.  This technique provides a measure of whole blood n-3 HUFA 
composition equivalent to samples collected by conventional venous puncture (Armstrong, 
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Metherel, and Stark, 2008) and reflects dietary fatty acid intake (Metherel et al., 2009).  Finger-
tip prick sampling does not require collection by a trained phlebotomist and eliminates the need 
for fatty acid extraction prior to preparation of fatty acids for gas chromatography analysis 
(Marangoni, Colombo, and Galli, 2004).  Consequently, this technique reduces the time and 
resources required for blood fatty acid determinations, and has the potential to enable screening 
of fatty acid profiles.     
 In addition to determining the individual fatty acid composition of various blood 
fractions, blood biomarkers incorporating multiple fatty acids can also be expressed.  For n-3 
HUFA, such composite measurements have been related to tissue status and disease risk.  The 
relative percentage of EPA + DHA in erythrocytes has been proposed as a risk factor for 
coronary heart disease mortality (Harris and Von Schacky, 2004) due to its' strong correlation 
with the EPA and DHA composition of cardiac tissue (Harris et al., 2004).  It has been suggested 
that ≥8% EPA + DHA in erythrocytes is associated with the greatest level of protection against 
coronary heart disease mortality while <4% is associated with the greatest risk (Harris and Von 
Schacky, 2004).  This range is an estimate based on measured and predicted erythrocyte % EPA 
+ DHA values associated with coronary heart disease mortality risk in several studies examining 
individuals with and without existing cardiovascular disease.  Only one case-control study has 
directly evaluated erythrocyte % EPA + DHA and cardiac outcomes (Siscovick et al., 1995).  
From this direct assessment, a 90% lower risk of primary cardiac arrest risk was observed at 
6.5% erythrocyte % EPA + DHA compared with 3.3%.  Further work is needed to clearly 
establish blood levels of EPA and DHA associated with cardio-protection, but blood biomarkers 
of n-3 HUFA status have the potential to serve as modifiable risk factors.   
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 The percentage of n-3 HUFA in total HUFA has also been examined as a marker of n-3 
HUFA status as it represents the competition between HUFA for incorporation into lipid 
structures, particularly esterification at the sn-2 position of phospholipids where HUFA are 
concentrated (Lands, 2008; Metherel et al., 2009; Stark, 2008b).  The % n-3 HUFA in total 
HUFA is consistent between various tissues and blood fractions when dietary intake and other 
metabolic factors are constant (Stark, 2008b).  As a result, the % n-3 HUFA in total HUFA can 
be determined for any available blood fraction, including whole blood, and does not require 
additional isolation of erythrocytes.  While a % n-3 HUFA in total HUFA of 20% is typical of 
North American populations, % n-3 HUFA in total HUFA of 40% is roughly equivalent to 8% 
EPA + DHA in erythrocytes (Armstrong, Metherel, and Stark, 2008; Lands, 2008).  Additional 
data is required to confirm the relationship between the % n-3 HUFA in total HUFA and 
erythrocyte % EPA + DHA biomarkers.  Further clinical validation is also necessary to verify the 
relationship of the % n-3 HUFA in total HUFA biomarker with disease risk and be considered as 
one of the many risk factors contributing to coronary heart disease risk.  The purpose of the % n-
3 HUFA in total HUFA biomarker is to model HUFA competition for phospholipid 
incorporation, not to stress a reduction in the dietary n-6:n-3 ratio.  Both the n-3 and n-6 series 
HUFA are implicated in pathways associated with reducing disease risk, such as resolution of 
inflammation (Serhan, 2010).  
 Biological and analytical variability are both important considerations when examining 
blood fatty acid status.  The analytical coefficient of variation has been observed to be <4% for 
the EPA and DHA content in total lipids of various blood fractions analyzed in quadruplicate 
from the blood of a single individual collected on a single occasion (Armstrong, Metherel, and 
Stark, 2008).  Isolation of phospholipid classes introduces some additional analytical variability 
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with coefficients of variation <10%.  The coefficient of variation from finger-tip prick samples 
collected from the same individual on one occasion is 1.5 - 6.4% for whole blood % EPA + DHA 
and 0.46 - 1.14 % for whole blood % n-3 HUFA in total HUFA (unpublished observations).   
 
Intakes of n-3 HUFA and Current Recommendations 
 Recommendations for n-3 HUFA intakes have been made by several North American and 
global groups.  While no formal recommendation for n-3 HUFA intakes has been made within 
the Dietary Reference Intakes, up to 10% of the Acceptable Macronutrient Distribution Range 
for 18:3n-3 may be consumed as EPA and DHA (Institute of Medicine of the National 
Academies, 2005).  This results in an Acceptable Macronutrient Distribution Range of 0.06-
0.12% of energy for EPA + DHA, with the lower bound reflecting median North American 
population-level intakes and the upper bound representing the highest intakes from foods 
consumed by the population.  Accordingly, for a healthy female between the ages of 19 and 70, 
consuming a typical North American diet of approximately 1800 kcal/d (Institute of Medicine of 
the National Academies, 2005), the Acceptable Macronutrient Distribution Range would be 
0.120 - 0.240g/d EPA + DHA and the male counterpart consuming roughly 2500 kcal/d would 
be 0.167 - 0.333 g/d.  These ranges reflect the upper ~50% of the distribution of usual intakes by 
North Americans.   
 Current North American and global recommendations for EPA and DHA intakes by 
healthy individuals are generally between 0.25 and 0.5g/d (Kris-Etherton et al., 2007; United 
States Department of Agriculture, 2010).  These recommendations are based on evidence from 
prospective studies and randomized trials which taken together, suggest that an EPA + DHA 
intake between 0.25 and 0.5 g/d lowers relative risk of coronary heart disease death and sudden 
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death compared with little or no intake (Mozaffarian and Rimm, 2006).  In addition, this intake 
goal could theoretically be achieved using whole food strategies through two, 4 oz servings of 
oily fish per week.  For secondary coronary heart disease prevention, 1 g/d of EPA and DHA is 
recommended by the American Heart Association and 2-4 g/d are recommended for 
triacylglycerol lowering (Kris-Etherton, Harris, and Appel, 2003; Lichtenstein et al., 2006).  
These recommendations are based on observations that EPA and DHA act through several 
cardio-protective mechanisms in a heterogeneous manner with the anti-arrhythmic effect 
levelling at intakes of 0.75 to 1g/d while the triacylglycerol-lowering effect continues linearly at 
intakes above 2 g/d (Mozaffarian and Rimm, 2006).  The distinct pathophysiologies of primary 
and secondary coronary heart disease likely account for the need for higher doses of EPA and 
DHA in secondary prevention.  The acceptable macronutrient distribution range for EPA + DHA 
provided by the World Health Organization is 0.25-2 g/d, emphasizing more consistent benefits 
with dosages between 1 and 2 g/d, particularly for secondary disease prevention (Elmadfa and 
Kornsteiner, 2009).  North American and global recommendations for EPA and DHA intakes are 
summarized in Table 2.1.   
 In formulating the Dietary Reference Intakes, the Institute of Medicine concluded that 
there was insufficient evidence to establish a Tolerable Upper Level of Intake for EPA and DHA 
based on adverse effects related to immune function, bleeding times, risk of hemorrhagic stroke 
and oxidative damage (Institute of Medicine of the National Academies, 2005).  Health Canada 
limits EPA and DHA intake from fish oil supplementation to 3 g/d (Health Canada, 2009) based 
on a report from the United States Food and Drug Administration which found insufficient 
evidence to determine the effect of EPA and DHA supplementation above this level on glycemic 
control in non-insulin dependent diabetes, bleeding times and circulating levels of low density 
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lipoprotein (Food and Drug Administration, 1997).  A Maximum Level for EPA and DHA has 
also been set at 3 g/d by the World Health Organization based on observations of reduced 
cytokine production and increased lipid peroxidation at high intakes of EPA and DHA from 
dietary supplements (Elmadfa and Kornsteiner, 2009).  Based on recent evidence showing that 
high blood n-3 HUFA status or n-3 fatty acid supplementation is not associated with serious 
bleeding in coronary heart disease patients or perioperative blood loss, bleeding concerns may 
warrant re-evaluation (Meredith et al., 2012; Salisbury et al., 2012; Watson et al., 2009). 
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Sources of n-3 HUFA in the Food Supply 
 In order to meet dietary recommendations, EPA and DHA can be obtained through whole 
foods, functional foods and nutraceutical sources (Patterson and Stark, 2008).  Whole food 
sources are those which inherently contain EPA and DHA.  Traditionally, seafood particularly 
fish, is the primary whole food dietary source of EPA and DHA (Gebauer et al., 2006; National 
Cancer Institute, 2009).  Oily fish such as sardines, mackerel and salmon provide up to several 
grams of EPA and DHA per serving, while shellfish, such as shrimp, and lean fish, such as 
tilapia, cod and haddock, supply less than one gram of EPA and DHA per serving.  Limited 
amounts of EPA and DHA occur naturally in other whole foods such as poultry and eggs.  These 
non-marine foods become important sources of EPA and DHA for individuals who do not 
consume seafood (Welch et al., 2010).  Whole food sources of n-3 HUFA are predominantly 
animal-derived (Novak and Innis, 2012; Stark and Patterson, 2012), with the exception of 
marine-based plants like seaweed and algae, and supply these fatty acids in triacylglycerol and 
phospholipid form.  Two, 4oz servings of fish per week are recommended to achieve current 
EPA and DHA intake recommendations for healthy adults (Kris-Etherton, Harris, and Appel, 
2003; Kris-Etherton et al., 2007; Lichtenstein et al., 2006; United States Department of 
Agriculture, 2010) and at this level of intake, the benefits of consuming a variety of fish 
outweigh the risks associated with environmental contaminants such as methylmercury 
(Mozaffarian and Rimm, 2006).  Adults with high fish intakes (≥5 servings/week) and pregnant 
and breast feeding women should limit intake of specific species with higher levels of 
methylmercury, such as swordfish (Health Canada, 2008).   
 Novel nutrient sources provide alternatives to the traditional whole food sources.  
Nutraceuticals provide EPA and DHA typically derived from fish or algal oils in pharmaceutical 
form.  A recent survey of nutraceutical products available in the Canadian retail market found 
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that 80% of products were in capsule, 17% in liquid and 3% in soft-chew form (Chalil, Patterson, 
and Stark, 2011).  Nutraceutical products supply EPA and DHA in varying concentrations.  In 
general, preparations of polyunsaturated fatty acid blends and products for children supply the 
lowest amount of EPA and DHA per serving, followed by fish body oils composed of 18% EPA 
and 12% DHA and concentrated oil preparations composed of 30-40% EPA and 20% DHA.  
Designer preparations supplying a higher concentration of either EPA or DHA, products derived 
from microalgae suitable for vegetarian and vegan consumers, and concentrated prescription 
products are also available.  EPA and DHA in concentrated products are typically in ethyl ester 
or re-esterified triacylglycerol form.  Evidence examining equal bioavailability of EPA and DHA 
in different chemical forms is mixed with some reports of greater blood biomarker response to n-
3 HUFA in triacylgylcerol form as compared with ethyl esters (Dyerberg et al., 2010; 
Neubronner et al., 2010) and others reports showing no difference (Harris et al., 2007; Krokan, 
Bjerve, and Mork, 1993; Nordoy et al., 1991).  Blood biomarker response to n-3 HUFA in 
triacylglycerol and ethyl ester form may be similar in blood fractions less responsive to recent 
dietary intake, like plasma phospholipids, as compared with blood fractions sensitive to recent 
dietary intake, like cholesterol esters (Hansen et al., 1993).  Levels of organic pollutants, like 
polychlorinated biphenyls, are typically lowest in Canadian nutraceutical products derived from 
lower rungs of the marine food chain, such as anchovy, mackerel and sardine oils, compared 
with those derived from larger fish, such as shark, seal and menhaden, and farmed fish such as 
salmon which may bio-accumulate pollutants (Rawn et al., 2009b; Rawn et al., 2009a).   
 Functional foods are foods or beverages which contain EPA and/or DHA through either 
direct addition or manipulation of production conditions.  For example, the DHA content of 
cow's milk can be increased by supplying feed material, such as fish meal, that contains 
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preformed DHA.  Microencapsulated oils, including those derived from algal and fish body oil 
sources, can be directly added to various food vehicles to enhance the EPA and DHA content.   
Although the functional foods available to consumers changes over time, Canadian products 
enriched with EPA and DHA have included cow's/soy milk, yogurt, cheese, margarine, eggs, 
peanut butter, bread, pork and juice.   
 Various studies comparing blood levels of EPA and DHA following supplementation 
from fish, nutraceutical or functional food sources suggest equal bioavailability from the various 
food matrices (Arterburn et al., 2007; Arterburn et al., 2008; Harris et al., 2007; Wallace et al., 
2000).  Conventionally, dietetic practice emphasizes food-based approaches to achieve 
nutritional guidelines.  Fish intake advice, for example, can also provide intake of a variety of 
important nutrients in addition to EPA and DHA including protein, vitamins A, B3, B6, B12, E 
and D and minerals including iron, calcium, selenium and zinc.  It has been acknowledged, 
however, that meeting EPA + DHA intake recommendations from a seafood-based whole food 
approach alone may not be feasible for many North Americans (Kris-Etherton, Harris, and 
Appel, 2003) and that fish is not well tolerated by all individuals (Burr et al., 1989).  
Nutraceuticals and functional foods offer potential alternatives to address these challenges.  
Selection of food and nutritive products may also be related to sex.  Women attach greater 
importance to healthy eating when making food choices as compared with men (Wardle et al., 
2004).  In addition, nutraceuticals are used more frequently by women (Greger, 2001; Marques-
Vidal et al., 2009), although sex differences in nutraceutical and functional food use are typically 
product-specific (de Jong N. et al., 2003).   
 Traditional whole foods, functional foods and nutraceuticals can, in theory, be used as 
dietary strategies to increase the EPA and DHA content of a typical Canadian diet to meet 
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recommendations for healthy individuals (Patterson and Stark, 2008).  Providing consumers with 
functional foods alone, or in combination with fish for ≤1 month can significantly increase intake 
and blood levels of EPA and DHA (Lovegrove et al., 1997; Mantzioris et al., 2000; Metcalf et 
al., 2003).  An increase in EPA and DHA intake measurements has also been observed when 
functional foods were provided for six months, but biomarkers of adherence were not assessed in 
this long term investigation (Patch et al., 2005).  Dietary advice to consume oily fish has also 
been observed to result in long term increases in measures of EPA and DHA intake and blood 
status in male, post-myocardial infarction patients, but nutraceuticals were also provided to this 
portion of the study population due to an inability to tolerate fish (Burr et al., 1989).   Through 
diet history interview assessment, adherence up to three months following dietary advice to 
increase intake of oily fish has been observed as part of a one-year trial (Neale et al., 2012).  
   
Measuring Dietary n-3 HUFA Intake  
 Dietary survey methods can be used to estimate intakes of EPA and DHA.  Quantitative 
methods, such as dietary records, measure the quantity of all foods consumed over one day and 
the number of measurement days is increased to better approximate usual intake (Gibson, 2005).  
Selection of the number of days is typically based on the day-to-day intake variability for the 
nutrient of interest and the financial and time-related burden of multiple days of recording for 
both the recorder and analyst.  Semi-quantitative methods, such as food frequency questionnaires 
(FFQ), consist of a list of pre-selected food items and require respondents to indicate the usual 
portion size and how frequently these items are consumed.  Respondents are asked to estimate 
habitual intake over a given period of time.  These questionnaires can either assess total dietary 
intake by querying the most commonly consumed foods by the population or a specific nutrient 
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by including only items which supply appreciable amounts of a nutrient of interest.  Due to its' 
brevity, the nutrient-specific FFQ typically provides a more expedient estimate of intake but does 
not permit examination of the selected nutrient in the context of other nutrients or total energy 
(Cade et al., 2002).  Overall, the food frequency questionnaire provides a faster estimate of 
habitual intakes than the multiple day dietary record but restricts measurement of nutrient intake 
to the foods included on the questionnaire.  In selecting an appropriate assessment method, 
considerations of precision and accuracy, recording and analysis time in addition to how well the 
methodological and statistical limitations have been characterized must be weighed (Cade et al., 
2002). 
 The FFQ requires the user to respond to pre-determined dietary intake questions and 
therefore, considerable attention is placed on developing and validating the FFQ.  A FFQ may be 
created by modifying an existing questionnaire or by using basic principles to develop a 
questionnaire de novo, with the latter option typically requiring a more extensive investment of 
resources (Subar, 2004).  Considerations include selecting the food list, portion sizes and 
frequency categories which reflect the intakes of the desired nutrient(s) by the population of 
interest.  Recent dietary surveys describing the population of interest may assist in this process 
(Cade et al., 2002).  A nutrient database must also be chosen or developed to reflect the food list.  
Before the FFQ can be employed, it should be validated against a reference method which can 
include another type of dietary survey or a biological measurement of nutrient intake.  The 
validation study typically includes correlation calculations in addition to other statistical 
procedures, such as the Bland-Altman method which evaluates agreement across the range of 
nutrient intakes (Bland and Altman, 2010).  As no measurement of dietary intake is without 
error, validation studies provide an indication of whether the FFQ and reference method give 
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related answers.  These types of comparisons can help determine whether the FFQ is sufficiently 
rigorous to achieve its' goal; usually measurement of habitual intake of a nutrient(s) by a specific 
population.  
 FFQ validated for use among Canadian populations are available to assess EPA and DHA 
intake based on traditional marine (Lucas et al., 2009) or whole food (Lien and Clandinin, 2009) 
sources alone.  A more comprehensive, nutrient-specific questionnaire incorporating the range of 
Australian conventional and novel dietary sources of n-3 HUFA has been developed.  This 
questionnaire was found to be a valid tool to assess usual n-3 HUFA intakes by Australians when 
compared with measurements from 3-d dietary records and blood fatty acid composition 
(Sullivan, Williams, and Meyer, 2006; Sullivan et al., 2008; Swierk et al., 2011).  This 
questionnaire has formed the basis for similar FFQ in other countries, including a Belgian 
adaptation used to survey EPA and DHA intakes and dietary sources by Flemish women of 
reproductive age (Sioen et al., 2010).   
 Misreport of intake is a potential source of error in dietary assessment and can result from 
both failure to record what was actually consumed or alterations in usual eating patterns in 
response to the recording process (Gibson, 2005).  Both over and under reporting of intake can 
occur.  Energy intake, an important variable as energy and nutrient intakes are mutually 
dependent, is typically under-reported when compared to estimates of energy expenditure of 
weight-stable individuals (Livingstone and Black, 2003).  Multiple and potentially interacting 
variables may influence energy misreport including biological characteristics such as sex and 
body mass index and attitudes towards food such as social desirability (Hill and Davies, 2001).   
 The rigor of food nutrient composition databases is an important variable in the 
translation of food sources identified through dietary surveys into nutrient intakes.  The Canadian 
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Nutrient File has been developed to characterize the nutrient composition of whole foods in the 
Canadian food supply.  Such national databases provide good estimates but cannot fully capture 
the variability inherent to the food supply and additional factors such as diverse cooking methods 
(Kitson et al., 2008).  Functional foods and nutraceuticals are generally not included in national 
databases and require separate characterization before nutrient intakes from these products can 
be assessed.   
 Levels of EPA and DHA in biological tissues offer an alternative and objective strategy 
to measure EPA and DHA intake which does not rely on self-report.  Since endogenous 
production of EPA and DHA is low, dietary intake has a profound effect on circulating levels of 
EPA and DHA (Pawlosky et al., 2003b).  Indeed, levels of EPA and DHA in blood have been 
observed to respond to dietary intake (Bjerve et al., 1993; Kobayashi et al., 2001).  
Consequently, there is potential to relate specific levels of EPA and DHA in easily sampled 
tissues, like blood, to dietary doses of these fatty acids.  In order to relate blood fatty acid 
composition with dietary intake of EPA and DHA, the specific dose-response relationship must 
be characterized.  For healthy adults, blood levels corresponding to EPA + DHA doses under 
1g/d have been examined in plasma (Higgins et al., 2001) but examination of additional blood 
fractions is limited.  Biological determinants of blood fatty acid composition should also be 
considered.  Due to sex differences in endogenous synthesis, blood levels of DHA are higher in 
women than men when background dietary n-3 HUFA intake is low (Bakewell, Burdge, and 
Calder, 2006; Metherel et al., 2009) while supplementation at high doses of EPA and DHA 
(4.8g/d) removes sex differences in blood fatty acid measurements (Metherel et al., 2009).   
 Both dietary survey and biochemical markers provide complementary information and 
act as surrogate measures of true dietary intake.  Dietary surveys indicate what is actually 
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consumed in the diet but depend upon the quality of the dietary assessment tool, the recall and 
reporting of the respondent, and the quality of nutrient composition databases.  In contrast, 
biochemical markers provide objective assessments but their ability to predict nutrient intake 




Table 2.1. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) intake recommendations for adults
1
 
Target Recommending Body Recommendation 
<1g/d for healthy individuals  






 2 fish servings /wk 
 USDA Dietary Guidelines for Americans; 2010
5
 0.25 g/d EPA+DHA 
      Healthy adults Dietitians of Canada & American Dietetic Association; 2007
6
 0.5 g/d EPA+DHA 




0.5 g/d EPA+DHA 




 g/d EPA+DHA  
≥1g/d for 2° prevention  
Patients with coronary 
heart disease 




 1 g/d EPA+DHA 
Triglyceride lowering 2-4 g/d EPA+DHA 
1
 EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid
 
2 
(Kris-Etherton, Harris, and Appel, 2003), 
3
(Lichtenstein et al., 2006), 
4
(Lloyd-Jones et al., 2010), 
5
(United States Department of 
Agriculture, 2010), 
6
(Kris-Etherton et al., 2007), 
7











RATIONALE AND OBJECTIVES 
 
Rationale 
 Traditional whole foods, functional foods and nutraceuticals could be used as cost-
effective dietary strategies to increase the EPA and DHA content of a typical Canadian diet and 
bridge the gap between observed and recommended intakes for healthy individuals (Patterson 
and Stark, 2008).  While each of these omega-3 sources has been used to increase intakes and 
blood levels of these fatty acids, it is unknown whether the same results would be achieved if 
healthy consumers were required to select and purchase items independently, over the long term 
based on dietary advice.  Furthermore, as selection of nutrient sources can vary between men and 
women, it is unknown whether the effectiveness of different dietary advice strategies varies by 
sex.  Simultaneous evaluation of long-term adherence to seafood, functional food and 
nutraceutical strategies in a self-selected manner would assist health care professionals in 
formulating effective dietary advice strategies.   
 In order for health care professionals to rapidly evaluate the success of their dietary 
advice, tools which efficiently and accurately estimate usual dietary intake of EPA and DHA are 
needed.  New dietary surveys should have the scope to assess EPA and DHA intake from their 
specific, concentrated dietary sources and provide measurements which compare well against 
estimates from other dietary survey and biomarker-based tools.  An FFQ incorporating Canadian 
whole food, functional food and nutraceutical sources of EPA and DHA and validated for use 
among Canadians has the potential to address the challenges of estimating usual intake of these 
fatty acids.      
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 Blood n-3 HUFA status offers a complementary, objective strategy to evaluate dietary 
intake.  From the existing literature, it is difficult to determine specific blood levels of EPA and 
DHA which correspond to recommended intakes of EPA and DHA for healthy individuals across 
a variety of markers as doses >1g/d of EPA + DHA are typically examined and methods to 
measure blood fatty acids are highly variable and not standardized.  Comprehensive blood 
analyses in response to EPA and DHA intakes under 1g/d are needed and should include whole 
blood due to its increased utility in high throughput finger-tip prick blood fatty acid 
determinations.  Furthermore, examining men and women is necessary to determine if different 
intake recommendations for EPA and DHA are required for each sex to achieve cardio-
protective blood levels of EPA and DHA. 
 Presently, long term adherence to seafood, functional food and nutraceutical dietary 
advice strategies to increase intakes of EPA and DHA by male and female Canadian adults will 
be evaluated.  In addition, survey and blood-based assessment tools to efficiently measure EPA 
and DHA intakes will be characterized; the relative validity of a nutrient-specific, semi-
quantitative FFQ, incorporating the range of Canadian EPA and DHA sources, will be assessed 
and a comprehensive examination of the dose response to EPA and DHA intakes of 0.25, 0.5 and 
1.0g/d in men and women will be examined.  
 
Objectives  
1.  To develop and validate a nutrient-specific FFQ to determine EPA and DHA intakes by 
Canadian adults from Canadian whole food, functional food and nutraceutical sources.  
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2.  To examine blood levels and dietary intakes of EPA and DHA 4, 8, 12, 24 and 52 weeks after 
receiving dietary advice to increase EPA and DHA intakes using a seafood, functional food, 
nutraceutical or combined approach in men and women.  
3.  To examine the dose-response of 0.25, 0.5 and 1 g/d of supplemental EPA and DHA on 
corresponding blood fatty acid levels and biomarkers in whole blood, erythrocytes and plasma 
phospholipids in men and women.   
 
Hypotheses 
1.  Correlations between FFQ measurements of EPA and DHA intake and whole blood EPA and 
DHA levels will be stronger than correlations between 3-d dietary record measurements of EPA 
and DHA intake and whole blood EPA and DHA levels.   
2.  Dietary intakes and blood levels of EPA and DHA will increase compared with baseline 
following all of dietary advice strategies with women demonstrating greater adherence as 
compared with men. 
3.  The strategy providing combined dietary advice about whole foods, functional foods and 
nutraceuticals containing EPA and DHA will result in the greatest adherence over one year and 
the highest increase in dietary intake and blood levels of EPA and DHA.   
4.  Blood biomarker levels of EPA and DHA will increase in response to dietary supplementation 
with the highest dose of EPA and DHA, 1g/d, resulting in the highest blood levels, but the blood 
levels achieved will be below targets associated with protection from cardiovascular disease.  
5.  Women will have higher blood levels of DHA as compared with males at baseline and the 
increases in blood levels of DHA in response to supplementation will be higher in females 




GENERAL METHODS AND MATERIALS 
 
Participants 
 A total of 100 participants took part in the studies described herein.  None of the 
participants had existing cardiovascular disease or diabetes mellitus.  The University of Waterloo 
Human Ethics Committee approved all procedures and protocols associated with these studies 
and all participants provided informed written consent.  All participants completed a 3-d dietary 
record, FFQ, fasted finger-tip prick blood sample and health screening form and provided 
anthropometric measurements including weight and height at screening or baseline.    
 
Sample and Data Collection 
 All sample and data collection took place in the Laboratory of Nutritional and 
Nutraceutical Research or Manulife Wellness Centre at the University of Waterloo.  Participants 
fasted for 8-12 h overnight before all blood sampling.  Fasting finger-tip prick whole blood 
samples were collected by puncturing the skin with a disposable lancing device (Capiject; 
Terumo, Somerset, NJ or Unistik 2; Lifescan, Milpitas, CA) and absorbing blood onto a 1cm
2
 
area of chromatography paper (Whatman, Maidstone, England) pre-washed in 4:1 
chloroform:methanol. Venous blood  samples were collected by venipuncture into evacuated 10 
mL tubes (Vacutainer; Becton Dickinson, Franklin Lakes, NJ) with whole blood samples 
aliquoted for storage prior to plasma and erythrocyte separation by centrifugation at 2300 rpm 
for 15 minutes.  Subsequently, aliquots of recovered plasma were collected and stored.  
Erythrocytes were washed with saline, followed by centrifugation at 2300 rpm for 15 minutes, 
twice prior to aliquoting and storage.  All venous blood fraction samples were stored at -80°C 
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until analysis as 1-2 mL aliquots.  Storage of blood samples at -80°C promotes long-term 
stability of the HUFA pool (Metherel, 2012). 
 Written and verbal instructions were provided for dietary surveys including 3-day dietary 
records (two weekdays and one weekend day) and the FFQ.  Completed dietary surveys were 
checked by a single researcher for completeness and clarification.  Dietary surveys were 
analyzed using the Food Processor SQL Edition dietary
 
analysis software with the latest version 
available at the time of the study (ESHA Research, Salem, OR; version 10.6.0 and 10.9.0).  The 
dietary
 
analysis software was also updated manually with the Canadian Nutrient File 2007b 
database (Health Canada, 2007a) and fatty acid compositions determined directly by gas 
chromatography in the laboratory of select functional food and nutraceutical products identified 
on the FFQ and 3-d dietary records.   
 
Fatty Acid Composition Determinations 
 Fatty acid compositions were determined for venous blood fractions, finger-tip prick 
blood samples and nutraceuticals and functional foods identified on diet intake surveys and food 
duplicate collections.  Venous blood samples were prepared by traditional lipid extraction 
followed by transesterification methods.  A 22:3n-3 ethyl ester (10 ug/sample, NuCheck Prep, 
Elysian, MN) internal standard was added prior to lipid extraction to quantify fatty acids and to 
verify complete transesterification to fatty acid methyl esters.  A Folch based method (Folch, 
Lees, and Sloane Stanley, 1957) was used to extract lipids from whole blood and plasma (100 uL 
aliquots), using 3 mL chloroform:methanol (2:1 v/v) with 50 ug/mL butylated hydroxytoluene 
(Sigma-Aldrich, Bellefonte, PA) and subsequent addition of 500 uL sodium phosphate.  
Butylated hydroxytoluene was added to prevent lipid oxidation during analysis.  A double lipid 
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extraction was performed on erythrocytes (200 uL aliquots, weighed) using 2 mL 
chloroform:methanol (1:1 v/v) with 50 ug/mL butylated hydroxytoluene and subsequent addition 
of 1.8 mL sodium phosphate buffer (Bligh and Dyer, 1959), with steps to ensure erythrocyte cell 
membrane lysis (Reed et al., 1960).  Fatty acids in the lipid extracts were then transesterified to 
fatty acid methyl esters using 14% boron trifluoride in methanol (1 mL, Thermo Scientific, 
Bellefonte, PA) with hexane (300 uL) on a 90°C heat block for 1 h (Morrison and Smith, 1964).  
Finger-tip prick blood samples were prepared for analysis by direct transesterification.  
Chromatography paper, pre-washed in 4:1 chloroform:methanol and saturated with 1 cm
2
 blood, 
was placed into the 14% boron trifluoride in methanol with hexane on a 90°C heat block for 1 h 
without prior lipid extraction (Armstrong, Metherel, and Stark, 2008; Fratesi et al., 2009; 
Metherel et al., 2009).  The fatty acid composition of nutraceutical and functional food products, 
and food duplicate collections were determined in triplicate analyses in the presence of butylated 
hydroxytoluene (Sigma-Aldrich) and 22:3n-3 ethyl ester internal standard (NuCheck Prep).  Oils 
isolated from nutraceuticals (10 uL, weighed) were prepared for analysis by extraction followed 
by transesterification as described for whole blood and plasma above.  For functional foods and 
food duplicate collections, AOAC method 996.06 (Mossoba et al., 2003), with adjustment of 
solvent volumes for samples containing 6.25 - 12.5 mg of total fat  was modified with an initial 
acid hydrolysis treatment to ensure the extraction of lipids from microencapsulated fish oil 
powder (Stark, 2012).   Fatty acid methyl esters were then prepared from lipid extracts by 
transesterification with boron trifluoride as the transesterification reagent as described above.  
The coefficient of variation for fatty acid composition associated with this procedure is 2.5 - 
3.5% (unpublished observations).   
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 The fatty acid methyl esters in hexane were collected into sealed vials to prevent 
evaporation and analyzed on a Varian 3900 gas chromatograph (Varian, Palo Alto, CA) with an 
autosampler following settings as previously described (Kitson et al., 2008).  Briefly, hydrogen 
was used as a carrier gas at a flow rate of 30 mL/min with a DB-FFAP 15m x 0.10 mm inner 
diameter x 0.10 μm film thickness capillary column (J & W Scientific, Agilent Technologies, 
Palo Alto, CA).  The flame ionisation detector was set at 300°C with a 50 Hz sampling 
frequency, a 200:1 split ratio and nitrogen and air make-up gas flow rates of 25 and 300 mL/min 
respectively.  The autosampler injector temperature was set at 250°C with an injection volume of 
1μl.  The temperature program was as follows: initial, 150°C with a 0.25 min hold; ramp: 
35°C/min - 200°C, then by 8°C - 225°C with a 3.2 min hold, then by 80°C/min - 245°C with a 
15 min hold.  Total run time was 23 min for each sample.  An external standard (NuCheck Prep) 
was run with each batch of samples for fatty acid identification and to verify a linear response of 
the flame ionisation detector.  Both identified and unidentified peaks were included in the total 
fatty acid summation when individual fatty acids were expressed as a percentage of the total fatty 
acid pool.   
Statistical and Data Analyses  
 All statistical analyses were performed using SPSS (IBM, Armonk, NY; release 18.0.0).   
Significance was set at p < 0.05.  Individual fatty acids were expressed as a percentage of total 
fatty acids.  The % n-3 HUFA in total HUFA was calculated using the following formula: 
(20:5n-3 + 22:5n-3 + 22:6n-3) / (20:5n-3 + 22:5n-3 + 22:6n-3 + 20:3n-6 + 20:4n-6 + 22:4n-6 + 
22:5n-6) x 100 (Stark, 2008a).  Variability associated with arithmetic mean values is expressed 





DIETARY AND BIOMARKER VALIDATION OF A FOOD FREQUENCY 
QUESTIONNAIRE TO MEASURE EPA AND DHA INTAKES FROM CONVENTIONAL 





 The purpose of a nutrient-specific FFQ is to rapidly assess usual intake of a nutrient of 
interest over the long term.  Habitual Canadian EPA and DHA intakes from whole food (Lien 
and Clandinin, 2009) and seafood sources (Lucas et al., 2009) can be measured using existing 
FFQ and novel functional food and nutraceutical products have been incorporated into FFQ in 
other countries (Sioen et al., 2010; Sullivan, Williams, and Meyer, 2006; Sullivan et al., 2008).  
As neither dietary surveys nor biomarkers assess EPA and DHA intake without measurement 
error, several recent studies have simultaneously used dietary records and blood samples as 
reference tools for validation of FFQ to measure n-3 HUFA intake (McNaughton, Hughes, and 
Marks, 2007; Swierk et al., 2011; Zhang et al., 2009).  Both two-way comparisons between FFQ 
and reference method measurements and three-way comparisons using the method of triads 
(Kaaks, 1997; Ocke and Kaaks, 1997) were used in these validation studies.  The purpose of the 
present study is to incorporate conventional and novel Canadian sources of EPA and DHA into a 
nutrient-specific FFQ and assess FFQ validity in measuring EPA and DHA intakes by Canadian 
adults using dietary record and blood biomarker reference measurements.   
                                                          
1 The contents of this chapter has been previously published and copyright has been assigned to 
the Academy of Nutrition and Dietetics.   
Patterson, A. C., Hogg, R. C., Kishi, D. M. et al. (2012) Biomarker and Dietary Validation of a 
Canadian Food Frequency Questionnaire to Measure Eicosapentaenoic and Docosahexaenoic 





Methods and Materials 
 Adult men and women were recruited from the Kitchener-Waterloo, Ontario area 
between January and September 2008 as part of the recruitment strategy described in Chapter 6 
and word-of-mouth.  A minimum recruitment of 50 participants was targeted based on biomarker 
and 3-d dietary record validation of an Australian FFQ which served as a template for the present 
FFQ (Sullivan, Williams, and Meyer, 2006; Sullivan et al., 2008).  Fifty participants would be 
needed to detect an effect size of 1 with 99% power, assuming a correlation between methods of 
0.6 (α = 0.05).  Effect size is the mean difference between assessment methods divided by the 
standard deviation of either method.  To be eligible to participate in the study, individuals had to 
be ≥18 years old and be free of any conditions which could alter blood fatty acid composition 
including diabetes mellitus, lipid metabolism disorders and pregnancy.  At the first visit, 
participants completed the FFQ (Appendix A), a health screening questionnaire (Appendix B) 
and received instructions to complete a 3-d dietary record.  A finger-tip prick blood sample and 
anthropometric measurements were also collected.  Completed dietary records were returned to 
the laboratory within two weeks when they were checked for completeness and clarification.  
Two researchers performed all recruitment, sample collection and sample and data analysis.    
 A survey of all Canadian whole food, functional food and nutraceutical sources of EPA 
and/or DHA was conducted to develop the FFQ.  Whole food sources were assessed through a 
nutrient-based search of the Canadian Nutrient File 2007b database (Health Canada, 2007a) and 
categorized as follows; marine-based products (including fresh, frozen and canned fish, shellfish, 
seafood paste and sauce, seaweed and fish broth), eggs (including amounts in baked-goods and 
cooking) and poultry, meat and related products (including deli meats and sausages).  Internet 
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searches and surveys of local grocery chains and specialty/health stores were conducted to 
compile available functional food and nutraceutical sources.  The functional foods from the 
following categories were found; eggs and egg products, dairy and dairy alternatives, nut and oil-
based spreads, breads and juice.  To integrate these Canadian sources into FFQ format, an 
existing Australian FFQ assessed for validity and reproducibility (Sullivan, Williams, and 
Meyer, 2006; Sullivan et al., 2008) was used as a template.  Serving sizes to reflect Canadian 
functional food products, such as portions of string cheese, were incorporated.  For each category 
of whole food, functional food or nutraceutical, the questionnaire solicits the following 
information through identification from a list or user input; the type/brand of product, frequency 
of intake and serving size usually consumed during the preceding 12 months.  To facilitate 
portion size estimation, visual aids including measuring cups and spoons, product packaging and 
illustrations of meat/fish portion sizes on plate settings were displayed.  The final FFQ included 
37 questions (Appendix A), was self-administered and was immediately checked for clarification 
and completeness upon completion.   
 
Statistical Analyses 
 Intakes of HUFA determined by the 3-d dietary records and FFQ did not follow a normal 
distribution and accordingly, non-parametric tests or loge transformations followed by parametric 
tests were conducted.  Wilcoxon signed rank test and the Bland-Altman method (Bland and 
Altman, 2010) were performed on EPA and DHA intakes measured by the FFQ and 3-d dietary 
record.  Pearson correlation coefficients were calculated between fatty acid measurements from 
the FFQ, 3-d dietary record and blood biomarker.  Correlation coefficients were evaluated as low 
(<0.4), moderate (0.4-0.6) and high (>0.6) (Nelson et al., 2001).  Participants were ranked 
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independently by EPA + DHA measures from the FFQ, 3-d dietary record and blood biomarker 
as well as the % n-3 HUFA in total HUFA from the blood biomarker and then divided into 
quartiles.  Percent agreement between quartiles of FFQ, 3-d dietary record and blood biomarker 
measurements was determined.   
 The Method of Triads, a strategy to compare individual measurements from the FFQ, 3-d 
dietary record and blood biomarker with an estimated true value, was also performed (Kaaks, 
1997; Ocke and Kaaks, 1997).  Two-way Pearson correlation coefficients were combined to 
produce a triangulated estimate of the true value and yield a new correlation coefficient (validity 
coefficient) for each of the FFQ, 3-d dietary record and blood biomarker measurements with this 
estimated true value as follows:    
Validity Coefficient FFQ with True   = √[(r FFQ & Dietary Record x r FFQ & Biomarker)/r Dietary Record & Biomarker] 
Validity Coefficient Dietary Record with True  = √[(r FFQ & Dietary Record x r Dietary Record & Biomarker)/r FFQ & Biomarker] 
Validity Coefficient Biomarker with True  = √[(r FFQ & Biomarker x r Dietary Record & Biomarker)/r FFQ & Dietary Record] 
For EPA, DHA and EPA + DHA measurements, the validity coefficients 'FFQ with True', 
'Dietary Record with True' and 'Biomarker with True' were each calculated.  To illustrate, the 
coefficient of correlation of the FFQ-derived DHA measurement with the estimated true DHA 
intake is described by the 'Validity Coefficient FFQ with True' for DHA.   
 The method of triads model assumes a linear relationship of FFQ, dietary record and 
blood biomarker measurements with the true value and that random errors between the three 
measurements are uncorrelated.  Because self-reported intakes assessed by FFQ and dietary 
record may share sources of error, positive correlation of random errors will lead to 
overestimation of the associated validity coefficients.  Validity coefficients should therefore be 
interpreted as upper limits of their real values (Ocke and Kaaks, 1997).  In addition, correlation 
between blood biomarker and intake measurements may be depressed by sources of random 
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variation, such as metabolic effects.  As a result, the correlation coefficients r FFQ & Biomarker and r 
Dietary Record & Biomarker are interpreted as lower limits of the validity coefficients (Ocke and Kaaks, 
1997).  Taken together, the true value of the validity coefficient falls within a range; the method 
of triads provides the upper bound of this range and the correlation coefficients r FFQ & Biomarker 
and r Dietary Record & Biomarker act as the lower bound. 
 
Results 
Participant Flow and Characteristics 
 A total of 88 participants were recruited and 78 were included in final analyses.  Two 
participants were excluded for implausible 3-d dietary record energy intake (Gibson, 2005) and 
eight for a missing FFQ, dietary record or blood sample.   The characteristics of the study sample 
are detailed in Table 5.1.  Participants were largely Caucasian, non-smokers and well-educated.   
Use of nutraceutical products was reported by 60% of participants and energy intakes measured 
by 3d food record were 2174 ± 549 kcal/d.  The study sample had an average age of 40.3 ± 9.9 y 
(95% CI: 38.0 - 42.5 y) and body mass index of 26.5 ± 5.5 kg/m
2 




Dietary Intake and Blood EPA and DHA Measurements 
 The FFQ took approximately 15 minutes to complete and dietary intakes and finger-tip 
prick whole blood composition for fatty acids of interest are presented in Table 5.2.  No 
significant differences were observed between mean EPA + DHA intakes reported by FFQ and 
3-d dietary record (p=0.93).  Median EPA + DHA intakes were 0.21 g/d by FFQ and 0.13 g/d by 
3-d dietary record.  The median whole blood % EPA + DHA was 2.44% and % n-3 HUFA in 




Comparisons of EPA and DHA Measurements by FFQ and Dietary Records and Whole Blood 
Fatty Acid Assessment 
 Results determined by Bland-Altman analyses for EPA, DHA and EPA + DHA intakes 
are depicted in Figure 5.1.  The FFQ gives a lower intake measurement at high intakes of EPA + 
DHA and a higher intake measurement at low intakes of EPA + DHA.  For a small proportion of 
the study population (5%, n=4/78), EPA + DHA intake measurements differed between FFQ and 
dietary record estimates. 
 Agreement analysis (Table 5.3) was similar across pairs of dietary assessment and blood 
biomarker measurements.  Agreement of quartile ranking based on FFQ measurement of EPA + 
DHA intake and blood biomarker % n-3 HUFA in total HUFA demonstrates that 42% of 
participants were classified into the same and 79% into the same or adjacent quartile.  By FFQ 
measurement of EPA + DHA intake, 42% of participants were classified into the same and 77% 
into the same or adjacent quartile as measurement of EPA + DHA by 3-d dietary record and 
blood biomarker.   
 Agreement analysis was also performed to compare 3-d dietary record with biomarker 
measurements.  Overall, a lower percentage of participants were classified into the same quartile 
as biomarker measurements by 3-d dietary record as compared with FFQ measurement.  
Agreement of quartile ranking based on 3-d dietary record measurement of EPA + DHA intake 
and blood biomarker % EPA + DHA demonstrates that 27% of participants were classified into 
the same quartile, 44% into the adjacent quartile and 29% were misclassified.  Agreement of 
quartile ranking based on 3-d dietary record measurement of EPA + DHA intake and blood 
biomarker % n-3 HUFA in total HUFA demonstrates that 38% of participants were classified 
into the same quartile, 36% into the adjacent quartile and 26% were misclassified. 
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 Correlation coefficients were low to moderate (Table 5.4).  The blood biomarker % n-3 
HUFA in total HUFA was  moderately correlated with estimates of intake with blood biomarker 
% n-3 HUFA in total HUFA and FFQ EPA estimates (r= 0.51, p< 0.001) being the strongest 
correlation.  The correlation between dietary record DHA intake estimates and blood biomarker 
%DHA in total fatty acids was the weakest  (r= 0.21, p= 0.07).   
 Moderate and high validity coefficients between assessment tools by three-way 
comparisons were observed (Table 5.5).  For the FFQ measurements with the true value, the 
validity coefficient for EPA + DHA was the strongest (Validity Coefficient FFQ with True = 0.71) 
while the validity coefficient for DHA fell outside the allowable range of 0 to 1 (Validity 
Coefficient FFQ with True = 1.005).  Such an occurrence is usually attributed to small sample sizes 
and is known as a Heywood case (Ocke and Kaaks, 1997).  EPA measurements produced the 
strongest validity coefficients for dietary record and biomarker estimates with the true value 
(Validity Coefficient Dietary Record with True = 0.61, Validity Coefficient Biomarker with True = 0.61).   
 
Discussion 
 The present FFQ is the first, to our knowledge, to specifically evaluate EPA and DHA 
intake from Canadian whole food, functional food and nutraceutical sources and to be 
simultaneously validated using dietary survey and blood biomarker reference methods.  The 
strength of the FFQ is that it can be rapidly completed and analyzed and identifies all Canadian 
dietary sources contributing to usual intake of EPA and DHA.  Although FFQ-based 
measurements showed reasonable agreement with measurements from 3-d dietary records and 
blood biomarkers, neither of the reference methods can truly be considered a gold standard.  
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Accordingly, comparisons between the three assessment tools are discussed herein to 
characterize the information each measurement tool provides.       
 As concentrated sources of EPA and DHA like oily fish and nutraceuticals are not 
typically consumed daily, the FFQ may provide a better estimate of usual EPA and DHA intake 
than a 3-d dietary record (Overby, Serra-Majem, and Andersen, 2009).  Although EPA and DHA 
intake measurements from the FFQ and 3-d dietary record differed for only 5% of the study 
population, a distinct relationship was observed between measurements from the two dietary 
surveys; the FFQ gave higher estimates of EPA and DHA intake than the 3-d dietary record at 
low intakes of EPA and DHA, and lower estimates at high intakes of EPA and DHA by Bland-
Altman analysis.  Furthermore, the range of EPA + DHA intakes from FFQ estimates (0.01-1.47 
g/d) was half as wide as the range from 3-d dietary records (0.01-2.92 g/d).  Challenges 
associated with using 3-d dietary records to measure habitual EPA and DHA intakes have been 
previously documented and were attributed to the inclusion or exclusion of concentrated sources 
of EPA and DHA on 3-d dietary records (Fratesi et al., 2009).  Use of novel products can be 
periodic and a 3-d recording period may not fully capture patterns of novel product use over 
time, which are presently not well characterized (Dwyer, Picciano, and Raiten, 2003).  A 
considerably greater number of recording days may be necessary to approximate usual EPA and 
DHA intakes using dietary records as it is typical for measures of short-term nutrient intake to 
show variability above and below long-term, habitual intake (Overby, Serra-Majem, and 
Andersen, 2009; Willett, 1998).  Additional recording days would greatly increase the burden of 
dietary record assessment for both the recorder and analyst and accordingly, the FFQ could be 
used to rapidly determine usual intake of EPA and DHA.    
 Differences between FFQ and 3-d dietary record measurements are further highlighted 
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through comparisons with the blood biomarker.  Discrepancies in the reference time frame may 
account for the low correlation between DHA measurements from the 3-d dietary record and 
blood biomarker (r= 0.21, p= 0.07).  DHA incorporates into and washes out of erythrocytes over 
the course of months as it is preferentially placed in the sn-2 position of phosphatidyl 
ethanolamine of the inner membrane leaflet of the erythrocyte, while EPA accumulates in 
phosphatidyl choline on the outer membrane leaflet where it can exchange more rapidly with 
plasma fatty acids (Metherel et al., 2009).  Therefore, measures of blood DHA may not match 
the short reference time frame of the 3-d dietary record.  In contrast, the stronger correlation 
between FFQ and blood biomarker DHA measurements (r= 0.42, p= <0.01) suggest a better 
alignment of the reference time frames.  The FFQ may better approximate usual intakes of DHA.  
Moderate correlation coefficients were also observed when intake measurements from a 
comparable Australian FFQ to measure n-3 HUFA intake from conventional and novel sources 
were compared with erythrocyte and plasma fatty acid composition (Sullivan, Williams, and 
Meyer, 2006).  Moderate correlations between dietary intake and biomarker measures may 
therefore be appropriate (Overby, Serra-Majem, and Andersen, 2009).  Two-way correlation 
between intake of EPA + DHA measured by the FFQ with whole blood % EPA + DHA, and 
with % n-3 HUFA in total HUFA biomarkers of n-3 HUFA status were within the generally 
deemed acceptable range of 0.4 - 0.7 (Subar, 2004).  Two-way correlations were within the 0.4 - 
0.7 range for EPA and DHA intake measurements from the 3-d dietary record and whole blood 
biomarkers expressed only as the % n-3 HUFA in total HUFA.  Though individual fatty acid 
levels may vary between blood sub-fractions and tissues, the % n-3 HUFA in total HUFA 
remains generally consistent between depots as it represents the competition between HUFA for 
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esterification at the sn-2 position of phospholipids (Armstrong, Metherel, and Stark, 2008; Stark, 
2008a).   
 Selection of the 3-d dietary record as a reference method was based on common practice.  
Intake of EPA and DHA measured by repeat 3-d dietary records may have resulted in better 
agreement with FFQ measurements in the present study, however selection of a single 3-d 
dietary record as a reference method presently was based on the Australian study (Sullivan et al., 
2008).  Dietary validation of the Australian FFQ used as a template for the present FFQ found 
high correlation and no systematic variation by the Bland-Altman method between EPA and 
DHA estimates from the FFQ and a 3-d dietary record (Sullivan et al., 2008).  Additional 
methodological considerations may have particularly strengthened comparisons between FFQ 
and dietary record measurements in the Australian validation study.  For instance, weighed food 
records were used which can diminish inaccuracies in portion size estimation.  While some 
context can be provided for the results of the present FFQ validation through the examination of 
similar validation studies, direct comparison of validation results has limitations as other FFQ 
pose different questions, examine different populations and employ different reference 
measurements, nutrient composition databases and statistical tests.   
 The dietary survey and biomarker tools used herein provide discrete approaches to 
estimate the true EPA and DHA intake.  Consequently, complete accordance of measurements 
from each of these three tools was not expected.  In addition to incongruence of the reference 
time frame outlined above, sources of error inherent to dietary surveys, including limitations of 
the nutrient composition database and misreport may also attenuate agreement between dietary 
survey and biomarker assessment.   
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 While the fatty acid composition of functional food and nutraceutical products identified 
by the FFQ was directly determined, fatty acid composition data in the food composition 
database could limit comparisons between dietary survey and blood biomarker measurements.  
The Australian national food composition database has been updated for n-3 HUFA content, 
including measurements of n-3 docosapentaenoic acid (Mann et al., 2003) but similar updates 
were not available in the Canadian database at the time of survey completion.  Among typical 
Canadian populations with low intakes of n-3 HUFA, n-3 docosapentaenoic acid intakes make an 
important contribution to total n-3 HUFA intakes and often exceed EPA intakes when fish is not 
consumed (Fratesi et al., 2009).  In vivo conversion and retroconversion between EPA, n-3 
docosapentaenoic acid and DHA has been observed in individuals with low n-3 HUFA intakes 
(Brossard et al., 1996; Kitson, Stroud, and Stark, 2010; Pawlosky et al., 2003b). As endogenous 
synthesis of DHA has been demonstrated to be higher by females than males when consuming 
low n-3 HUFA intakes (Burdge and Wootton, 2002; Burdge, Jones, and Wootton, 2002; Kitson, 
Stroud, and Stark, 2010; Pawlosky et al., 2003b), sex differences were also considered.  
However, sex stratification did not strengthen agreement between dietary intake and biomarker 
measurements and no sex differences in dietary or blood measurements of EPA or DHA were 
observed in the present study.  Furthermore, it is important to consider the contribution of 
functional food and nutraceutical sources to dietary intake however, measurement of EPA and 
DHA intake from novel sources requires frequent database and FFQ updating due to changes in 
product availability.  
 Dietary intake assessment may be influenced by misreport.  Those who under-report 
energy intake may simultaneously over-report intake of perceived healthy foods, including fish 
(Livingstone and Black, 2003).  Such selective misreport could impact both FFQ and dietary 
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record assessments.  While this nutrient-specific FFQ provides a relatively quick estimate of 
EPA and DHA intake, it does not provide a measure of total energy intake.  Methods to 
statistically account for selective misreport are not defined and adjustment of dietary record 
measurements using the residual method (Willett, 1998) yielded no improvement in correlation 
coefficients in the present study.  Finally, in the present study n-3 HUFA intakes assessed by 3-d 
dietary record were not anticipated to vary greatly by season over the nine month recruitment 
period.  Greater use of fish liver oils, a source of fat soluble vitamins, in winter has been 
observed in Polish consumers (Kolanowski, 2008) however, the fish body oils consumed by 
participants in the present study were not anticipated to be taken seasonally.  A prior Canadian 
study has also found no seasonal variability in intakes of EPA and DHA from whole food 
sources (Lien and Clandinin, 2009).  A one year reference period has previously been used for 
food frequency questionnaire determination of EPA and DHA intake from both food and 
nutraceutical sources (Zhang et al., 2009) and was selected in the present study to capture 
potential variability in novel product use over time (Dwyer, Picciano, and Raiten, 2003) and 
probe usual intake.  Intake over the prior year has been queried in seminal semi-quantitative food 
frequency questionnaires (Block et al., 1986; Willett et al., 1985) on the basis that respondents 
will rely on generic memory to recall usual intake in the past and that responses will be 
independent of fluctuation in usual intake over time (Willett, 1998).  In practice, diet recall 
respondents do not fully restrict their responses to intake during the reference period (Smith, 
1993).  Although FFQ respondents were asked to consider the past year, diet recall will include 
both description of the typical diet, regardless of the reference period, and specific memory about 





 Comparison of FFQ with food record and blood biomarker estimates suggests that the 
FFQ is an adequate tool for ranking and estimating habitual EPA and DHA intakes.  Comparison 
of dietary survey with biomarker measurements, particularly blood DHA measurements, 
suggests that the FFQ has a longer reference time frame than the 3-d dietary record for 
measurement of EPA + DHA intake.  The FFQ appears to have a theoretical advantage over the 
3-d dietary record as the FFQ captures EPA and DHA intake from all dietary sources, instead of 
just those consumed on recording days.  This is important in measurement of n-3 HUFA intakes 
as in the food supply, these fatty acids are found concentrated in a limited number of sources.  
The FFQ can also have benefits over a 3-day food record in situations where rapid assessment of 
habitual intake is needed, as the FFQ is more expedient to complete and assess.  Finally, as the 
FFQ provides an overview of all dietary EPA and DHA sources, it could also be used to identify 
the primary dietary sources and detect underused sources which could be promoted to achieve 




Table 5.1.  Characteristics of food frequency questionnaire (FFQ) study participants
1 
Characteristic  n %
2
 
Sex   
Female 46 59 
Male 32 41 
Cultural/Racial Background   
Caucasian 66 85 
Chinese 6 8 
Latin American 3 4 
West Asian 2 3 
Mixed 1 1 
Education    
Some High School 1 1 
High School or Current Undergraduate Student 19 24 
Trade, Technical/Vocational School or Business College 5 6 
Community College, CEGEP or Nursing School 9 12 
Bachelor's Undergraduate Degree or Teacher's College 26 33 
Master's Degree 13 17 
Earned Doctorate 2 3 
Professional Degree
3
 3 4 
Annual Household Income, Canadian Dollars, n=77   
<$25,000 8 10 
$25,000-$50,000 14 18 
$50,000-$75,000 18 23 
$75,000-$100,000 12 15 
>$100,000 25 32 
Smoking, n=77   
Non-Smoker 61 78 
Ex-Smoker 14 18 
Current Smoker 2 3 
Regular Nutraceutical Use 47 60 
Oral Contraceptive Use 8 10 
1 
n= 78 unless stated otherwise  
2 
Percentage of total study population 
3 
Medicine, dentistry, veterinary medicine, optometry or law  
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Table 5.2.  Food frequency questionnaire (FFQ) and dietary record intakes and blood biomarker 
fatty acid composition of FFQ validation study participants
 





, g/d     
 EPA 0.06 (0.02 - 0.14) 0.01 0.61 0.84 
 DHA 0.13 (0.04 - 0.39) 0.01 1.00 0.94 
 EPA + DHA 0.19 (0.06 - 0.61) 0.01 1.47 0.93 
Dietary Record
2
, g/d     
 EPA 0.04 (0.02 - 0.08) 0.01 1.09  
 DHA 0.10 (0.04 - 0.29) 0.01 2.01  
 EPA + DHA 0.16 (0.05 - 0.48) 0.01 2.92  
Blood Biomarker
2
     
 EPA, wt% 0.61 ± 0.41 0.08 3.22  
 DHA, wt% 1.95 ± 0.59 0.81 4.47  
 EPA + DHA, wt% 2.56 ± 0.90 1.15 7.69  
 % n-3 HUFA 24.35 ± 5.47 14.45 45.32  
1 
Wilcoxon signed rank test (2-tailed) of difference between FFQ and dietary record means 
2 
Means expressed as geometric mean (95% confidence interval). 
3 
Blood biomarker (whole blood) values were expressed as the weight percentage of total fatty 
acids (wt%) or the percentage of n-3 highly unsaturated fatty acids in total highly unsaturated 





Table 5.3.  Agreement of quartile assignment by the sum of eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) intakes by food frequency questionnaire (FFQ) and 
dietary record and n-3 HUFA blood biomarkers
1 







FFQ vs. Dietary Record 
 1 (n=19) 8 6  (6 below) 5  (5 below) 
 2 (n=20) 8 10  (8 below, 2 above) 2  (2 below) 
 3 (n=20) 5 9  (5 below, 4 above) 6  (6 above) 
 4 (n=19) 12 2  (2 above) 5  (5 above) 
 Total  33 (42%) 27 (35%) 18 (23%) 
FFQ vs. Blood Biomarker EPA+DHA,wt%
1
 
 1 (n=19) 7 5  (5 below) 7  (7 below) 
 2 (n=20) 8 10  (3 below, 7 above) 2  (2 below) 
 3 (n=20) 8 9  (6 below, 3 above) 3  (3 above) 
 4 (n=19) 10 3  (3 above) 6  (6 above) 
 Total  33 (42%) 27 (35%) 18 (23%) 
FFQ vs. Blood Biomarker % n-3 HUFA in total HUFA
1
 
 1 (n=19) 8 6  (6 below) 5  (5 below) 
 2 (n=20) 7 11 (5 below, 6 above) 2  (2 below) 
 3 (n=20) 8 9  (6 below, 3 above) 3  (3 above) 
 4 (n=19) 10 3  (3 above) 6  (6 above) 
 Total 33 (42%) 29 (37%) 16 (21%) 
1 
Blood biomarkers were expressed as the sum of the weight percentage of eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) in total fatty acids (EPA+DHA, wt%) or the percentage 
of n-3 highly unsaturated fatty acids in total highly unsaturated fatty acids  
 2 
Participants not classified into same or adjacent quartile  
50 
 
Table 5.4.  Pearson coefficients of correlation between food frequency questionnaire (FFQ), dietary record 





  Blood biomarker fatty acids
3
 











        
 EPA 0.31** 0.48** 0.37**  0.31** 0.48** 0.45** 0.51** 
 DHA 0.28* 0.49** 0.37**  0.29* 0.42** 0.41** 0.47** 
 EPA+DHA 0.30** 0.49** 0.38**  0.30** 0.45** 0.43** 0.49** 
Dietary record
2 
    - - - - 
 EPA - - -  0.37** 0.25* 0.33** 0.44** 
 DHA - - -  0.35** 0.21 0.29** 0.42** 
 EPA+DHA - - -  0.36** 0.24* 0.32** 0.45** 
1 




Loge transformations were applied to intake values (expressed as g/d) prior to statistical analyses 
3 
Blood biomarker values were expressed as the weight percentage of total fatty acids (wt%) or the 




Table 5.5.  Method of triads validity coefficients (VC) and VC ranges of food frequency questionnaire (FFQ), 
dietary record and blood biomarker fatty acid measurements with the true value
1
 
 FFQ with True Dietary Record with True Biomarker with True
 
Fatty Acid VC VC Range VC VC Range VC VC Range 





 0.49 0.21-0.49 0.42 0.42-0.42 
EPA+DHA 0.71 0.43-0.71 0.53 0.32-0.53 0.60 0.43-0.60 
1 
Validity coefficients (VC): correlation coefficients of the FFQ and dietary record fatty acid intake and blood 
biomarker weight % of total fatty acids measurements with the estimated true value.  True value: estimated by 
combining two-way Pearson correlation coefficients between FFQ, dietary record and biomarker 
measurements.  FFQ: food frequency questionnaire, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid 
2 




Figure 5.1.  Agreement between food frequency questionnaire (FFQ) and 3-d dietary record 
estimates of the sum of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) intake 




ONE YEAR ADHERENCE TO CONVENTIONAL AND NOVEL DIETARY ADVICE 
STRATEGIES TO INCREASE INTAKES OF EPA AND DHA 
 
Introduction 
 The disparity between recommended EPA and DHA intakes and those observed by 
Canadians could be resolved by increased consumption of seafood, functional food and/or 
nutraceuticals (Patterson and Stark, 2008).  Providing consumers functional foods and/or fish can 
increase EPA and DHA intake (Lovegrove et al., 1997; Mantzioris et al., 2000; Metcalf et al., 
2003; Patch et al., 2005), but greater adherence to dietary recommendations is achieved when 
food products are provided as compared with a self-selected approach (Metz et al., 1997).  
Dietary advice to increase intake of oily fish can result in adherence, as assessed by diet history 
interviews for up to three months (Neale et al., 2012).  Long term adherence to seafood, 
functional food and nutraceutical-based dietary advice in a self-selected manner has not been 
evaluated through objective dietary assessment tools.  The aim of the following study was to 
assess through dietary survey and blood n-3 HUFA biomarkers, the one-year adherence to 
Seafood, Functional Food, Nutraceutical and Combined dietary advice strategies to increase EPA 
and DHA intake to 1g/d by adult men and women. 
 
Methods and Materials 
 Participants aged 35-50 y were recruited from the Kitchener-Waterloo, Ontario area 
between January and September 2008.  Local newspaper advertisement and flyers posted at local 
community centres, grocery stores and on the University of Waterloo campus were used to 
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recruit participants (Appendix B).  Recruitment of 40 participants was targeted to provide 80% 
power to detect 1.5 unit differences in erythrocyte % DHA based on 10 subjects per dietary 
advice group, as determined from variability observed in previous work examining blood fatty 
acids pre and post supplementation with EPA and DHA (α = 0.05) (Metherel, 2007).  At a 
screening visit, individuals provided a finger-tip prick whole blood sample, completed a semi-
quantitative FFQ specific for EPA and DHA intake (Patterson et al., 2012) and health screening 
form (Appendix B), and were given instructions for completing a 3-d dietary record (Appendix 
B).  Individuals consuming nutraceuticals containing EPA and DHA and those with >4% EPA + 
DHA in total fatty acids from finger-tip prick whole blood samples were excluded from the 
study.  Males and females separately were sequentially assigned to receive Seafood, Functional 
Food, Nutraceutical and Combined dietary advice in the order in which they were admitted to the 
study.   Neither participants, nor the researchers were blinded to participant allocation and a 
single researcher recruited, allocated, provided dietary advice, collected samples, completed 
sample analysis and performed data analysis. 
 Participants attended a baseline visit approximately two weeks after screening where they 
were assigned to each of the four dietary advice groups.  At this baseline visit, dietary advice was 
provided as a structured interview and handout (Appendix B) and participants were asked to 
follow the advice for the subsequent 52 weeks.  A 3-d dietary record, anthropometric 
measurements and a venous blood sample were collected at baseline and at follow-up visits in 
weeks 4, 8, 12, 24 and 52.    
 The dietary advice targeted an intake of 1 g/d of EPA + DHA from seafood, functional 
food, nutraceutical or combined sources.  Participants in each of the dietary advice groups 
received the same information regarding the health benefits associated with EPA and DHA 
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intake.  The Seafood advice group was asked to substitute seafood in place of other meat and 
meat alternatives in their regular diets.  Information on local seafood retailers, safe seafood 
preparation and cooking techniques, recipes, sample daily menus and recommendations for 
avoiding frequent intake of fish with high mercury content was provided.  Differences in the 
EPA + DHA content of oily and lean fish were discussed and the amount EPA + DHA of all 
seafood itemized in the Canadian Nutrient File 2007b (Health Canada, 2007a) was provided to 
help participants estimate EPA + DHA intake.   The Functional Food advice group was asked to 
substitute EPA and/or DHA-containing functional foods in place of similar foods (e.g., n-3 eggs 
in place of regular eggs) in their regular diets.  Information on how to identify functional foods 
containing EPA and/or DHA from product labels, recipes, sample daily menus, and the amount 
of EPA + DHA per serving of available functional foods along with cost comparisons at local 
retail outlets was provided to the Functional Food advice group.  The Nutraceutical advice group 
was advised to supplement their regular diet with a nutraceutical product.  Information on the 
different types of nutraceutical products available (e.g., capsules, liquid, soft chews, etc), 
interpretation of product labels, and cost associated with consuming 1 g/d EPA + DHA from 
various nutraceutical products from local retail outlets was provided.  The Combined advice 
group was given the Seafood, Functional Food and Nutraceutical advice and advised how to 
simultaneously substitute/supplement their diet with all three sources by providing sample daily 
menus.  Outside of recommendations to increase EPA + DHA intake through 
substitution/supplementation, all groups were requested to otherwise maintain their usual diet 
and physical activity regimes.  Participants were responsible for purchasing their own food 
and/or nutraceutical products.  At the follow-up visits in weeks 4 through 52, the 3-d dietary 
records detailing intake of recommended foods/nutraceuticals were reviewed in-person, 
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challenges associated with following the dietary advice were discussed and continued adherence 
was encouraged.  The week 0 (dietary advice) visit took up to one hour and visits in weeks 4 
through 52 took up to 30 minutes, including blood sample and anthropometric measurement 
collection.  Researchers were available to answer any questions from participants between study 
visits by phone or email.   
 The anti-coagulant ethylenediamine tetraacetic acid (Sigma-Aldrich, Bellefonte, PA) was 
added to venous blood samples following collection in preparation for whole blood, plasma and 
erythrocyte fatty acid determination (Chapter 4).  Serum was also collected for blood lipid 
determinations.  For serum collection, whole blood samples were collected into 5 mL serum 
separating tubes.  The whole blood samples clotted for 1 h and were subsequently centrifuged at 
2300 rpm for 15 minutes to recover serum.  Serum aliquots were stored at -80°C prior to total, 
HDL and LDL (calculated) cholesterol and triacylglycerol determination by a commercial 
laboratory (Lifelabs, Toronto, ON, Canada).   
 Participants were instructed to collect duplicates of all foods, beverages and 
nutraceuticals consumed on the three days corresponding with the 3-d dietary record returned at 
the week 4 visit.  Returned duplicate collections were then weighed, blended to homogeneity in a 
4-Liter
 
blender (Waring Laboratory & Science, Torrington, CT) and stored at –80°C until fatty 
acid analysis as described in Chapter 4.   
 
Statistical Analyses 
 Measurements of serum triacylglycerol concentration and HUFA intakes from 3-d dietary 
records were loge transformed to permit parametric analyses, and their values are presented as 
geometric means with 95% confidence intervals.  The linear mixed model procedure was used 
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for analysis of variance.  Following the determination of a significant F-value, individual means 
were examined with Bonferroni's post hoc analyses.   
 Blood n-3 HUFA status (assessed by the whole blood % n-3 HUFA in total HUFA), 
adherence to dietary advice (assessed through erythrocyte % DHA) and dietary intake of EPA + 
DHA from 3-d dietary records, were evaluated as the primary study outcomes.  These 
measurements, along with anthropometric and blood lipid measurements, were compared 
between advice groups using a three-factor (advice group, sex and time) repeated measures linear 
mixed model procedure.  Measurements of EPA and DHA intake by 3-d dietary records and 3-d 
food duplicate collections in week 4 were compared by paired t-tests.  EPA and DHA intake 
between diet advice groups at week 4 was examined by the linear mixed models procedure with 
diet advice as a factor, independently for 3-d dietary records and 3-d food duplicate collections.  
The association of sex, body mass and dietary fatty acid intake with blood fatty acid 
measurements were examined by linear regression.  Specifically, the association of dietary DHA 
intake with erythrocyte % DHA, and dietary EPA + DHA intake with whole blood % n-3 HUFA 
in total HUFA was examined.  Regression analyses were performed with dietary DHA and EPA 
+ DHA intake expressed as g/d, % energy, and nutrient residuals (Willett and Stampfer, 1986).   
 Statistical analyses were performed for participants completing the entire 52-week study, 
described herein as 'completers' to assess the biological effect of the dietary advice on blood fatty 
acid levels.  The main study outcomes (whole blood % n-3 HUFA in total HUFA, erythrocyte % 
DHA and dietary intake of EPA + DHA from 3-d dietary records) and anthropometric 
measurements were also examined according to intention to treat to assess the potential use of 
the dietary advice in clinical practice.  Participants who started, but did not complete the 52-
week protocol were included in statistical procedures as described above, using baseline values 
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for missing data values. The presentation of the following results focuses on the ‘completer’ 
analyses, with a summary of the intention to treat analyses afterwards.  
 
Results 
Participant Flow and Characteristics  
 Fifty-nine people responded to advertisements and were screened for study participation.  
Nine people were not admitted to the study as they did not meet eligibility requirements; eight 
had blood levels of EPA + DHA above cut-off and/or were consuming a fish oil nutraceutical, 
and one individual wished to begin a weight-loss diet.  Five individuals initially recruited left the 
study following baseline dietary advice intervention; one became pregnant, one was attempting 
to become pregnant, one was diagnosed with gallstones, one was unable to attend study visits, 
and one could no longer be contacted.  As blood fatty acid composition would change with 
pregnancy and gallstone treatment, these two participants were excluded from all analyses 
herein, including intention to treat.  Forty-five individuals participated in the year-long study and 
were considered 'completers' during analysis and 48 individuals were included in the intention to 
treat analyses.  The four completer dietary advice groups consisted of the following; 11 (6 F, 5 
M) were assigned to each of the Seafood, Functional Food and Combined advice groups and 12 
(6 F, 6 M) participants were assigned to the Nutraceutical advice group.  Individuals not 
completing the study and included in the intention to treat analysis had been randomized to 
Seafood advice (1 F, 1 M) and Functional Food advice (1 F). Participants were mainly 





Anthropometric Measurements and Blood Lipid Measurements  
 For completers, dietary advice groups were similar in age (baseline: 43.7 ± 4.4 y) and 
body mass index (baseline: 27.3 ± 5.3 kg/m
2
).  Overall, men had a higher body mass than women 
(completers; men: 87.6 ± 17.6 kg, women: 71.7 ± 15.6 kg, effect of sex, p < 0.01).  The dietary 
advice groups had similar levels of total cholesterol (baseline: 4.7 ± 0.8 mmol/L) and LDL 
cholesterol (baseline: 2.8 ± 0.7 mmol/L).  Overall, males had higher levels of triacylglycerols 
[men: 1.4 (1.1 - 1.6) mmol/L, women: 0.8 (0.7 - 0.8) mmol/L] and lower levels of HDL 
cholesterol (men: 1.2 ± 0.3 mmol/L, women: 1.5 ± 0.3 mmol/L) (effect of sex, p < 0.01, for both 
measurements).  Body mass did not change over time.  As anticipated for doses of EPA + DHA 
<2g/d, blood lipid measurements did not change over time (Kris-Etherton, Harris, and Appel, 
2003).  Study participants reported no adverse events with the dietary advice.  
 
Blood Fatty Acids and Fatty Acid Biomarkers 
 The % n-3 HUFA in total HUFA in whole blood was 24.0 ± 4.8% at baseline.  With the 
exception of women in the Seafood and Functional Food advice groups, the % n-3 HUFA in total 
HUFA in whole blood increased at various time points after dietary advice for men and women 
in each advice group (effect of  advice group x time x sex interaction, p < 0.01) (Figure 6.1, 
meaningful comparisons shown).  Specifically, the % n-3 HUFA biomarker increased from 
baseline for men in the Seafood advice group in weeks 4 through 52.  For men in the Functional 
Food advice group, the biomarker increased in week 4 from baseline.  In the Nutraceutical 
advice group, the biomarker increased from baseline for men in weeks 8 through 52 and for 
women in weeks 4 through 52.  The % n-3 HUFA biomarker increased in weeks 4, 12, 24 and 52 
for the men in the Combined advice group from baseline. Women in the Combined advice group 
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had increased % n-3 HUFA biomarker at all time points after baseline.  The whole blood % n-3 
HUFA in total HUFA was also higher for women in the Nutraceutical advice group at weeks 24 
and 52 as compared with week 8 for men in the Functional Food advice group.  Increases in the 
whole blood % n-3 HUFA in total HUFA post-intervention were generally accompanied by an 
increase in the % total HUFA (effect of  advice group x time interaction, p < 0.04), with no 
change in the % n-6 HUFA.   
 Overall, the % DHA in erythrocytes increased from baseline (4.0 ± 1.0 %) in weeks 4 and 
8, reached a maximum in week 12 (4.9 ± 0.8 %), and subsequently returned to baseline levels in 
weeks 24 and 52 (effect of time, p < 0.01) (Figure 6.2).  For all time points combined, the % of 
DHA in erythrocytes was higher with Seafood advice (4.7 ± 1.0 %) as compared with 
Nutraceutical (4.0 ± 0.9 %) and Functional Food (4.0 ± 0.8 %) advice (effect of advice group, p 
< 0.01).  The Seafood advice group appeared to have a higher % DHA in erythrocytes at baseline 
however no significant time x advice group interaction was observed (p = 0.30).  
 In contrast with the % of DHA in erythrocytes, the % of DHA in whole blood and plasma 
and the % of EPA in all three blood fractions was higher in weeks 4 through 52 as compared 
with the baseline measurement (Figure 6.2).  This observation, coupled with the relatively slow 
incorporation and washout of DHA into/from the inner erythrocyte membrane, confirms that 
erythrocyte DHA is an appropriate marker of sustained adherence to dietary advice over the 52 
week study.   
 
Dietary Intake of EPA + DHA 
 At baseline, EPA + DHA intake was 0.12 (0.07 - 0.21) g/d.  Intake of  EPA + DHA 
increased at each post-intervention time point in the Seafood, Nutraceutical and Combined 
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advice groups from the advice group's own baseline measurement (effect of advice group x time 
interaction, p = 0.03, meaningful comparisons shown) (Figure 6.3).  For the Functional Food 
group, EPA + DHA intake did not increase significantly post-intervention.  No significant 
differences in EPA + DHA intake were observed between advice groups at each time point.   
 
Food Duplicate Collections  
 Measurement of EPA intake in the Seafood advice group was higher when assessed by 3-
d dietary record as compared with food duplicates in week 4 (p = 0.04) with no other differences 
between estimates of EPA and/or DHA by 3-d dietary record and food duplicate collections 
(Table 6.2).  Unlike dietary records, no differences in food duplicate EPA composition (g/d) 
were observed between the Seafood and Functional Food advice groups.  
 
Relationship of body mass index, sex and dietary n-3 HUFA intake with blood n-3 HUFA 
 Body mass index was inversely associated and being female was positively associated 
with the % of DHA in erythrocytes and the % n-3 HUFA in total HUFA in whole blood (Table 
6.3).   Dietary EPA + DHA intake was also positively associated with the % n-3 HUFA in total 
HUFA in whole blood (Table 6.3).  Regression results were similar with DHA and EPA + DHA 
intakes expressed as % energy and nutrient residuals and absolute body mass was also inversely 
associated with erythrocyte % DHA (data not shown).  
 
Intention to Treat Analyses 
 Overall, findings by intention to treat analyses were similar to those by completer 
analyses.  Participant characteristics (Table 6.1) and anthropometric measurements were similar 
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following completer and intention to treat analyses.  Also similar to completers, the % n-3 
HUFA in total HUFA in whole blood increased from baseline for Seafood advice group men in 
weeks 4 through 52 while no changes from baseline were observed for Seafood advice group 
women by intention to treat (effect of advice group x time x sex interaction, p = 0.01).  For 
women in the Functional Food advice group, the % n-3 HUFA in total HUFA in whole blood did 
not increase from baseline, similar to completers.  The pattern of a higher % of DHA in 
erythrocytes in weeks 4 through 12 relative to baseline was also observed by intention to treat 
(effect of time, p < 0.01).  Intake of EPA + DHA was unaltered by intention to treat; intake of 
EPA + DHA increased from baseline in the Seafood, Nutraceutical and Functional Food advice 
groups, but not in the Functional Food advice group (effect of advice group x time interaction, p 
= 0.04).  Results of regression analyses were also unaltered following intention to treat. 
 
Discussion 
 An examination of changes in the % of DHA in erythrocytes suggest that adherence to 
dietary advice was maintained during the initial 12 weeks in the study but not sustained in weeks 
24 and 52.  In contrast, changes in the % of DHA in plasma and whole blood, and the % of EPA 
in erythrocytes, plasma and whole blood suggest continued adherence after week 12, as did the 
% n-3 HUFA in total HUFA in whole blood and intake estimates by 3-d dietary records.  Based 
on the % n-3 HUFA in total HUFA in whole blood, n-3 HUFA status increases for men and 
women following Nutraceutical and Combined advice and for men following Seafood and 
Functional Food advice.  Dietary estimates from 3-d dietary records indicate that intake of EPA 
+ DHA significantly increases following Seafood, Nutraceutical and Combined dietary advice 
strategies.    
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 A strength of the present investigation is the combination of multiple assessment tools to 
characterize EPA + DHA intake and blood status over the 52-week period.  The return of the % 
of DHA in erythrocytes to baseline levels after week 12 for the study population overall indicates 
poor adherence when participants were not in contact with the investigators.  In contrast, the % 
n-3 HUFA in total HUFA in whole blood increased with dietary advice in general and remained 
increased above baseline throughout the study, indicating good adherence.  DHA has been 
demonstrated to incorporate into and plateau in erythrocytes within 4 weeks (Barcelo-Coblijn et 
al., 2008; Katan et al., 1997) and washout can take >6 weeks with DHA supplementation of  > 
1g/d (Brown, Pang, and Roberts, 1991).  In contrast, with supplementation of 3.2 g/d EPA + 1.6 
g/d DHA for one month, the % n-3 HUFA in total HUFA in whole blood rapidly increases and 
decreases within 1 week of initiation and cessation, respectively (Metherel et al., 2009).  By 
considering both the changes in the % of DHA in erythrocytes and the % n-3 HUFA in total 
HUFA in whole blood, it appears that adherence in the present study was inconsistent through 
weeks 24 and 52.  A pattern of poor adherence after the week 12 visit, followed by 
“compensatory” EPA + DHA intake shortly before the weeks 24 and 52 visits would potentially 
result in % n-3 HUFA in total HUFA in whole blood values above baseline and relatively low % 
of DHA in erythrocytes. 
  DHA is preferentially incorporated into phosphatidyl ethanolamine of the inner leaflet of 
lipid membrane bilayers while EPA incorporates into phosphatidyl choline of the outer leaflet 
(Lemaitre-Delaunay et al., 1999).  Fatty acid remodelling of inner cell membranes is relatively 
slow (Seigneuret and Devaux, 1984), therefore EPA can increase and decrease rapidly in 
erythrocytes, while DHA turnover is relatively slow (Metherel et al., 2009).  In contrast, plasma 
EPA and DHA respond relatively rapidly to dietary intake changes (Metherel et al., 2009).  
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While plasma phospholipids are predominantly phosphatidyl choline, plasma also contains 
triacylglycerols and cholesteryl esters that can incorporate fatty acids.  In addition, plasma fatty 
acid composition is largely influenced by the liver, the primary site of lipid and fatty acid 
metabolism, whereas remodelling of erythrocyte fatty acids would occur in the circulation.   
Biomarkers of n-3 HUFA, like the % n-3 HUFA in total HUFA, appear to be appropriate 
for characterizing short term changes in EPA and DHA intake and describing the n-3 HUFA 
status of those with stable EPA and DHA intakes.  DHA in erythrocytes reflects n-3 HUFA 
intake over longer periods and appears to characterize adherence to increases in n-3 HUFA 
intake well.  The use of erythrocytes also has limitations as there are additional analytical and 
storage considerations, such as hemolysis and iron-mediated HUFA oxidation following 
erythrocyte storage at -20ºC but not -80ºC (Metherel, 2012).   
 Adherence to dietary advice up to, but not beyond the initial 12 weeks of the study may 
be related to follow-up frequency and/or participant fatigue.  Study visits occurred monthly from 
baseline to week 12, and subsequently took place 3 months later at week 24 and then 6 months 
later at week 52.  A similar pattern of adherence up to 12 weeks, but not 52 weeks, was observed 
in a study examining adherence to dietary advice to consume fatty fish in a self-selected manner 
(Neale et al., 2012).  In this fish advice study, dietary counselling was provided at the same time 
points as the present study, plus an additional visit at week 36, and adherence was measured by 
diet history.  Taken together, this fish-based advice study and the present show that dietary 
advice for consumers to increase intake of EPA and DHA sources can be effective and suggest 
that regular follow-up and motivation may be needed to maintain long-term adherence.   
 Sex and advice group differences were found by examining the % n-3 HUFA in total 
HUFA in whole blood and not the % of DHA in erythrocytes.  This may be an indication that the 
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% of DHA in erythrocytes may not be sensitive enough to detect subtle differences that affect 
EPA and DHA status in other tissues.  Tissue differences in n-3 HUFA levels are well 
documented (Stark et al., 2005).  Increases in % n-3 HUFA in total HUFA in whole blood of 
men but not women after receiving Seafood advice could be interpreted as men achieving higher 
intakes of EPA + DHA following Seafood advice or that the men engaged in greater 
"compensation" fish consumption as compared with women.  As adult men typically consume 
larger portions of meat and meat alternatives as compared with women, it is plausible that their 
intake of EPA + DHA from seafood substitution could be greater (Garriguet, 2007), and 
compensation intakes of EPA + DHA would be higher.  In contrast, men and women could both 
increase intakes of nutraceuticals prior to study visits without the need for dietary change.  This 
may account for sustained increases in the % n-3 HUFA in total HUFA in whole blood of men 
and women after Nutraceutical and Combined advice.  Dietary assessments performed by both 
sexes can be subject to response bias as women are influenced by social desirability, a tendency 
to avoid criticism, and men are influenced by social approval, a tendency to seek praise (Hebert 
et al., 1997).  Knowing blood samples would be measured for n-3 HUFA status at each study 
visit could have lead to compensatory adherence immediately prior to study visits. 
 The amount of EPA + DHA per serving of functional food products likely contributes to 
lower n-3 HUFA intake and blood status measurements following Functional Food advice.  As a 
prelude to the present study, fish, nutraceuticals or functional foods were substituted into 
theoretical typical Canadian diets to examine the feasibility of these dietary strategies to provide 
dietary EPA and DHA (Patterson and Stark, 2008).  While functional food substitution increased 
the EPA + DHA content of the theoretical typical Canadian diet, levels attained were below 
those achieved following nutraceutical or seafood substitution.  At the time of the present study, 
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functional foods available to consumers provided between 0.01 and 0.25 g EPA + DHA per 
serving and several functional foods needed to be combined and consumed daily to achieve EPA 
+ DHA intake recommendations provided as part of the dietary advice.  The amount of EPA + 
DHA provided by seafood and nutraceuticals also varies from source to source but can supply 
more than functional foods.  Oily fish like farmed Atlantic salmon supplies 2.2 g of EPA + DHA 
per 100g portion (Health Canada, 2007a) and accordingly, oily fish would not need to be 
consumed daily to achieve 1 g/d EPA + DHA.  Fish oil capsules supplying 0.5 g EPA + DHA are 
readily available to consumers and a small dose of two capsules per day could be used to achieve 
study EPA + DHA intake targets for participants following Nutraceutical advice.  Functional 
food advice may be appropriate for those finding fish and nutraceutical intakes unacceptable, or 
targeting the low end of EPA + DHA intake recommendations.  Functional foods could be also 
included as part of a combined approach.   
 Unlike nutraceuticals, functional foods supply a variety of nutrients.  For example, eggs 
are a low cost source of protein (Drewnowski, 2010) and lutein and zeaxanthin, which have 
benefits for macular health, (Vishwanathan et al., 2009), but also supply dietary cholesterol 
which may increase circulating LDL cholesterol levels for individuals with a specific genotype 
(Herron et al., 2006).  The purpose of the Functional Food advice strategy was to observe, 
through a substitution approach with existing consumer products, whether EPA and DHA intake 
could increase following advice based on functional food products.  Whether the nutritional 
advantages of a functional food supplying EPA and DHA outweigh any potential disadvantages 
may vary at the individual level.  In the future, advances in nutrigenomics testing could help 
individuals identify whether a specific functional food product supplying EPA and DHA is 
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appropriate for them (Nielsen and El-Sohemy, 2012) however, the focus herein was long-term 
adherence to EPA and DHA intake from different conventional and novel dietary sources.  
 Agreement between dietary survey intake measurements and fatty acid analyses of food 
duplicate collections, with the exception of EPA intakes by the Seafood advice group, indicate 
that differences in the adherence pattern between 3-d dietary records and the % of DHA in 
erythrocytes for weeks 24 and 52 are likely attributable to self-report.  Dietary intervention can 
impact diet self-report as a result of a desire to give socially desirable responses and seek 
approval (Kristal et al., 1998).  As a result, dietary intakes of EPA and DHA measured by the 3-d 
dietary records herein give an indication of EPA + DHA intakes achievable following each of the 
dietary strategies, but are not an optimal measure of long-term adherence.  The estimated intakes 
of EPA by the Seafood advice group in weeks 4 through 52 may be an overestimation if the 
discrepancy between 3-d dietary records and duplicate food collections is due to the food 
composition database rather than participant food collection/recording error.   
 The n-3 HUFA intakes and adherence to dietary advice over time attained in the present 
study may be greater than those achievable by the general population.  For ethical reasons, study 
recruitment materials advertised the study as an omega-3 fatty acid intervention and may have 
attracted individuals with an interest in consuming these fatty acids.  However, once recruited for 
the study, all participants received the same information regarding health benefits of EPA and 
DHA and advice was consistently provided by the same investigator.  Major study conclusions 
were the same following intention to treat and completer analysis however; loss to follow-up in 
both Seafood and Functional Food advice groups could indicate difficulty adhering to dietary 
strategies involving food substitution instead of nutraceutical addition.  For interpretation of 
blood n-3 HUFA biomarkers, the assumption was made that EPA and DHA in the various 
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dietary sources would be equally bioavailable.  Some of the nutraceutical and functional food 
products selected by participants supplied EPA and DHA in ethyl ester form and may (Harris et 
al., 2007; Krokan, Bjerve, and Mork, 1993; Nordoy et al., 1991) or may not (Dyerberg et al., 
2010; Neubronner et al., 2010) be equally as bioavailable.  This study examined adherence to 
dietary advice in a population with no prior history of cardiovascular disease and therefore 
cannot be generalized to those with a history of cardiovascular disease following EPA + DHA 
intake recommendations for secondary coronary heart disease prevention.  A larger study 
population would have increased the power to detect differences in blood and dietary n-3 HUFA 
measurements between advice groups and sexes.  
 
Conclusion 
 The % of DHA in erythrocytes captures long term adherence to n-3 HUFA intakes and 
could be an appropriate marker of adherence in long term trials.  Short term blood biomarkers of 
n-3 HUFA status can increase for men following dietary advice to consume EPA + DHA from 
seafood, functional food or nutraceutical sources alone or in combination while n-3 HUFA 
biomarkers can increase for women following Nutraceutical or Combined advice.  Any of these 
strategies could be used to increase intakes of EPA + DHA to those currently recommended for 
healthy individuals (0.25 - 0.5 g/d) while functional foods should be consumed in combination 
with other sources to achieve higher intakes of EPA + DHA (≥0.5 g/d).  Strategies to improve 
adherence to such dietary advice beyond 12 weeks are needed and the effect of increased follow-
up frequency over the long term warrants investigation.  Sex differences in blood n-3 HUFA 
biomarker responses also indicates that advice tailored to the traits of individuals should be 
explored.           
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Table 6.1.  Characteristics of dietary advice study participants. 
  






















          Female 24 (26) 53 (54) 6 (7) 55 (54) 6 (7) 55 (58) 6 50 6 55 
Male 21 (22) 47 (46) 5 (6) 46 (46) 5 (5) 45 (42) 6 50 5 45 
Cultural/Racial Background 
          Caucasian 39 (40) 87 (83) 10 (11) 91 (85) 10 (10) 91 (83) 10 83 9 82 
Chinese 3 (3) 7 (6) 0 (0) 0 (0) 1 (1) 2 (2) 1 8 1 9 
Latin American 2 (3) 4 (6) 1 (1) 9 (8) 0 (1) 0 (2) 1 8 0 0 
West Asian 0 (1) 0 (2) 0 (1) 0 (8) 0 (0) 0 (0) 0 0 0 0 
Mixed 1 (1) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 0 1 9 
Education  
          Some High School 1 (1) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 0 1 9 
High School or Current Student 3 (4) 7 (8) 1 (2) 9 (15) 0 (0) 0 (0) 2 17 0 0 
Trade, Technical/Vocational School or Business College 4 (4) 9 (8) 0 (0) 0 (0) 2 (2) 18 (17) 1 8 1 9 
Community College, CEGEP or Nursing School 7 (7) 16 (15) 3 (3) 27 (23) 1 (1) 9 (8) 2 17 1 9 
Bachelor's Undergraduate Degree or Teacher's College 20 (20) 44 (42) 4 (4) 36 (31) 7 (7) 64 (58) 4 33 5 45 
Master's Degree 8 (9) 18 (19) 3 (4) 27 (31) 1 (1) 9 (8) 1 8 3 27 
Earned Doctorate 1 (1) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 1 8 0 0 
Professional Degree
2
 1 (2) 2 (4) 0 (0) 0 (0) 0 (1) 0 (8) 1 8 0 0 
Annual Household Income, Canadian Dollars 
          <$25,000 3 (3) 7 (6) 0 (0) 0 (0) 1 (1) 9 (8) 0 0 2 18 
$25,000-$50,000 6 (7) 13 (15) 1 (2) 9 (15) 3 (3) 27 (25) 1 8 1 9 
$50,000-$75,000 15 (16) 33 (33) 6 (6) 55 (46) 1 (2) 9 (17) 3 25 5 45 
$75,000-$100,000 4 (5) 9 (10) 0 (1) 0 (8) 2 (2) 18 (17) 2 17 0 0 
>$100,000 16 (16) 36 (33) 4 (4) 36 (31) 4 (4) 36 (33) 5 42 3 27 
undisclosed 1 (1) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 1 8 0 0 
Smoking 
          Non-Smoker 30 (33) 67 (69) 6 (8) 55 (62) 8 (9) 73 (75) 8 67 8 73 
Ex-Smoker 13 (13) 29 (27) 4 (4) 36 (31) 2 (2) 18 (17) 4 33 3 27 
Current Smoker 2 (2) 4 (4) 1 (1) 9 (8) 1 (1) 9 (8) 0 0 0 0 
Regular Nutraceutical Use 31 (33) 69 (69) 7 (8) 64 (62) 8 (9) 73 (75) 8 67 8 73 
Oral Contraceptive Use 2 (2) 4 (4) 1 (1) 9 (8) 1 (1) 9 (8) 0 0 0 0 
Values outside brackets represent completers and (values inside brackets represent intention to treat participants). 
         
1 Percentage of dietary advice group population. 2 Medicine, dentistry, veterinary medicine, optometry or law. 





Figure 6.1.  Whole blood % n-3 HUFA in total HUFA by men (A) and women (B) completers in 
each advice group over time.  (*) represents a significant difference from baseline within each 
advice group (by sex) by Bonferroni's post-hoc test following a significant F-value by the linear 
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Figure 6.2.  Percent DHA (A) and EPA (B) over time in erythrocytes, plasma and whole blood 
by completers.  (*) represents a significant difference from the week 0 measurement within each 
blood fraction over time by Bonferroni's post-hoc test following a significant F-value by the 
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Figure 6.3.  Intake, by completers, of the sum of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) from 3-d dietary records in Seafood, Functional Food, 
Nutraceutical and Combined advice groups.  Values are geometric means.  (*) represents a 
significant difference from the week 0 measurement in each dietary advice group by Bonferroni's 
post-hoc test following a significant F-value by repeated measures linear mixed model 













































Table 6.2. EPA and DHA estimates by 3-d dietary records and 3-d food duplicate collections by 
completers. 
  3-d Dietary Records 3-d Food Duplicates 




      All, n=45 0.37 
 
(0.27 - 0.51) 0.30 
 





 (0.30 - 0.75) 0.31 
a,b
 (0.22 - 0.44) 
Functional Food 0.15 
b
 (0.05 - 0.48) 0.12 
b
 (0.05 - 0.29) 
Nutraceutical 0.60 
a
 (0.51 - 0.71) 0.62 
a
 (0.32 - 1.19) 
Combined 0.40 
a,b
 (0.29 - 0.55) 0.32 
a,b




      All, n=45 0.46 
 
(0.35 - 0.59) 0.38 
 
(0.30 - 0.49) 
Seafood 0.82 
a
 (0.53 - 1.27) 0.57 
a
 (0.39 - 0.82) 
Functional Food 0.30 
b
 (0.12 - 0.79) 0.22 
b
 (0.11 - 0.44) 
Nutraceutical 0.39 
a,b
 (0.32 - 0.47) 0.46 
a,b
 (0.28 - 0.76) 
Combined 0.44 
a,b
 (0.29 - 0.65) 0.37 
a,b
 (0.25 - 0.55) 
1 
Values are geometric means and were loge transformed for statistical analyses. 
2 
Significant difference between dietary record and food duplicate measurements within row by 
paired t-test (p < 0.05). 
Different letters represent differences between advice groups for a fatty acid measurement within 







Table 6.3.  Results of linear regression determining the association of sex, body mass index and n-3 HUFA intake on blood 
biomarkers for completers (n=45) 
  
Erythrocyte DHA 
wt% of total fatty acids   
Whole Blood 
% n-3 HUFA in total HUFA 
  B p 95% CI 
 
B p 95% CI 
Sex 0.26 0.02 0.04 - 0.48 
 
3.51 <0.01 2.10 - 4.92 
Body Mass Index, kg/m
2
 -0.05 <0.01 -0.07 - -0.03 
 
-0.19 <0.01 -0.33 - -0.05 
DHA / EPA + DHA Intake
1
, g/d 0.06 0.19 -0.03 - 0.14   1.90 <0.01 1.42 - 2.38 
1
DHA intake evaluated for association with erythrocyte DHA; EPA + DHA intake evaluated for association with whole 





BLOOD BIOMARKER RESPONSES TO LOW DOSES OF EPA AND DHA 
 IN MEN AND WOMEN 
 
Introduction  
 Data linking diet and blood n-3 HUFA levels is mainly limited to interventions with EPA 
+ DHA doses of 1g/d or higher (Blonk et al., 1990; DiStasi D. et al., 2004; Katan et al., 1997) 
and background dietary intake of EPA and DHA is not estimated.  In addition, at low levels of 
EPA + DHA intake typical of Western diets, women have higher blood levels of DHA as 
compared with men (Bakewell, Burdge, and Calder, 2006; Stark, 2008a), but this sex difference 
disappears with high dose fish oil supplementation (Metherel et al., 2009).  Characterization of 
the blood dose-response relationship following low intakes of EPA + DHA in men and women is 
necessary to enable a mechanistic link between dietary EPA and DHA intake and proposed EPA 
+ DHA blood level targets for coronary heart disease protection (Armstrong, Metherel, and 
Stark, 2008; Harris and Von Schacky, 2004; Stark, 2008a).  Clearly defining the diet-blood 
relationship will also be informative for establishing dietary recommendations for EPA + DHA.  
The aim of the present study is to examine whole blood, plasma phospholipid and red blood cell 
n-3 HUFA levels in men and women in response to intakes of 0.25 and 0.5 g/d EPA + DHA.  
The dose-response to 1.0 g/d EPA + DHA will also be examined in a subset of participants. 
 
Methods and Materials 
 Participants aged 18-35 y were recruited from October 7-21, 2011 from the University of 




(50/50% males/females) was initially targeted.  This provides 80% power to detect a 0.8 unit 
difference in % DHA in erythrocytes measurements between men and women, as determined 
from variability of observed in previous work in a similar population (α = 0.05) (Metherel et al., 
2009).  At a screening visit, individuals provided a finger-tip prick whole blood sample and 
completed a semi-quantitative FFQ specific for EPA and DHA intake (Patterson et al., 2012) and 
health screening form (Appendix C).  Individuals consuming nutraceuticals containing EPA and 
DHA and those with >3% EPA + DHA in total fatty acids as determined by finger-tip prick fatty 
acid profiling were excluded from the study.   
 At baseline, anthropometric measurements and a fasting venous blood sample were 
collected.  Participants were instructed to not consume any seafood, EPA/DHA-enriched 
functional foods or EPA/DHA-containing nutraceuticals other than those provided, and to 
otherwise maintain their usual diet and physical activity regimes during the study period.  Verbal 
and written instructions were provided to complete a 3-d dietary record to measure background 
caloric and macronutrient intake during the study (Appendix C).  Dietary records were returned 
within two weeks.  Fish body oil, supplying EPA and DHA largely in triacylglycerol form, was 
provided in 1g capsules (Webber Naturals Pharmaceuticals, Coquitlam, BC; NPN# 80002435). 
The ratio of EPA to DHA in the fish oil was 1.8:1 and the fatty acid composition of the fish oil 
capsules, assessed by gas chromatography, is presented in Appendix C.  Although industrial 
deodorization fish oil can generate trans isomers of fatty acid, their concentrations are typically 
low (Sciotto and Mjos, 2012).  The present gas chromatography protocol was not able to resolve 
all trans isomers.  Participants were instructed to consume one capsule per day (providing 0.24 
g/d EPA + DHA) in weeks 1 through 4.  More fish oil capsules were provided at week 4 and 




weeks 5 through 8.  A convenience subset of participants (n=5; 1 F, 4 M) continued the study in 
weeks 9 through 12 and consumed four capsules per day (providing 0.95 g/d EPA + DHA).  
Adherence to the supplementation protocol was verified with finger-tip prick blood samples 
analyzed for fatty acid composition weekly from baseline through week 8 and again in week 12.  
Additional strategies were discussed to ensure adherence with the study protocol such as 
routinely taking capsules at the same time every day and setting a daily electronic reminder.  
Capsules were provided in excess and counts were performed weekly from baseline through 
week 12 as an additional measure of adherence.   
 Venous blood samples were collected in tubes spray-coated in lithium heparin 
(Vacutainer; Becton Dickinson, Franklin Lakes, NJ) at baseline, weeks 4 and 8 (n=20), and at 
week 12 (n=5) for whole blood, plasma phospholipid and erythrocyte fatty acid determinations.  
A 22:3n-3 ethyl ester internal standard (NuCheck Prep, Elysian, MN) was used for all venous 
blood fatty acid analyses.  Individual fatty acids were expressed as a percentage of total fatty 
acids and as a concentration (fatty acid mass per mass of sample).  The baseline FFQ and 
anthropometric measurements were repeated at week 8.  Participants were instructed to consider 
their intake during the study period only for the week 8 FFQ.   
 Plasma phospholipid lipid classes were isolated using thin layer chromatography.  Plasma 
total lipids were extracted in the presence of 1,2-diheptadecanoyl-sn-glycero-3-
phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL), triheptadecanoin (Nu-Check Prep, 
Elysian, MN) and cholesteryl heptadecanoate (Nu-Check Prep, Elysian, MN) as internal 
standards.  Total lipids were applied to silica gel plates (250 µm thickness, 60 Å pore size, 
Whatman, Maidstone, England), which had been pre-washed in 4:1 chloroform:methanol and 




Ottawa, ON).  The plates were then treated with a 0.1% solution of dichlorofluorescein (Sigma, 
St. Louis, MO) and examined under ultraviolet light to visualize and the isolated phospholipid 
fraction was collected, in the presence of the anti-oxidant butylated hydroxytoluene, for 
transesterification and fatty acid analysis.   
Participants were not blinded to the intervention.  A single researcher who was not 
blinded performed recruitment, sample collection, partial sample analyses and all data analysis.  
Additional researchers performed fatty acid analyses of the blood samples that were identified by 
a numeric code. 
 
Statistical Analyses 
 Entry characteristics, including baseline anthropometric and dietary intakes were 
compared between males and females using independent t tests.  Sex differences were not 
examined at week 12 due to the small sample (n=5).  Baseline and week 8 anthropometric and n-
3 HUFA intake measurements were compared by paired t tests.  The linear mixed models 
procedure for repeated measures was used to examine the effect of EPA + DHA dose, sex and 
their interaction as fixed factors on blood fatty acid measurements in plasma phospholipids, 
erythrocytes and whole blood in weeks 0 through 8 (n=20).  This procedure was also conducted 
on the subgroup (n=5) for weeks 0 through 12 with EPA + DHA dose alone included as a fixed 
factor in the model.  Blood n-3 HUFA biomarker measurements were compared between blood 
fractions at baseline and following the 0.25 and 0.5 g/d EPA + DHA doses by the linear mixed 
models procedure.  Following the determination of a significant F-value by the linear mixed 
models procedure, individual means were examined with Bonferroni's post hoc analyses.  




blood n-3 HUFA biomarkers.  The association of sex, body mass index and dietary fatty acid 
intake with blood fatty acid measurements were examined by linear regression.  Specifically, the 
association of dietary DHA intake with the % DHA in erythrocytes and dietary EPA + DHA 
intake with % n-3 HUFA in total HUFA in whole blood was examined (n=20).   
 
Results 
Participant Flow, Characteristics and Anthropometric Measurements 
 A total of 35 (17 M, 18 M) individuals were screened and 21 (11 M, 10 F) individuals 
met the eligibility criteria and participated in the 8-week study.  Of those who were screened but 
not admitted to the study; 11 had blood levels of EPA + DHA above the cut-off and/or were 
consuming fish oil nutraceuticals, one had anemia, one would not be able to attend weekly study 
visits, and one could not consume the gelatin fish oil capsules for religious reasons.  During the 
study period, one female participant increased fish consumption, as determined by high blood 
EPA + DHA and self report, despite explicit instructions to avoid seafood.  Given the primary 
purpose of the present study on the metabolic relationship between diet intake and blood levels 
of EPA + DHA, this individual was excluded from data analyses.  A total of 20 (11 M, 9 F) 
participants were included in the final results. 
 The final study population consisted of adult men and women, 23.3 ± 4.0 years of age.  
At baseline, men had a higher body mass (men: 83.4 ± 15.4 kg, women: 64.2 ± 4.4 kg) than 
women (p < 0.01).  By paired t test, body mass did not change between baseline and week 8 for 
men (p = 0.23) or women (p = 0.20).  Body mass index was similar for men and women 
(baseline; men: 25.9 ± 3.8 kg/m
2
, women: 23.4 ± 2.6 kg/m
2
) (p = 0.11). One female participant 




were otherwise reported.   
 
Dietary Intake 
 Background energy and macronutrient intakes were determined by 3-d dietary record at 
baseline.  Energy intake was higher by men (men: 2699 ± 754 kcal/d, women: 1862 ± 412 kcal/d, 
p = 0.01) but the percentage of energy from protein (men: 17.3 ± 4.2 % kcal/d, women: 16.4 ± 
3.6 % kcal/d, p = 0.62), carbohydrate (men: 49.2 ± 4.6 % kcal/d, women: 55.6 ± 9.2 % kcal/d, p 
= 0.06) and total fat (men: 32.3 ± 4.0 % kcal/d, women: 28.8 ± 5.3 % kcal/d, p = 0.12) was 
similar between men and women. Background EPA + DHA intake was 0.07 ± 0.05 g/d at 
baseline and 0.03 ± 0.03 g/d at week 8 as determined by FFQ (Table 7.1).  Background intake of 
EPA + DHA did not differ by sex at baseline or week 8 (baseline: p = 0.93, week 8: p = 0.31).  
For women, background EPA intake decreased in week 8 from the baseline measurement (p = 
0.04).  By summing background intake estimated by the FFQ and EPA + DHA supplied by the 
fish oil capsules, EPA + DHA intake was 0.27 ± 0.03 g/d (men) and 0.26 ± 0.02 g/d (women) in 
weeks 1-4, 0.51 ± 0.03 g/d (men) and 0.50 ± 0.02 g/d (women) in weeks 5-8 and 0.98 ± 0.02 g/d 
(men & women, n=5) in weeks 9-12.      
 
EPA and DHA in Finger-Tip Prick Whole Blood 
 The % EPA and % DHA in finger-tip prick whole blood rose following one week of 
supplementation and reached a plateau after two weeks at each of the 0.25g/d and 0.5g/d EPA + 
DHA doses (effect of dose, p < 0.01, for both % EPA and % DHA) (Figure 7.1).  This pattern 
indicates good compliance with the fish oil supplementation protocol and that four weeks were 




0.25 and 0.5 g/d EPA + DHA doses.  The % EPA in finger-tip prick whole blood was higher in 
males at baseline (males: 0.46 ± 0.13, females: 0.31 ± 0.05) and higher in females at week 8 
(males: 1.07 ± 0.18, females: 1.24 ± 0.15, effect of dose x sex interaction, p < 0.01). 
 
Omega-3 Blood Biomarkers 
 Intake of EPA + DHA was highly correlated with both the % n-3 HUFA in total HUFA 
in whole blood (n=20: r =0.88, n=5: r =0.86, p < 0.01 for both) and the % EPA + DHA in 
erythrocytes (n=20: r =0.66, n=5: r =0.78, p < 0.01 for both) (Figure 7.2).  The % n-3 HUFA in 
total HUFA in whole blood was also highly correlated with the % EPA + DHA in erythrocytes 
(n=20:  r =0.77 and n=5: r =0.82, p < 0.01 for both) Figure 7.3.  The 95% confidence intervals 
for the % n-3 HUFA in total HUFA biomarker were distinct at each level of EPA + DHA intake 
in each of the venous blood fractions and in finger-tip prick blood (Table 7.2).  For the % EPA + 
DHA in erythrocytes, the 95% confidence intervals measured at baseline and following 0.25 g/d 
EPA + DHA overlapped in each of the venous blood fractions.  Following 1 g/d EPA + DHA, 
the % n-3 HUFA in total HUFA in whole blood by finger-tip prick was 34.7 ± 2.1 % (95% CI: 
32.04 - 37.3 %) and the % EPA + DHA in erythrocytes was 6.1 ± 0.3 % (95% CI: 5.7 - 6.4 %).  
 As in finger-tip prick blood, the % n-3 HUFA in total HUFA increased following the 
0.25g/d and the 0.5 g/d EPA + DHA doses in venous blood fractions (effect of dose, p < 0.01, for 
each blood fraction) (Figure 7.4).  Differences between blood fractions for the % EPA + DHA 
measurement varied following baseline and post-supplementation measurements but generally, 
values were lowest in the finger-tip prick whole blood, intermediate in venous whole blood and 





EPA and DHA in Specific Blood Fractions 
 In general, the EPA and DHA responses in whole blood reflected observations in finger-
tip prick blood.  The % EPA in whole blood increased with increasing EPA + DHA intakes 
however the increase in the % DHA was only significant after the 0.5 g/d EPA + DHA dose 
(effect of dose, p < 0.01, for both fatty acids) with evidence of higher DHA levels in women 
(effect of sex, p = 0.01).  The consumption of 1g/d EPA + DHA resulted in further increases in 
the % EPA and % DHA in whole blood (effect of dose, p < 0.01, for both fatty acids).  In 
addition to these relative percentage changes in EPA and DHA, the total concentration of fatty 
acids in whole blood increased during the intervention as concentrations of total saturated, 
monounsaturated, and polyunsaturated fatty acids all increased (p < 0.01, for each).  The changes 
in the % EPA and DHA in erythrocytes were similar to those in whole blood, but total fatty acid 
concentrations did not change (p = 0.15).  In plasma phospholipids, the % EPA responded to 
increasing intakes similar to whole blood and erythrocytes.  The % DHA increased in the plasma 
phospholipid of women only at 0.5g/d EPA+DHA (effect of dose x sex interaction, p = 0.01).  
The subgroup (n=5) taking 1.0 g/d EPA+DHA was predominantly male (n=4) and significant 
increases in the % DHA in phospholipids was observed relative to baseline and 0.5 g/d of EPA + 
DHA (effect of dose, p < 0.01).  The total fatty acid concentration in plasma phospholipids 
increased at 0.5 g/d EPA + DHA in men and at 0.25 g/d EPA + DHA in women (effect of dose x 
sex interaction, p < 0.01) with men having higher total fatty acid concentrations in plasma 
phospholipids after 0.5 g/d EPA + DHA.  These changes in total fatty acid concentration were 
similar in each of the major fatty acid classes (effect of dose x sex interaction, saturates: p = 





Sex Differences in Omega-3 HUFA Ratios 
 The ratio of DHA:EPA was higher in women as compared with men at baseline in each 
of the venous blood fractions and in finger-tip prick blood (Figure 7.5, meaningful comparisons 
shown).  Following one week of supplementation, the DHA:EPA ratio decreased in both men 
and women and sex differences disappeared (effect of dose x sex interaction in finger-tip prick 
blood, p < 0.01).  The ratio of DHA:DPAn-3 was higher in women than men in each blood 
fraction and increased in week 8 in whole blood (effect of time, p < 0.01).       
 
Relationship of body mass index, sex and dietary n-3 HUFA intake with blood n-3 HUFA 
 Overall, the % DHA in erythrocytes was positively associated with DHA intake and 
female sex, and the % n-3 HUFA in total HUFA in whole blood was positively associated with 
EPA + DHA intake and female sex (Table 7.3).   There was no association of body mass index 
or body mass (data not shown) with blood n-3 HUFA biomarkers.   
 
Discussion 
 The aim of this study was to examine blood biomarker response following intakes of 0.25 
and 0.5 g/d EPA + DHA in men and women.  The response to 1 g/d EPA + DHA was also 
examined in a small subset of participants.  Strengths of this study are the combination of 
detailed dietary intake information, through controlled dietary supplementation and measurement 
of background EPA + DHA intake, with comprehensive blood fatty acid assessment, and weekly 
visitations that included blood fatty acid profiling to encourage adherence.  A dose-response 
relationship was observed for blood n-3 HUFA biomarkers with low doses of EPA + DHA.  The 




from blood n-3 HUFA biomarkers or conversely, predicting the blood biomarker response to 
dietary EPA + DHA intake.  The linear relationship presented in Figure 7.3 has application in 
conversion between commonly reported blood n-3 HUFA biomarkers.  The ratio of blood 
DHA:EPA was greater in women than men at baseline and this sex difference disappeared with 
supplementation.  
 Quartiles of the % EPA + DHA in erythrocytes associated with risk of primary cardiac 
arrest have been examined (Siscovick et al., 1995).  Specifically, 2-4% EPA + DHA in 
erythrocytes was associated with the greatest risk of primary cardiac arrest.  Relative to this 
quartile, quartiles defined by 4.1-4.6%, 4.7-5.4% and 5.5-10.9% EPA + DHA in erythrocytes 
were associated, respectfully, with 50%, 70% and 90% primary cardiac arrest risk reduction.  In 
the present study, the baseline 3.80 ± 0.55% EPA + DHA in erythrocytes falls within the quartile 
associated with the greatest risk of primary cardiac arrest.  Supplementation at 0.25 g/d EPA + 
DHA resulted in 4.15 ± 0.56 % EPA + DHA in erythrocytes, which would correspond with 50% 
risk reduction, and supplementation at 0.5 g/d EPA + DHA resulted in 4.94 ± 0.57 % EPA + 
DHA in erythrocytes, which would correspond with 70% risk reduction.  Supplementation at 1 
g/d EPA + DHA resulted in 6.1 ± 0.3 % EPA + DHA in erythrocytes, which would correspond 
with 90% risk reduction.  Relating results of the present dose-response study with quartiles of 
primary cardiac arrest risk suggests that current intake guidelines of <1 g/d EPA + DHA for 
healthy individuals may result in partial, but not maximal coronary heart disease protection.     
 Current evidence suggests that EPA and DHA have shared and complementary benefits 
for cardiovascular health (Mozaffarian and Wu, 2012).  Expressing n-3 HUFA status as a 
biomarker, such as the % n-3 HUFA in total HUFA which models competition between HUFA 




and DHA are typically consumed together but in varying ratios.  The distinct 95% confidence 
intervals for the % n-3 HUFA in total HUFA measured following baseline and the 0.25 and 0.5 
g/d EPA + DHA doses provides support for application of n-3 HUFA biomarkers towards 
characterizing intakes of EPA and DHA (Table 7.2).  The % n-3 HUFA in total HUFA is a ratio, 
therefore its value is consistent when determined from blood fatty acid composition expressed as 
a percentage of the total fatty acid pool or as a concentration and thereby overcomes any effects 
of total blood fatty acid concentration changes. Using the equation in Figure 7.3, levels of the % 
EPA + DHA in erythrocytes associated with primary cardiac arrest (Siscovick et al., 1995) can 
be converted to the whole blood % n-3 HUFA in total HUFA.  Specifically, the % EPA + DHA 
in erythrocytes quartiles of 2.0 - 4.0%, 4.1 - 4.6%, 4.7 - 5.4% and 5.5 - 10.9% is equivalent to 
15.5 - 25.1%, 25.5 - 27.9%, 28.4 - 31.8% and 32.3 - 58.1% n-3 HUFA in total HUFA in whole 
blood.  Supplementation with 0.25 g/d, 0.5 g/d and 1.0 g/d in the present study was associated 
with 27%, 31% and 35% n-3 HUFA in total HUFA. 
 A prior dose-response study equated intake of 0.5 and 1 g/d EPA + DHA with 8% and 
10% EPA + DHA in erythrocytes, respectfully (Harris and Von Schacky, 2004).  Background 
dietary EPA + DHA intake was not considered in calculation of the total EPA + DHA dose and 
high baseline % EPA + DHA in erythrocytes of 4.7 ± 0.9% suggests 0.4 - 0.5 g/d of EPA + DHA 
were regularly consumed based on the present data.  The 8% and 10% values were based on fatty 
acid determinations using a 10-minute heating protocol that fails to transesterify fatty acids in 
amide linkages of sphingolipids to fatty acid methyl esters (Armstrong, Metherel, and Stark, 
2008).  Although sphingomyelin is a minor component of erythrocyte lipids (8% by wt of total 
lipids (Christie, 1985)), the EPA and DHA content of sphingolipids is lower than 




results in a lower summation of the total fatty acids that in turn overestimates the % of EPA + 
DHA in total fatty acids.  Unfortunately, the number and identity of fatty acids included in the 
total fatty acids is typically undefined.  The number of fatty acids included can vary due to 
chromatography techniques, but also the practice of only including fatty acids that have been 
identified.  The ability to identify fatty acids is also dependent on analytical methods and 
includes differences in peak identification practices such as external references of mathematical 
determinations in addition to chromatography protocols.  Any omission of a fatty acid from the 
total fatty acids summation leads to a smaller denominator and a higher estimated % EPA + 
DHA.  Total fatty acids included in calculations herein include all those presented in a prior 
blood fatty acid characterization study (Armstrong, Metherel, and Stark, 2008) and unidentified 
peaks determined to be fatty acids are included in the calculation of total fatty acids.  In contrast, 
the % n-3 HUFA in total HUFA has a clearly defined numerator and denominator (Stark, 
2008b).  Methodological consistency and transparency is critical to establish a clear link between 
EPA + DHA intake and blood biomarker targets and method standardization is needed to 
facilitate between-study comparisons.   
 Blood levels of DHA are generally higher in women as compared with men in societies 
consuming low n-3 HUFA intakes (Bakewell, Burdge, and Calder, 2006; Crowe et al., 2008; 
Giltay et al., 2004; Metherel et al., 2009).  Although baseline sex differences in % DHA in blood 
did not reach statistical significance in the present study, the baseline sex differences in the ratio 
of DHA:EPA in erythrocytes, plasma phospholipid and whole blood were significant and 
disappeared with EPA + DHA supplementation.  Sex differences in endogenous synthesis of 
DHA along the n-3 elongation/desaturation pathway may contribute to baseline sex differences 




in endogenous DHA synthesis, likely through feedback inhibition.  The conversion of stable-
isotope labelled 22:5n-3 to DHA is greater in women than men consuming very low amounts of 
EPA + DHA (0.06 g/d) and sex differences in 22:5n-3 to DHA conversion disappear following 
higher intakes of EPA + DHA (0.56 g/d) (Pawlosky et al., 2003a).  Although tracer studies with 
fatty acid stable isotopes is the preferred measure of endogenous DHA synthesis, substrate to 
product ratios for n-3 HUFA are often interpreted as crude indicators of endogenous synthesis. 
The ~2:1 ratio of EPA:DHA in the fish oil capsules may also contribute to the convergence of 
the DHA:EPA ratio between men and women, and the decrease of the ratio with fish oil 
supplementation.   
 Levels of n-3 HUFA biomarkers achieved following supplementation by the present 
study population reflect those of adults under the age of 35, consuming <0.25 g/d EPA + DHA at 
baseline as determined by FFQ.  The n-3 HUFA levels achieved reflect 4-week supplementation 
periods at each dose.  Weekly finger-tip prick analysis suggests four weeks were sufficient for 
whole blood n-3 HUFA levels to plateau following 0.25 and 0.5 g/d EPA + DHA doses.  The 
potential for plasma phospholipid and erythrocyte n-3 HUFA levels to continue to rise beyond 
four weeks cannot be discounted but is not anticipated for these low EPA + DHA doses based on 
prior work (Barcelo-Coblijn et al., 2008; Katan et al., 1997).  The stepwise supplementation 
protocol was selected to allow further time for full fatty acid incorporation into blood pools at the 
higher doses while keeping the overall study duration sufficiently short to promote adherence 
with the protocol.  This design has been previously used to examine the blood dose-response 
relationship to n-3 HUFA supplementation (Von Schacky C., Fischer, and Weber, 1985).  
Although no control group was examined, background intakes of EPA + DHA were measured by 




A larger study population would add to the predictive quality of dose-response curves and a 
wider range of ages would assist in generalization of predictive equations to additional 
populations including infants, children and the elderly.   
  Sex-specific changes in plasma phospholipid total fatty acid concentrations following the 
0.5 g/d EPA + DHA dose may contribute to the sex differences in the % DHA in plasma 
phospholipid response.  Sex and dose-related differences in triacylglycerol-lowering following 
EPA + DHA supplementation, accompanied by lower VLDL cholesterol and higher LDL and 
HDL cholesterol, have been observed (Caslake et al., 2008).  Sex-related differences in the % 
DHA in plasma phospholipid response may be related to lipoprotein metabolism.  This 
observation provides support that the plasma phospholipid is not an ideal blood fraction for 
routine n-3 HUFA status assessment.  The requirement of additional time and resources for 
plasma phospholipid isolation prior to fatty acid analysis make it unfeasible for routine fatty acid 
profiling to determine n-3 HUFA status.   
 The observation of measureable increases in n-3 HUFA biomarkers over baseline levels 
following an EPA + DHA dose as low as 0.25 g/d is potentially of great interest to food, 
beverage, and nutraceutical industries and related ingredient suppliers.  The ability to enhance 
the n-3 HUFA composition of a functional food product is limited by potential changes to 
sensory properties and regulations specific to countries (Health Canada, 2007b; Kishi et al., 
2011).  Nutraceutical products supplying doses of EPA + DHA ≤0.5 per serving are widely 
available to consumers and additional low-dose products have become available recently such as 
smaller, easy-to-swallow capsules, and products for children.  The ability of a low dose of EPA + 
DHA to increase blood n-3 HUFA biomarkers above levels associated with the lowest coronary 








 Levels of the % n-3 HUFA in total HUFA blood biomarker determined in this dose-
response study could be applied towards determining whether EPA and DHA intake is below, at, 
or above currently recommended levels for adults.  The % n-3 HUFA in total HUFA is a 
particularly useful biomarker of n-3 HUFA status due to ease of sample preparation, equivalent 
magnitude in whole blood and erythrocytes at each level of EPA and DHA intake, 
responsiveness to increases in EPA + DHA intake as low as 0.18 g/d, a specifically defined 
numerator and denominator, resistance to changes in total blood fatty acid concentration, and 
applicability to high-throughput fatty acid analyses through minimally-invasive finger-tip prick 
assessment.  Supplementation with 0.25 g/d EPA + DHA at a ratio of 2:1 removed baseline sex 
differences in the blood DHA:EPA ratio.  This finding could be applied towards EPA + DHA 
dose targeting in costly fatty acid stable isotope studies to determine the n-3 HUFA dose at 
which sex differences in endogenous DHA synthesis disappear.  Understanding sex differences 
in endogenous DHA synthesis has application in establishing dietary intake recommendations 












mean ± sd 95% CI CV 
 
mean ± sd 95% CI CV 
  g/d g/d % 
 
g/d g/d % 
Week 0  
       EPA 0.02 ± 0.02 (0.01 - 0.03) 90 
 
0.02 ± 0.01 (0.01 - 0.03) 60 
DHA 0.05 ± 0.04 (0.02 - 0.08) 83 
 
0.05 ± 0.03 (0.03 - 0.08) 58 
EPA + DHA 0.07 ± 0.06 (0.03 - 0.11) 85 
 
0.07 ± 0.04 (0.04 - 0.11) 56 
Week 8  
       EPA 0.01 ± 0.01 (0.00 - 0.02) 96 
 
0.01 ± 0.01 (0.00 - 0.01) 113 




 (0.01 - 0.03) 89 
EPA + DHA 0.04 ± 0.03 (0.02 - 0.05) 71   0.02 ± 0.02 (0.01 - 0.04) 100 
1





Figure 7.1. EPA, DHA and sum of n-3 HUFA in finger-tip prick whole blood at week 0 and 
following EPA + DHA intakes of 0.25g/d (weeks 1-4) and 0.5g/d (weeks 5-8).  Different letters 
represent differences in individual means were determined by Bonferroni's post-hoc test 

























































Figure 7.2.  Response of the % n-3 HUFA in total HUFA in whole blood (A) and the % EPA + 
DHA in erythrocytes (B) to intake of EPA + DHA.  Intake is the sum of background EPA + 
DHA measured by FFQ and EPA + DHA supplied by fish oil supplementation.  Whole blood 
measurements are from finger-tip prick samples.  Linear dose-response equations are presented 
for participants consuming 0.25 g/d EPA + DHA in weeks 1-4 and 0.5 g/d EPA + DHA in weeks 
5-8 (n=20) and the sub group also consuming 1.0 g/d EPA + DHA in weeks 9-12 (n=5) from fish 
oil supplements.      
y = 21.50x + 20.45 



































EPA + DHA Intake, g/d 
n=20 n=5 
y = 2.63x + 3.56 








































Figure 7.3. Relationship between the % n-3 HUFA in total HUFA in whole blood and the % 
EPA + DHA in erythrocytes.  Whole blood measurements are from finger-tip prick samples.  
Linear dose-response equations are presented for participants consuming 0.25 g/d EPA + DHA 
in weeks 1-4 and 0.5 g/d EPA + DHA in weeks 5-8 (n=20) and the sub group also consuming 1.0 
g/d EPA + DHA in weeks 9-12 (n=5) from fish oil supplements. 
  
n=20:  y = 4.7945x + 5.889 




















































Table 7.2. n-3 HUFA biomarkers in erythrocytes, plasma phospholipid and whole blood fractions with supplementation. 
  Baseline   0.25 g/d EPA + DHA   0.5 g/d EPA + DHA 
  mean ± sd %CV 95% CI 
 
mean ± sd %CV 95% CI 
 
mean ± sd %CV 95% CI 
 
All Participants (n=20) 
Erythrocytes 
           EPA + DHA, wt% 3.80 ± 0.55 14.5 (3.60 - 4.05) 
 
4.15 ± 0.56 13.5 (3.96 - 4.40) 
 
4.94 ± 0.57 11.5 (4.74 - 5.19) 
HUFA Score 23.97 ± 2.03 8.5 (23.05 - 24.98) 
 
26.25 ± 2.11 8.0 (25.32 - 27.26) 
 
30.03 ± 2.08 6.9 (29.12 - 31.06) 
Plasma Phospholipid 
           EPA + DHA, wt% 3.75 ± 0.57 15.2 (3.49 - 4.03) 
 
4.03 ± 0.65 16.3 (3.74 - 4.28) 
 
4.93 ± 0.73 14.8 (4.71 - 5.25) 
HUFA Score 24.07 ± 2.66 11.0 (22.99 - 23.32) 
 
29.56 ± 2.04 6.9 (28.48 - 30.81) 
 
35.04 ± 3.71 10.6 (34.10 - 36.42) 
Venous Whole Blood 
           EPA + DHA, wt% 3.01 ± 0.36 11.9 (2.85 - 3.60) 
 
3.42 ± 0.37 10.9 (3.25 - 3.60) 
 
4.49 ± 0.55 12.3 (4.36 - 4.70) 
HUFA Score 23.28 ± 2.40 10.3 (22.35 - 24.31) 
 
26.60 ± 1.94 7.3 (25.68 - 27.64) 
 
31.47 ± 2.50 7.9 (30.64 - 32.60) 
Finger-Tip Prick Whole Blood 
EPA + DHA, wt% 2.34 ± 0.33 14.1 (2.19 - 2.50) 
 
3.06 ± 0.39 12.7 (2.87 - 3.24) 
 
4.11 ± 0.61 14.8 (3.83 - 4.30) 
HUFA Score 21.92 ± 1.97 9.0 (20.99 - 22.84) 
 
25.93 ± 1.96 7.6 (25.01 - 26.85) 
 








Figure 7.4.  The % n-3 HUFA in total HUFA (A) and % EPA+ DHA (B) throughout fish oil 
supplementation (weeks 1-4: 0.25 g/d EPA + DHA, weeks 5-8: 0.5 g/d EPA + DHA).  Columns 
with different letters within a time point are significantly different by Bonferroni's post-hoc test 
following a significant F-value by the linear mixed model procedure (p < 0.05).  (*) Represents a 
significant difference from the baseline measurement and (**) represents a significant difference 
from the week 4 measurement within each blood fraction.  Finger-tip prick determinations at 

























































































0.5 g/d EPA + DHA 0.25 g/d EPA + DHA 
Week 







   
Figure 7.5. DHA:EPA ratio for men and women in (A) finger-tip prick blood, (B) whole blood, (C) erythrocytes and (D) plasma 
phospholipids with supplementation. (*) represents a significant difference from men at a time/dose, (a) and (b) respectively represent 
a significant difference from the week 0 (0 g/d EPA+DHA) and week 4 (0.25 g/d EPA+DHA) measurements within each sex by Bonferroni's 
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Table 7.3.  Results of linear regression models determining the association of sex, body mass or body mass index and n-3 HUFA intake 
on n-3 HUFA blood biomarkers 
  Erythrocyte DHA, wt% of total fatty acids   Whole Blood % n-3 HUFA in Total HUFA 
  B p 95% CI   B p 95% CI 
Model 1 
       Sex 0.71 <0.01 0.35 - 1.06 
 
3.73 <0.01 1.34 - 4.12 
Body Mass, kg <0.01 1.00 -0.01 - 0.01 
 
0.04 0.10 -0.01 - 0.08 
DHA or EPA + DHA Intake
1
, g/d 3.52 0.04 0.11 - 6.92 
 
14.87 <0.01 12.75 - 17.00 
Model 2 
       Sex 0.64 <0.01 0.39 - 0.88 
 
2.14 <0.01 0.95 - 3.33 
Body Mass Index, kg/m
2
 -0.01 0.54 0.39 - 0.88 
 
0.05 0.56 -0.12 - 0.23 
DHA or EPA + DHA Intake
1
, g/d 3.98 <0.01 -0.05 - 0.03   14.71 <0.01 12.55 - 16.87 
1
DHA intake evaluated for association with red blood cell DHA; EPA + DHA intake evaluated for association with whole blood % n-3 






SUMMARY AND GENERAL DISCUSSION 
 
 The purpose of this thesis was to address the gap between observed and recommended 
intakes of EPA and DHA (Institute of Medicine of the National Academies, 2005; Kris-Etherton, 
Harris, and Appel, 2003; Kris-Etherton et al., 2007; United States Department of Agriculture, 
2010) through an examination of long-term adherence to conventional and novel dietary advice 
strategies.  Furthermore, the blood biomarker response to low intakes of EPA + DHA that are 
currently recommended was characterized to facilitate objective assessment of EPA + DHA 
intake and to inform the relationship between EPA + DHA intake and disease risk.  Due to 
infrequent consumption of concentrated n-3 HUFA sources, dietary survey assessment of EPA + 
DHA intake is challenging (Fratesi et al., 2009; Overby, Serra-Majem, and Andersen, 2009).  To 
complement biomarker and 3-d dietary record assessments, validation of an FFQ to measure 
EPA + DHA intakes from Canadian whole food, functional food and nutraceutical dietary 
sources was performed.  Overall, this thesis research is distinct in that it simultaneous 
characterizes EPA and DHA intake through comprehensive blood fatty acid and dietary survey 
assessment, examines sex effects on study outcomes, and considers conventional and novel 
dietary sources.  This information is useful for both basic research and clinical practice. 
 Findings herein facilitate interpretation of null conclusions in recent trials examining 
reduction in cardiovascular endpoints with EPA and DHA supplementation <1g/d.  In the Alpha-
Omega trial, an intervention targeting an intake of 0.38g/d EPA + DHA from a functional food 
margarine over 40 months did not reduce the rate of secondary cardiovascular events (Kromhout, 




trial, present findings indicate that adherence over 40 months to functional food intake is 
unlikely. Accordingly, findings herein do not support intention to treat analyses used to examine 
the effect of EPA + DHA intake on Alpha-Omega trial endpoints.  The % of EPA and DHA in 
plasma cholesteryl esters increased relative to the placebo group at 3, 20 and 40 months post-
intervention in a random subset of Alpha-Omega trial participants and was interpreted as a 
marker of adherence (Kromhout, Giltay, and Geleijnse, 2010).  EPA + DHA levels in plasma 
cholesteryl esters can change rapidly in response to recent dietary intake (Marsen et al., 1992).  
While the fatty acid composition of cholesteryl esters can reflect dietary fatty acids, it also 
reflects the specificity of lecithin:cholesterol acyl transferase for 18:1n-9 and 18:2n-6 and may 
be a poor marker of long term adherence relative to other fatty acid determinations of plasma 
fractions and erythrocytes (Stark, 2008a).  Presently, examining the % of DHA in erythrocytes 
was required to properly characterize long term adherence as plasma-based and EPA + DHA 
composite biomarkers appear to be influenced by recent diet intakes.  Accordingly, adherence 
was likely overestimated in the Alpha-Omega trial.  Examination of % DHA in erythrocytes as a 
marker of adherence and blood n-3 HUFA biomarkers in relation to the rate of cardiovascular 
events could be applied in future long-term trials.  Furthermore, the predictive equations 
developed herein have potential utility for interpreting the intervention literature when intake 
estimates are neglected. 
 The present observation of cessation of adherence following 12 weeks indicates that 
strategies to promote long-term adherence to intake of dietary n-3 HUFA sources are needed.  
Fatty acid profiling of finger-tip prick whole blood (Armstrong, Metherel, and Stark, 2008; 
Stark, 2008a) and the EPA + DHA specific FFQ can be rapidly evaluated.  To further promote 




by the FFQ to variability in EPA + DHA intake could be used to create a short screener tool from 
the present FFQ (Briefel, 2007).  The FFQ could also be made electronically available (Swierk et 
al., 2011) to facilitate provision of feedback, which could be made available instantly using 
automated software analysis.  Self monitoring with feedback can result in long-term weight loss 
following weight loss intervention (Burke et al., 2012) and application of feedback to sustaining 
EPA + DHA intake is worthy of investigation.  The FFQ and finger-tip prick fatty acid profiling 
are also useful research tools to  screen candidates for study participation.  Alternatively, routine 
clinical screening could be applied towards identifying individuals with low n-3 HUFA 
intakes/blood status so they can receive targeted advice to increase EPA + DHA intake. 
 Relating blood n-3 biomarkers to EPA + DHA intake and to coronary heart disease risk 
categories could be informative for deriving nutrient intake recommendations, especially given 
proposals that dietary reference intakes for EPA + DHA be made (Harris et al., 2009; Kris-
Etherton, Grieger, and Etherton, 2009).  Dietary guidelines, which inform consumers how to 
achieve nutrient intake recommendations through dietary sources, have conventionally promoted 
whole food sources.  Canada's food guide recommends two servings of fish per week (Health 
Canada, 2011).  Advice to use nutraceuticals are now appearing in official dietary guidelines, 
such a daily vitamin D supplement is recommended to Canadian adults over 50 years (Health 
Canada, 2011).   Based on the increase in blood n-3 HUFA biomarkers and dietary EPA + DHA 
intakes following dietary advice to consume nutraceuticals and full retention of participants in 
Nutraceutical and Combined advice groups presently, dietary recommendations for EPA + DHA 
nutraceuticals should be considered for inclusion in dietary guidelines.  Sex-specific advice may 
also be warranted as blood n-3 HUFA biomarkers increased for men but not women following 




 Risk of primary cardiac arrest has been evaluated in relation to quartiles of % EPA + 
DHA in erythrocytes (Siscovick et al., 1995).  This type of categorical classification helps 
account for inter-individual variability in the relationship between blood biomarkers and disease 
risk.  Presently, ranking individuals based on FFQ intake estimates resulted in reasonable 
agreement with ranks based on blood biomarker and dietary records.  FFQ intake measurements 
could also be expressed categorically to reduce measurement error associated with dietary 
assessment.  Categorization as meeting or not meeting intake guidelines would facilitate 
translating FFQ intake measurements to consumers, although may artificially relay the 
impression that risk is an all-or-nothing phenomenon.  
 Body mass negatively associated with n-3 HUFA blood biomarkers in the dietary advice 
study, but not in the controlled dose-blood response study.  The tight dietary controls in the latter 
study combined with the lack of a body mass association indicates that this may not be related to 
metabolic processing, but rather may be an indication of differences in adherence associated with 
body mass.  Higher baseline body mass index was an independent predictor of attrition in a trial 
examining dietary advice strategies for weight loss (Greenberg et al., 2009), a lower body mass 
index has been associated with following a Mediterranean dietary pattern (Schroder et al., 2004), 
and osteoporotic women with a lower body mass index had greater adherence to calcium and 
vitamin D supplementation as compared with women with a higher body mass index (Sanfelix-
Genoves et al., 2009).  It is also possible that the small study population in the dose-blood 
response study diminished the ability to detect an association of body mass with blood n-3 
HUFA biomarkers. 
 The overarching aims of this work were to examine practical strategies to meet EPA and 




its relationship to n-3 HUFA blood biomarker status.  Examination of the dose-response to low 
intakes of EPA + DHA facilitates an important connection between EPA + DHA intake, blood 
levels and disease risk.  Application of n-3 HUFA blood biomarkers to monitor adherence and 
evaluate disease risk has significant implications for interpreting long term trials examining n-3 
HUFA intake and chronic disease relationships.  Furthermore, equating n-3 HUFA blood 
biomarkers achieved following low doses with quartiles of primary cardiac risk reduction 
highlights need for defined and consistent EPA + DHA intake recommendations.  In practice, 
however, long term adherence to sustained intake of EPA + DHA presents a challenge for 
consumers and strategies, such as trait-based preferences, follow-up frequency and self-
monitoring, to improve adherence should be explored.  Finally, accurate dietary assessment is 
facilitated through combining multiple assessment tools.  Self-reported intakes by FFQ can be 
verified against predictive dose-response equations when combined with biomarker assessment 
and this comprehensive approach should be considered in study designs involving EPA and 
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Food Frequency Questionnaire 
 
INSTRUCTIONS:  Please answer the following background questions and subsequent 40 questions 
about your usual eating habits over the past 12 months.  
 
Date you answered this questionnaire: ______________________ 
 
Age:
(  ) Under 19 years (  ) 30-34 years  (  ) 45-49 years  (  ) 60-64 years 
(  ) 19-24 years  (  ) 35-39 years  (  ) 50-54 years  (  ) 65 years and over 
(  ) 25-29 years  (  ) 40-44 years  (  ) 55-59 years 
  




1.  What is your cultural/racial background? 
 
(  ) Caucasian 
(  ) Chinese 
(  ) South Asian (ex: East Indian, Pakistani, 
      Sri Lankan) 
(  ) African 
(  ) Filipino 
(  ) Latin American 
(  ) Southeast Asian (ex: Cambodian, 
Indonesian, Laotian, Vietnamese) 
(  ) Arab 
(  ) West Asian (ex: Afghan, Iranian) 
(  ) Japanese 
(  ) Korean 
(  ) Aboriginal  








2. What is the highest level of education you 
have attained? 
 
(  ) Some High School 
(  ) High School Diploma 
(  ) Diploma/Certificate from trade, technical or 
vocational school or business college 
(  ) Diploma/Certificate from community college, 
CEGEP or nursing school 
(  ) Bachelor’s undergraduate degree or 
teacher’s college 
(  ) Master’s degree 
(  ) Degree in Medicine, Dentistry, Veterinary 
Medicine, Optometry or Law 
(  ) Earned doctorate (ex: Ph.D.) 
(  ) Other: __________________________ 
 
3.  What is your annual household income? 
 
(  ) less than $25,000 
(  ) $25,000 - $50,000 
(  ) $50,000 - $75,000 
(  ) $75,000 - $100,000 




4.  What type of milk do you usually use? 
 
(  ) I do not drink milk 
(  ) Regular cow’s milk (non-omega-3) 
(  ) Regular soy milk (non-omega-3) 





(  ) Nielson, Dairy Oh! Homogenized milk 
(  ) Silk Plus, Omega-3 DHA soy milk 
(  ) So Good, Omega-3 DHA soy milk 
(  ) Other Omega-3 enriched milk 





5. How much omega-3 milk do you usually use 
per day (including milk added to tea, coffee, 
cereal, etc.)?  
 
(  ) None 
(  ) 1 tablespoon 
(  ) 2 tablespoons 
(  ) ¼ cup (62.5 mL) 
(  ) ½ cup (125 mL) 
(  ) 1-2 cups (250-500 mL) 
(  ) 2-3 cups (500-750 mL) 
(  ) 3 cups (750 mL) or more 
 
6. What kinds of margarine/spread do you 
usually use? (ex: On bread, vegetables, in 
cooking and baking, etc.) 
 
(  ) I don’t use any margarine/spread 
(  ) Regular margarine (non-omega-3) 
(  ) Becel, Omega-3 Plus Margarine 
(  ) Other Omega-3 enriched margarine 
Please specify brand:   
______________________________ 
 
7. How much omega-3 margarine/spread do 
you usually use per day?  
 
(  ) None 
(  ) 1-2 teaspoons 
(  ) 1 tablespoon 
(  ) 2 tablespoons 
(  ) 3 tablespoons 
(  ) 4 tablespoons 
(  ) 5-7 tablespoons 
(  ) 8 or more tablespoons 
 
8. What kinds of eggs do you usually eat 
(include eggs in baked goods/cooking)? 
 
(  ) Naturegg Breakfree omega-3 liquid eggs 
(  ) Naturegg Omega-3 eggs (in shell) 
(  ) Naturegg Omega-3 Pro eggs (in shell) 
(  ) Complements Omega-3 eggs  
(  ) President’s Choice Omega-3 eggs 
(  ) Gray Ridge Omega-3 large eggs 
(  ) Gray Ridge Omega-3 extra-large eggs 
(  ) Regular Chicken eggs 
(  ) Duck eggs 
(  ) Other Omega-3 enriched eggs 







9. On average, how many eggs do you usually 
eat per week (including eggs in baked 
goods/cooking)?   
 
(  ) I don’t eat eggs 
(  ) Less than 1 egg   
(  ) 1 to 2 eggs            
(  ) 3 to 5 eggs           
(  ) 6 or more eggs  
 
10. What kind of juice do you usually drink? 
 
(  ) I don’t drink juice 
(  ) Regular juice (non-omega-3) 
(  ) Tropicana Essentials, Omega-3 orange juice 
(  ) Minute Maid Fruit Solutions, Omega-3 mango, 
orange & passion juice 
(  ) President’s Choice, Oh Mega J orange juice 
(  ) Other Omega-3 enriched juice 
Please specify brand:  
___________________________ 
  
11. How much omega-3 juice do you usually 
drink per day?  
 
(  ) None 
(  ) less than one cup (<250 mL) 
(  ) 1 cup (250 mL) 
(  ) 1-2 cups (250-500 mL) 
(  ) 2-3 cups (500-750 mL) 
(  ) 3 cups (750 mL) or more 
 
12. What kind of yogurt do you usually eat? 
 
(  ) I don’t eat yogurt 
(  ) Regular yogurt (non-omega-3) 
(  ) Danone Danino yogurt 
(  ) Danone Danino Go yogurt drink  
(  ) Other Omega-3 enriched yogurt 
Please specify brand:         
_____________________________ 
 
13. How much omega-3 yogurt do you usually 
eat per week?   
 
(  ) none 
(  ) less than 1, 100 g pot 
(  ) 1, 100 g pot 
(  ) 2 to 3, 100 g pots 
(  ) 4 to 5, 100 g pots 
(  ) 6 to 7, 100 g pots 








14. What kind of bread do you usually eat? 
 
(  ) I don’t eat bread 
(  ) Regular bread (non-omega-3) 
(  ) Wonder+ Omega-3 bread with DHA 
(  ) Other Omega-3 enriched bread 
Please specify brand/type:  
 
 
15. How much omega-3 bread do you usually 
eat per day (fresh and toasted)? 
 
(  ) none 
(  ) less than 1 piece 
(  ) 1 piece 
(  ) 2 pieces 
(  ) 3 pieces 
(  ) 4 pieces 
(  ) 5-7 pieces 
(  ) 8 or more pieces 
 
16. What kind of cheese do you usually eat?  
 
(  ) I don’t eat cheese 
(  ) Regular cheese (non-omega-3) 
(  ) Black Diamond, Smart Growth Cheese 
Strings with DHA 
(  ) Other omega-3 enriched cheese 
Please specify brand:  
 _______________________________ 
 
17. How much omega-3 cheese do you usually 
eat per week? 
 
(  ) None 
(  ) less than 1oz (~1 cheese string) 
(  ) 1 oz (~1 cheese string) 
(  ) 2-3 oz (2-3 cheese strings) 
(  ) 4-5 oz (4-5 cheese strings) 
(  ) 6-7 oz (6-7 cheese strings) 
(  ) 8 or more oz (8+ cheese strings) 
 
18.  What kind of nut butter (ex: peanut) do you 
usually eat? 
 
(  ) I don’t eat nut butter 
(  ) Regular nut butter (non-omega-3) 
(  ) Life Brand, Omega-3 Peanut Butter 
(  ) Other omega-3 enriched nut butter 







19.  How much omega-3 nut butter do you eat 
per week? 
 
(  ) None 
(  ) less than 1 tablespoon (tbsp) 
(  ) 1 tbsp 
(  ) 2-3 tbsp 
(  ) 4-5 tbsp 
(  ) 6-7 tbsp 
(  ) 8 or more tbsp 
 
20.  On average, how often do you eat fish 
paste? (ex: Surimi, often in Asian dishes) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Specify the type of fish paste, brand and 
amount usually eaten (number of teaspoons) 
Type of fish paste Brand  #tsp 
__________________________________ 
 
21.  On average, how often do you eat seaweed? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of seaweed (or dish 
containing seaweed) and amount eaten on a 
typical occasion 

















22.  On average, how often do you eat 
seafood-containing sauce? (ex: fish sauce 
oyster sauce, etc (often in Asian dishes))? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of seafood sauce, 
brand and amount usually eaten (# tsp) 














23. On average, how often do you eat fish-based 
broth (ex: fish broth-based soup)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the brand (or ‘homemade’) and 
amount of fish broth usually eaten  
Brand    Amount 
_________________________________ 
 
24.  How many fish oil supplements (ex:capsules) 
do you usually take per day  
 
(  ) None 
(  ) Number: _____ 
 
Please Specify brand and name of fish oil 
capsules: (ex: Jamieson, omega-3 Complete) 
Brand   Product Name 
__________________________________ 
__________________________________
25.  When you eat meat or poultry, what size serving do you usually eat? 
 
 
(  ) Less than A   (  ) B    (  ) C 
(  ) A    (  ) Between B and C  (  ) More than C 
(  ) Between A and B 
 
 
26. On average, how often do you eat chicken 
or turkey?  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the types of chicken/turkey eaten 
most frequently and whether the skin is eaten 
(ex: Turkey thigh, with skin) 
__________________________________ 
A: Deck of cards sized 
portion = 3oz / 90g 




27. On average, how often do you eat duck or 
goose? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of duck/goose eaten 
most frequently and whether the skin in eaten. 
(ex: Duck breast, without skin) 
 
 
28. How often do you usually eat beef? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of beef most often 
eaten (ex: Rump steak): 
 
 
29. On average, how often do you eat lamb? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of lamb most often 











30. On average, how often do you eat veal? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of veal most often eaten 
(ex: Veal steak): 
 
 
31. On average, how often do you eat pork? (do 
not include ham or bacon) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of pork most often eaten 
(ex: Pork chop): 
 
 
32. On average, how often do you eat bacon?  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the number of slices of bacon 















33. On average, how often do you eat ham (not 
deli/sandwich meat)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the number of slices of ham 
usually eaten on each occasion: 
 
 
34. On average, how often do you usually eat 
sliced deli meat (ex: luncheon meats or 
salami)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type (ex: lean turkey 
breast), brand and the number of slices of 
sliced deli meat most often eaten: 
Type  Brand  # slices 
 
 
35. On average, how often do you eat 
sausages? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type (ex: Beef, pork, turkey) 
and number of sausages usually eaten on 
each occasion: 





36. On average, how often do you eat canned 
fish? (ex: canned tuna, salmon, sardines, etc.) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify up to 4 types of canned fish that 
you regularly eat, including the brand and the 
amount typically eaten. (ex: White tuna in water, 
Goldseal, ½ 120g tin) 
 






37. On average, how often do you eat fresh or 
frozen fish? (Include fish meals at home, at a 
restaurant and take out).  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify up to 4 types of fresh or frozen 
fish that you regularly eat and the amount 
typically eaten  
 
(Include the brand for frozen fish. If type of fish is 
unknown for restaurant fish please write 
‘restaurant fish’).  
(ex: Wild Atlantic Salmon, Highliner, 150g) 
 













38. How often do you eat fresh, frozen or 
canned shellfish? (ex: shrimp, oysters, 
scallops, crab, calamari, lobster, etc).  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 









Please specify the type and amount of shellfish 
eaten on a typical occasion: 





39. Are there any other meat, poultry or fish 
products that you eat regularly?  
 
Please specify the type, amount and how 
often other meat or fish products are eaten 
 






40.  Have you changed your diet in any significant way over the past year?  
  
(  ) Yes 
 (  ) No 
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Dietary Advice Package 
 
GENERAL INFORMATION 
What are Omega-3 Fatty Acids? 
 
Omega-3 polyunsaturated fats are a type of dietary fat that have been associated with preventing 
disease and promoting optimal health.  In order to maximize heath benefits, it is important to understand 
that there are various types of omega-3 fatty acids.   
 
One type of omega-3 fatty acid is called alpha-linolenic acid (ALA).  ALA can be found in 
various plant-based foods such as flax seeds (linseed), soybeans, canola, walnuts, pumpkin seeds and their 
oils.  However, specific cardiovascular benefits such as reduction in heart attacks and stroke have been 
associated with intakes of two other omega-3 fatty acids called Eicosapentaenoic Acid (EPA) and 
Docosahexaenoic Acid (DHA).  EPA and DHA are most commonly found in fish oils.  ALA can be 
converted into EPA and DHA in the body however, this process occurs at very low rates in humans.  For 
this reason, this study will focus on increasing your dietary intake of EPA and DHA.   
 
Why Should I Increase my EPA and DHA Intake? 
 
Populations with high intakes of EPA and DHA, such as Greenland Inuit and Japanese 
populations, have a low incidence of deaths due to heart disease.  EPA + DHA intake in Japanese 
populations approaches 2 g per day and intake is even greater in Greenland Inuit populations.  In 
comparison, Western populations consume very low amounts of EPA and DHA and Canadian mortality 
rates due to heart disease are much higher compared to those of Greenland. Various studies have 
estimated that typical Canadian adult consumption of EPA + DHA is around 0.1 to 0.25 g per day.  The 
American Heart Association has recommended intakes of 1 g/day of EPA + DHA for heart disease 
prevention.  Therefore, there is evidence to indicate that increasing EPA+DHA intakes may have 
cardiovascular benefits for Canadians.   
 
How can I Increase my EPA and DHA Intake? 
 
There are various means to increase your EPA + DHA intake to meet a potential target of 1 g per 
day of EPA+ DHA. The traditional source of EPA + DHA is fatty fish.  EPA + DHA can also be 
consumed in the form of fish oil capsules, often referred to as ‘nutraceuticals’.  Finally, the food industry 
has developed various omega-3 enriched foods, referred to as ‘functional foods’, which may include dairy 
products, eggs and egg products, oil-based spreads, peanut butter and juices, etc.   
At present it is unknown which source of EPA + DHA is the most effective and sustainable 
method to increase EPA+DHA intakes in Canadians at risk for heart disease.  Accordingly, this study will 
ask you to use a combination of the fish, nutraceutical and functional food strategies of increasing EPA + 
DHA intake, while other participants are being asked to follow one of the other strategies, in order to 






How Can I used the Combined Strategy to Increase my EPA+DHA Intake? 
 
 The ultimate goal is to attempt to consume American Heart Association recommendations of 1 
g/day of EPA+DHA (or EPA+DHA consumption that averages to 1 g/day over the course of a week).  To 
accomplish this goal you may incorporate fish, nutraceutical and functional food strategies into your 
regular diet.  More details about each of these strategies are detailed on the following pages.   
 As an example, on one day you may choose to eat fish with a high EPA + DHA content for 
dinner as an alternative to meat, poultry or meat alternatives to meet your 1 g of EPA+DHA goal.  The 
next day you may consume omega-3 liquid eggs instead of regular eggs for a breakfast (0.5 g of 
EPA+DHA ) and a fish oil capsule containing 0.5 g of EPA+DHA for a total of 1 g of EPA+DHA.  We 
recommend that you try many fish and functional food sources to determine which sources best fit your 
taste preferences, food preparation habits and budget so that you can sustain your EPA+DHA intake over 
the course of the year.  We recommend that you supplement your diet with a fish oil nutraceutical on days 
when your EPA+DHA intake from fish or functional foods is less than 1 g.   
 Other than substituting fish and EPA+DHA-enriched functional foods into your regular diet and 






Sample Daily Diet (1) 
Meal Food Amount mg EPA+DHA 
Breakfast Naturegg, Breakfree omega-3 liquid eggs 100g 500 
 Becel, omega-3 margarine with EPA+DHA 1 tsp 25 
 President’s Choice, Oh Mega J orange juice 1 cup 50 
 Wonder+, Headstart bread with DHA 2 pieces 15 
 Becel, omega-3 margarine with EPA+DHA 2 tsp 50 
 Banana 1 medium  
Snack Apple 1 medium  
 Black Diamond, Smart Growth Cheese String 1  20 
Lunch Wonder+, Headstart bread with DHA 2 pieces 15 
 Becel, omega-3 margarine with EPA+DHA 2 tsp 50 
 Ham lunchmeat with Low fat Swiss cheese 1 oz each  
 Romaine lettuce and tomato   
 President’s Choice, Oh Mega J orange juice 1 cup 50 
Snack Danone, Danino omega-3 yogurt 100g pot 40 
 Baby carrots 10  
Dinner Fish sticks (Haddock) 100g 238 
 Mixed green salad with ranch dressing  1.5 cups  
 Brown rice 1 cup  
 Becel, omega-3 margarine with EPA+DHA 1 tsp 25 
 Silk Plus, Omega-3 DHA soy milk 1 cup 30 






Sample Daily Diet (2) 
Meal Food Amount mg EPA+DHA 
Breakfast Oatmeal with syrup ¾ cup  
 Coffee 1 cup  
 Banana 1  
Lunch Whole wheat tortilla 1  
 Tuna salad (made with canned white tuna)  60 g tuna  
(1/2 can) 
~515 
 Mixed green salad with French dressing 1 cup  
 Water 500 mL  
Snack Granola bar 1  
Dinner  Grilled chicken breast  125 g  
 Cooked mixed vegetables 1 cup  
 Baked Potato with light sour cream 1  
 1 fish oil nutraceutical  1 500 
 Water 500mL  
 Apple 1  
 Chocolate chip cookies 2  




Sample Daily Diet (3) 
Meal Food Amount mg EPA+DHA 
Breakfast Waffles with syrup 2  
 Applesauce ½ cup  
 Tea 1 cup  
Snack Cheddar Cheese 1.5 oz  
 Crackers 6   
Lunch Beef and barley soup 1.5 cups  
 Raw veggies with dip   
 Fruit Salad ¾ cup  
 Fruit Juice 1 cup  
Snack Digestive cookies 4  
Dinner  Baked rainbow trout (farmed) 120 g (4 oz) ~1400 
 Grilled mixed vegetables 1 cup  
 Whole wheat roll 1  
 Melon 1 cup  
 Vanilla Pudding  ¾ cup  
TOTAL   1400mg (1.4g) 
*Sample Diet #3 contains more than 1g of EPA+DHA so less EPA+DHA could be consumed on another 








Sample Daily Diet (4) 
Meal Food Amount mg EPA+DHA 
Breakfast Smoothie with:  1  
      Danone Danino yogurt 100 g 40 
      Nielson Dairy Oh! 2% milk  1/2 cup 5 
      Banana and Berries   
 Wonder+, Headstart bread with DHA 1 piece 7.5 
 Life Brand peanut butter with EPA+DHA 1 tbsp 25 
 Coffee 1 cup  
Snack Walnuts and Dried Cranberries handful  
Lunch President’s Choice Blue Menu, Ginger Glazed 
Salmon (frozen personal entrée) 
1 (~2.5 oz 
salmon) 
~750 
 Salad with oil and vinegar dressing  1 cup  
 President’s Choice, Oh Mega J orange juice 1 cup 50 
Snack Low fat muffin 1  
Dinner  Omelet with:  1  
      Naturegg Omega-3 shelled eggs 2 150 
      Ham and Spinach ¼ cup each  
 Grilled Mixed Vegetables   1 cup  
 Fruit Pie 1 slice  
 Nielson Dairy Oh! 2% milk 1 cup 10 






















FISH (Traditional Whole Foods) STRATEGY 
 
COMMON CONCERNS REGARDING FISH CONSUMPTION 
Mercury and Fish   
 
 Mercury occurs naturally in the environment and as a result of human activities such as mining.  
Mercury in fish has been given much media attention in recent years because at very high intakes it has 
the potential to affect the nervous system.  However, the majority of fish sold in Canada contains levels of 
mercury considered safe for consumption and Health Canada recommends that fish be included in any 
healthy, Canadian diet.  In addition, many carefully controlled studies have concluded that mercury does 
not increase overall cardiovascular disease risk and the net effect of fish consumption is beneficial for the 
heart.  
 Different fish contain different amounts of mercury. Canada has a two-tier system for acceptable 
levels of mercury in fish for sale to consumers.  Most fish and shellfish sold in Canada are classified as 
Tier One and contain low levels of mercury.  The Canadian Food Inspection Agency tests fish and 
shellfish regularly to ensure that Tier One fish and shellfish sold in Canada have a low mercury content; 
less than 0.5 parts per million(ppm).  0.5ppm is a very small amount of mercury representing 0.0000005 
grams of mercury per gram of fish.  Health Canada has not put a limit on how much of these Tier One 
fish may be consumed as it is believed that adults consuming tier one fish regularly will not be exposed to 
mercury levels that pose a threat to human health. 
Tier Two fish contain slightly higher levels of mercury (less than 1 part per million or 0.000001g 
mercury/g fish) but are generally consumed in lower amounts.  Tier Two fish include fresh/frozen tuna 
(not canned), shark, swordfish, escolar, marlin, and orange roughy.  Health Canada states that you may 
consume up to 5 oz/150 g per week of these Tier Two fish species combined (Note that a 3oz serving of 
fish is approximately the size of a deck of cards or a cheque book). Women who are or may become 
pregnant and breastfeeding mothers may consume up to 150 g of Tier Two fish per month.  Young 
children between 5 and 11 years of age can eat up to 125 g per month and very young children between 1 
and 4 years of age should eat no more than 75 g per month of these Tier Two fish. 
 Separate advice has been issued by Health Canada only for canned albacore (white) tuna. This 
advice does NOT include canned light tuna which has a lower mercury content.  Women who are or may 
become pregnant and breastfeeding mothers may consume up to 300 g (~10 oz) per week of canned 
albacore tuna (about two 170-g cans of albacore tuna per week).  Children between the ages of 5 and 11 
years of age may consume 150 g (~5 oz) per week (two servings or about 1, 170-g can) and children 
between the ages of 1 and 4 may eat 75 g (~2.5 oz) per week (one serving or about ½ of a 170-g can).  
There are no consumption limits on albacore (white) tuna for individuals who do not fall into these 
categories.  
    
 
Summary of Health Canada Fish Consumption Guidelines with Reference to Mercury 
 Source Max Limit Total Mercury 
in fish  
Health Canada Consumption 
Limits  
Tier 1 Most retail fish 0.5 ppm 
(0.0000005g  mercury/ g fish) 
No consumption limits 




and orange roughy 
1.0 ppm 
(0.000001g mercury/ g fish) 
·150g/week for adults 
·150g/month: pregnant women, 
women of child-bearing age & 
breastfeeding women 
·125g/month: children between 5 




·75g/month: children between 1 
and 4 yrs 
Other Canned albacore 
(white) tuna 
 
NOT light tuna 
0.5 ppm 
(0.0000005g  mercury/ g fish) 
·300g/week (2, 170g cans): 
pregnant women, women of child-
bearing age & breastfeeding 
women 
·150 g/week: children between 5 & 
11 yrs 
·75 g/week: children between 1 & 
4 yrs 
 
PCB and Dioxin contamination associated with fish 
 
 Polychlorinated biphenyls (PCBs) were used in commercial and industrial processes before they 
were banned in 1977.  Dioxins are a by-product of processes such as pesticide production and paper 
bleaching.  Regulations have worked to reduce dioxin emissions by more than 90% since the late 1980’s.  
While levels of PCBs and dioxins in the environment are declining, these chemicals persist for long 
periods of time and are present in many foods at low concentrations.  Fish have been given much media 
attention for their PCB and dioxin content, however, beef, chicken, pork, dairy products and vegetables 
provide greater exposure to these two compounds than fish.  The coronary heart disease benefits 
associated with EPA+DHA in fish greatly outweigh any risks associated with the PCB and dioxin content 
of fish.   
 
Selecting Fish: Wild vs. Farmed Fish 
 
 You may have heard media reports contrasting wild and farmed fish.  Reports have found that 
some farmed fish may contain higher levels of contamination than wild fish.  However, Health Canada 
maintains that levels of contamination in both farmed and wild fish sold in Canada do not represent a 
health risk.  Reports have also been released by Health Canada stating that farmed fish industries are 
carefully monitored by the government of Canada for environmental impact and human health and that 
both wild and farmed fish industries provide safe and healthy foods.  Some farmed fish may have a 
slightly higher EPA + DHA content versus their wild counterparts because they are fed a consistent diet 
of fishmeal and fish oils.  It is your choice whether you choose wild or farmed fish sources.   
 
INCORPORATING FISH INTO YOUR DIET 
 
 The ultimate goal is to attempt to reach American Heart Association recommendations of 1 g/day 
(1000 mg/day) of EPA+DHA through fish, functional food and nutraceutical consumption.  The tables 
shown on pages 28-31 illustrate the amount of EPA+DHA per 100g of various species of fish to assist 
you in reaching this goal.  Your EPA + DHA consumption may be less than 1 g on some days and greater 
than 1 g on others but average to 1 g/day over the course of a week.  These tables on pages 28-31 also list 
approximate mercury content of various fish species.  We recommend you use these tables to select fish 
with the highest EPA + DHA content and the lowest mercury content (Tier One fish) most frequently.   
 Fish can be incorporated into your diet when you would normally consume meat, poultry or a 
meat alternative.  The cost associated with fish can vary widely from being very economical (canned fish 
or some varieties of frozen whole fish) to more expensive (fresh fillets of some varieties).  We 
recommend that you select sources of fish that fit your budget so that you can maintain high fish intakes 







Fish can be purchased fresh or frozen.  Fresh fish should be used within two days of purchase.  
Otherwise, fresh fish should be stored in the freezer. Frozen seafood can be thawed by placing it in the 
refrigerator overnight.  For faster thawing, immerse fish sealed in a plastic bag in cold water or defrost it 
in the microwave until the fish is bendable but still icy.  
Fish can be purchased from grocery and specialty stores, the farmer’s market, etc.  You may wish 
to try a local fish store such as T & J Seafood [26 Elm Street , Kitchener (519-578-3080)] or Caudle’s 
Catch Seafood Ltd. [St. Jacob’s farmer’s market and 60 Otonabee Dr., Kitchener (519-894-0442) 
http://www.caudlescatchseafood.com/index.html] 
Additional ingredients such as fish and oyster sauce, fish broth and seaweed also contain some 
EPA and DHA.  These ingredients can be purchased in the Asian section of your grocery store or at an 
Asian grocery such as Korean and Japanese Grocery [510 King St. W., Kitchener (519-569-7199)]. 
 
Preparing Whole Fish (adapted from http://www.gortons.com/cookbook/cleanfreshfish.php)  
 
Whole fish can be an economical way to purchase fish.    
  
1. Wash the fish in cold water. 
2. If your fish requires scaling (fish with delicate scales such as salmon do not require scaling), hold 
the fish by the tail and scrape towards the head with a knife. 
3. Remove the tail and fins with kitchen scissors (optional). 
4. With the fish on its side, press down on the top side with one hand while slicing from the belly 
(2/3 of the way from the head to the tail) to the base of the head.  Be sure to use a sharp knife and 
not to cut too deeply. 
5. Intestines can be removed by pulling them towards the tail.  Scrape out any other organs with a 
knife (such as the kidney - a while sack beside the spine). 
6. Wash the inside and outside of the fish in cold water. 
7. To remove the head, cut straight through the spine, just below the gills (optional).  
 
Whole fish can now be cooked.  Be careful of bones when eating.   
Fish can also be cooked whole and filleted later.  Have a look at the following web site if you require 
some step-by-step pictures: http://beyondsalmon.blogspot.com/2006/03/how-to-cook-whole-fish.html. 
 
How to Know When Fish is Cooked 
 
A meat thermometer will tell you that fish is cooked when the middle of the thickest part of the fish 
reaches an internal temperature of 145 degrees F.  A general rule is to cook fish for about 10 minutes per 
inch (measure fish at thickest part). 
If you do not have a meat thermometer: 
 Fish: When cutting into the thickest part of the flesh, it should appear opaque and should separate 
easily. Check the flesh of microwaved fish in more than one spot.  
 Shrimp and Lobster: The flesh should appear pearly-opaque.  
 Scallops: The flesh should turn milky white or opaque and firm.  
 Clams, Mussels, and Oysters: When their shells open they are ready to eat. Throw out those 







FISH COOKING METHODS AND RECIPES 
 
 The taste of fish can vary between species and the method of preparation can also affect the taste 
and texture.  As a result, we recommend you try a variety of species and preparation methods detailed on 
the following pages to determine the fish and fish preparation methods that best suit your tastes.  Try 
searching on the internet or in your favourite cookbooks for other fish recipes.  Prepared fish meals can 
also be purchased.  
  
Poaching Fish: (http://allrecipes.com/HowTo/Healthful-Ways-to-Cook-Fish/Detail.aspx) 
 -Select a pan large enough to lay fish in a single layer. 
-Select a liquid in which to poach fish.  Chicken or vegetable stock add a nice flavour to the fish.  
Peppercorns, lemon juice, herbs, etc can be added to stock for extra flavour. 
-Pour in enough liquid to just barely cover fish. 
-Bring liquid to a simmer (not boiling).  Ideal temperatures for poaching are 165-180 degrees F.  
 
Poached Fish with Dill Mustard Sauce  
(from: http://allrecipes.com/Recipe/Quick-Poached-Salmon-with-Dill-Mustard-Sauce/Detail.aspx) 
INGREDIENTS 
 1/2 cup plain yogurt  
 1/4 cup Dijon mustard  
 1 tablespoon honey  
 1/4 cup fresh lemon juice  
 3 tablespoons chopped fresh dill  
 1 pound (455 g) fish  
 1 cup white wine  
 1/2 cup water  
 1/4 cup chopped shallots  
DIRECTIONS (Poached Fish with Dill Mustard Sauce) 
1. In a small bowl, blend the plain yogurt, Dijon mustard, honey, lemon juice, and dill. Cover, and 
refrigerate until serving.  
2. In a medium saucepan over medium heat, place the fish in the white wine and water. Adjust the 
amount of water as necessary to just cover the fish. Sprinkle with shallots. Cover the saucepan, 
and cook 10 to 12 minutes, until fish is easily flaked with a fork. Drain, and serve with the yogurt 
sauce.  
Makes 4 servings 
 
 
Grilling Fish: (http://allrecipes.com/HowTo/Healthful-Ways-to-Cook-Fish/Detail.aspx) 
-Dense fish may be placed directly on a grill (you may have to first spray/brush grill with a non-
stick cooking spray or cooking oil). 
-Delicate fish can be cooked on a grilling basket or on aluminum foil. 
-Place the fish around the edges of the grill, away from the hottest part of the fire.  
-Grill fish on a medium to medium-high heat. 









Glazed Fish  
(from: http://allrecipes.com/Recipe/Glazed-Salmon-Fillet-2/Detail.aspx ) 
 
INGREDIENTS 
 2 tablespoons and 2 teaspoons reduced-sodium soy sauce  
 1 tablespoon + 1 teaspoon brown sugar  
 1/8 teaspoon crushed red pepper flakes  
 1/8 teaspoon ground ginger  
 1/8 teaspoon sesame oil  
 1 pound (455 g) fish (ex: salmon) 
DIRECTIONS (Glazed Fish) 
1. In a bowl, combine the first five ingredients.  
2. Grill fish, covered, over medium heat or broil 4-6 in. from the heat for 5-6 minutes on each side 
or until fish flakes easily with a fork 
3. Baste frequently with glaze as fish cooks.  
 
Makes 4 servings 
 
 




 1 (16 ounce) can salmon, drained and flaked  
 2 eggs  
 1/4 cup chopped fresh parsley  
 2 tablespoons finely chopped onion  
 1/4 cup Italian seasoned dry bread crumbs  
 2 tablespoons lemon juice  
 1/2 teaspoon dried basil  
 1 pinch red pepper flakes  
 1 tablespoon vegetable oil  
 2 tablespoons light mayonnaise  
 1 tablespoon lemon juice  
 1 pinch dried basil  
 
DIRECTIONS 
1. In a medium bowl, mix together the salmon, eggs, parsley, onion, breadcrumbs, 2 tablespoons of 
lemon juice, 1/2 teaspoon of basil, and red pepper flakes. Form into 6 firmly packed patties, about 
1/2 inch thick.  
2. Grill, flipping when light grill marks appear. 
3. In a small bowl, mix together the mayonnaise, 1 tablespoon of lemon juice and a pinch of basil. 
Use as a sauce for your patties.  
 








Steaming Fish: (http://allrecipes.com/HowTo/Healthful-Ways-to-Cook-Fish/Detail.aspx) 
-To flavour fish, rub with ex: herbs, ginger, spices, chili peppers, etc 
 -Place fish on a metal or bamboo steamer in a single layer 
     
  
-Pour about 1 ½ inches of water into a pan or pot and place the steamer above the water 
(steamer should not touch water)  
-Cover the pot and bring water to a boil 
-After about 10 minutes check fish for doneness (fish should be flaky but moist which 
may take 15-20 minutes) 
 




 1 1/2 pounds (680 g) halibut or any white-fleshed fish, cut into 4 pieces  
 3 green onions, cut into 3 inch lengths  
 2 fresh mushrooms, sliced  
 6 leaves napa cabbage, sliced into 4 inch pieces  
 2 slices fresh ginger root, finely chopped  
 2 cloves garlic, chopped  
 1/4 cup low-sodium soy sauce  
 1/8 cup water  
 crushed red pepper flakes to taste  
 fresh cilantro sprigs, for garnish  
 
DIRECTIONS 
1. Arrange 1/2 of the green onions on the bottom of the steamer (it is important to steam in a 
container such as a pot in order to retain the steam and juices around the fish). Place 1/2 of the 
mushrooms and Napa cabbage sections on top of the onions. Place fish on top of the vegetables. 
Sprinkle ginger, garlic, and red pepper flakes over fish. Top with the remaining green onions, 
mushrooms, and napa cabbage. Drizzle soy sauce and water over everything.  
2. Place steamer in pot or another container containing 1 inch of boiling water, and cover. Steam for 
15 to 20 minutes, or until fish flakes easily. Garnish with cilantro, if desired.  
 
Makes 4 servings 
 
 
Baking/Broiling Fish:  (http://www.heb.com/mealtime/CT-easyFish.jsp ) 
 -Preheat oven to 450 degrees F. 
-Spray/brush a baking sheet or shallow baking dish with non-stick cooking spray or a cooking oil. 
-Place fish on baking sheet in a single layer. 
-Season fish as desired. 




-If using a meat thermometer, fish is cooked when the internal temperature of the thickest part 
reaches 145 degrees F. 
 
Mediterranean Baked Fish (http://allrecipes.com/Recipe/Mediterranean-Baked-Fish/Detail.aspx ) 
 
INGREDIENTS 
 1 cup thinly sliced leeks, white parts only  
 2 garlic cloves, minced  
 2 teaspoons olive oil  
 12 large fresh basil leaves  
 1 1/2 (680 g) pounds fish fillets  
 1 teaspoon salt  
 2 plum tomatoes, sliced  
 1 (60 g) can sliced ripe olives, drained  
 1 medium lemon  
 1/8 teaspoon pepper  
 4 sprigs fresh rosemary  
 
DIRECTIONS  
1. In a non-stick skillet, sauté leeks and garlic in oil until tender; set aside.  
2. Coat a 13” x 9” x 2” baking dish with non-stick cooking spray. Arrange basil in a single layer in 
dish and top with fish fillets. Sprinkle with salt. Top with leek mixture.  
3. Arrange tomatoes and olives over fish. Thinly slice half of the lemon and place over the top. 
Squeeze juice from remaining lemon over all. Sprinkle with pepper.  
4. Cover and bake at 425 degrees F for 15-20 minutes or until fish flakes easily with a fork. Garnish 
with rosemary.  
 
Makes 4 servings 
 
Fish Parmesan (http://allrecipes.com/Recipe/Baked-Trout-Fillets/Detail.aspx ) 
 
INGREDIENTS 
 1 pound fish fillets  
 1 cup sour cream  
 1/4 cup grated Parmesan cheese  
 1 tablespoon lemon juice  
 1 tablespoon finely chopped onion  
 1/2 teaspoon salt  
 Paprika  
 
DIRECTIONS 
1. Place fish in a greased shallow 3-Litre. baking dish. In a small bowl, combine the sour cream, 
Parmesan cheese, lemon juice, onion and salt; spread over fish. Sprinkle with paprika. Bake, 
uncovered, at 350 degrees F for about 20 minutes or until fish flakes easily with a fork.  
 
Makes 4 servings 
 
Microwaving Fish:  (http://www.heb.com/mealtime/CT-easyFish.jsp ) 
 -Spray/brush a microwave-safe dish with non-stick cooking spray or cooking oil. 




-Microwave on High for 5-10 minutes depending on the strength of your microwave and the 
thickness of the fish. 
 




 450 g fish fillets  
 1 cup chopped fresh tomato  
 1/2 avocado, chopped  
 1 garlic clove, crushed  
 1 tablespoon balsamic vinegar  
 1 teaspoon olive oil  
 1/2 cup cooked corn kernels  
 1/4 cup minced red onion  
 1/4 cup chopped fresh cilantro  
 Salt and pepper, to taste  
 1 lime, cut in wedges  
 
DIRECTIONS (Fish with Summer Tomato Salsa) 
1. In a small bowl, combine tomato, avocado, garlic, balsamic vinegar, olive oil, corn, onion, 
cilantro, salt and pepper. Refrigerate 30 minutes.  
2. Place fish in a shallow, lightly oiled microwave bowl. Cover and microwave on high 5-10 
minutes or until fish is cooked as desired.  
3. Serve fish surrounded by the salsa and lime wedges.  
 
Makes 4 servings 
 
 
Other Fish Recipes 
 
Pasta de Sardine (http://allrecipes.com/Recipe/Pasta-De-Sardine/Detail.aspx ) 
 
INGREDIENTS 
 8 ounces (225 g) dry fettuccine pasta  
 2 tablespoons olive oil  
 1 medium yellow onion, chopped  
 3 cloves garlic, crushed  
 1 lemon, juiced  
 1 (106 g) can sardines in tomato sauce (could use fresh sardines) 
 1 pinch red pepper flakes, or to taste  
 1/4 cup freshly grated Parmesan cheese  
 
DIRECTIONS (Pasta de Sardine) 
1. Bring a large pot of lightly salted water to a boil. Add pasta, and cook for about 8 minutes, or 
until almost tender.  
2. While the pasta is cooking, heat olive oil in a skillet over medium heat. Add the onion, and cook 
for a few minutes until soft, then add the garlic, and cook until fragrant. Stir in the sardines with 





3. When the pasta is almost done, drain, and add it to the sardine sauce. Stir, cover, and turn the heat 
off. Let stand for a few minutes to absorb the flavors of the sauce. Squeeze juice from the lemon 
over the pasta. Divide onto serving plates, and top with red pepper flakes and grated Parmesan 
cheese.  
 
Makes 4 servings 
 
 




 1, 213g can of salmon (or any other canned fish) 
 Enough low-fat mayonnaise or cream cheese to hold salmon together (try 2-4 tbsp) 
 ¼ cup diced celery  
 ½ tsp lemon juice 
 ¼ tsp dried dill 
 ¼ cup (4 tbsp) chopped walnuts (optional) 
 Bread, tortilla wraps, bagels, English muffins, etc 
 Lettuce 
 Pepper to taste 
 
DIRECTIONS 
 Drain salmon and flake with a fork. 
 Mix in mayonnaise/cream cheese, celery, lemon juice, dill, walnuts and pepper. 
 Spread on your favourite bread, top with lettuce and refrigerate until serving.  
 Try adding other ingredients to change the flavour of your sandwich such as relish, chopped 
onions, olives, tomatoes, cucumbers, pickles and apples. 
 
 
Fish Stock (adapted from http://allrecipes.com/Recipe/Fish-Stock/Detail.aspx)  
 
INGREDIENTS 
 5 cups water  
 1/2 pound of firm fillets, cubed (ex: cod, halibut) 
 1 stalk celery, cut into 2 inch pieces  
 1 small onion, quartered and sliced thickly  
 1 bay leaf  
 1/2 teaspoon salt  
 1/2 teaspoon ground black pepper  
 
DIRECTIONS 
1. Combine water, fish, celery, onion, bay leaf, and salt and pepper in a large pot. Bring to rolling 
boil over high heat. Reduce heat to low, cover, and cook for approximately 1/2 hour or until fish 
falls apart.  
2. Strain broth thoroughly. Be especially careful to remove all bones. Use as directed in any recipe 
that calls for stock or fish stock.  
3. To make into a soup try adding the following to the fish stock and let simmer:  
 Asian noodles (ex: rice or egg noodles, follow directions on package) 




 Low sodium soy sauce and sesame oil to taste (start with small amounts ~1/2 tsp) 
 Asian vegetables ex: bok choy, mushrooms 






SELECTING FISH BASED ON EPA, DHA and MERCURY CONTENT 
 
Select fish with the highest EPA+DHA and the lowest Mercury content (Tier 1 fish) most often  
 
Fish/Seafood with VERY HIGH EPA+DHA Content (more than 1.2 g (1200mg) of EPA + DHA / 100g fish) 
Fish Species and Description  g DHA / 
100 g fish 
g EPA / 
100 g fish 
g DHA + EPA/ 




Fish, anchovy, raw 0.911 0.538 1.449 1 0.043
a
 
Fish, anchovy, canned in oil, drained  1.292 0.763 2.055 1 0.043
a
 
Fish, herring, Atlantic, kippered 1.179 0.970 2.149 1 0.140
 b
 
Fish, herring, Atlantic, cooked 1.105 0.909 2.014 1 0.140
 b
 
Fish, herring, Pacific, cooked 0.883 1.242 2.125 1 0.040
 b
 
Fish, mackerel, Atlantic, cooked 0.699 0.504 1.203 1 0.220
 b
 
Fish, mackerel, Pacific and jack, mixed species, cooked 1.195 0.653 1.848 1 0.088
 b
 
Fish, sablefish, cooked 0.920 0.867 1.787 1 0.220
 a
  
Fish, sablefish, smoked 0.945 0.891 1.836 1 0.220
 a
  
Fish, salmon, Atlantic, farmed, cooked 1.457 0.690 2.147 1 0.140
 b
 
Fish, salmon, Atlantic, wild, cooked 1.429 0.411 1.840 1 0.140
 b
 
Fish, salmon, Chinook, cooked 0.727 1.010 1.737 1 0.040
 b
 
Fish, salmon, Coho, farmed, cooked 0.871 0.408 1.279 1 0.040
 b
 
Fish, salmon, pink (humpback), fillet, cooked 0.751 0.537 1.288 1 0.040
 b
 
Fish, salmon, pink (humpback), canned 1.083 0.604 1.687 1 0.040
 b
 
Fish, salmon, sockeye (red), fillet, cooked 0.700 0.530 1.230 1 0.040
 b
 
Fish, salmon, sockeye (red), canned 1.113 0.739 1.852 1 0.040
 b
 
Fish, tuna, fresh, bluefin, cooked  1.141 0.363 1.504 2 0.380
 b
 
Fish, whitefish, mixed species (ex: lake whitefish), cooked 1.206 0.406 1.612 1 0.069
 a
 












Fish with HIGH EPA+DHA Content (0.8-1.2 g (800-1200mg) of EPA + DHA /100g fish) 
Fish Species and Description  g DHA / 
100 g fish 
g EPA / 
100 g fish 
g DHA + EPA/ 
100 g fish 
Tier Mercury Concentration 
(ppm) 
Fish, bass, striped, cooked 0.750 0.217 0.967 1 0.219
 a
 
Fish, bluefish, cooked  0.665 0.323 0.988 1 0.337
 a
 
Fish, salmon, chum, canned 0.702 0.473 1.175 1 0.040
 b
 
Fish, salmon, Coho, wild, cooked 0.658 0.401 1.059 1 0.040
 b
 
Fish, sardine, Atlantic, canned in oil 0.509 0.473 0.982 1 0.016
 a
 
Fish, smelt, rainbow, cooked 0.536 0.353 0.889 1 Not Determined 
Fish, swordfish, cooked 0.681 0.138 0.819 2 0.976
 a
 
Fish, trout, mixed species, cooked 0.677 0.259 0.936 1 0.072 (freshwater)
 a
 
Fish, trout, rainbow, farmed, cooked 0.820 0.334 1.154 1 0.072
 a
 
Fish, trout, rainbow, wild, cooked 0.520 0.468 0.988 1 0.072
 a
 




*Albacore tuna has specific consumption guidelines for pregnant, breastfeeding or women of child-bearing age and children. 
 
Fish/Seafood with MODERATE TO LOW EPA+DHA CONTENT ( less than 0.8g (800 mg) of EPA+DHA/100g fish) 
Fish Species and Description  g DHA / 
100 g fish 
g EPA / 
100 g fish 
g DHA + EPA/ 
100 g fish 
Tier Mercury Concentration 
(ppm) 
Crustaceans, crab, Alaska king, cooked 0.118 0.295 0.413 1 0.060
 a
 
Crustaceans, crab, blue, cooked 0.231 0.243 0.474 1 0.060
 a
 
Crustaceans, crab, Dungeness, cooked 0.113 0.281 0.394 1 0.150
 b
 
Crustaceans, crab, queen (snow), cooked 0.145 0.332 0.477 1 0.060
 a
 
Crustaceans, lobster, northern, cooked 0.031 0.053 0.084 1 0.310
 a
 
Crustaceans, shrimp, mixed species, cooked 0.144 0.171 0.315 1 Not Detectable
 a
 
Crustaceans, spiny lobster, mixed species, cooked 0.139 0.341 0.480 1 0.169
 a
 
Fish, catfish, farmed, cooked 0.128 0.049 0.177 1 0.049
 a
 
Fish, catfish, wild, cooked 0.137 0.100 0.237 1 0.049
 a
 
Fish, cod, Atlantic, cooked 0.154 0.004 0.158 1 0.060 
b
 






Fish, flatfish (flounder and sole), cooked 0.258 0.243 0.501 1 0.045
 a
 
Fish, grouper, cooked 0.213 0.035 0.248 1 0.465
 a
 
Fish, haddock, cooked 0.162 0.076 0.238 1 0.031
 a
 
Fish, hake (Whiting), mixed species, cooked 0.235 0.283 0.518 1 0.014
 a
 
Fish, halibut, Atlantic and Pacific, cooked 0.374 0.091 0.465 1 0.252
 a
 
Fish, ocean perch (rockfish), Pacific, cooked 0.262 0.181 0.443 1 0.220
 a
 
Fish, ocean perch, Atlantic, cooked 0.271 0.103 0.374 1 0.080
 b
 
Fish, perch, mixed species, cooked 0.223 0.101 0.324 1 0.140
 a
 
Fish, pike, northern, cooked 0.095 0.042 0.137 1 Not Determined 
Fish, pike, walleye, cooked 0.288 0.110 0.398 1 Not Determined 
Fish, pollock, Atlantic, cooked 0.451 0.091 0.542 1 0.020
 b
 
Fish, orange roughy, cooked 0 0.002 0.002 2 0.554
 a
 
Fish, salmon, chinook, smoked/lox 0.267 0.183 0.450 1 Not Determined 
Fish, sea bass, mixed species, cooked 0.556 0.206 0.762 1 0.219
 a
 
Fish, shark (dog fish), mixed species, fried 0.431 0.258 0.689 2 0.990
 a
 
Fish, snapper, mixed species, cooked 0.273 0.048 0.321 1 0.190
 c
 
Fish, tilapia, cooked 0.130 0.005 0.135 1 0.010
 a
 
Fish, tuna, light, canned in oil, drained solids 0.101 0.027 0.128 1 0.118
 a
 
Fish, tuna, light, canned in water, drained solids 0.223 0.047 0.270 1 0.118
 a
 
Fish, tuna, skipjack, fresh, cooked 0.237 0.091 0.328 1 0.205
 a
 
Fish, tuna, yellowfin, fresh, cooked 0.232 0.047 0.279 1 0.325
 a
 
Mollusks, clam, cooked 0.146 0.138 0.284 1 0.010
 b
 
Mollusks, mussel, blue, cooked 0.506 0.276 0.782 1 <0.150
 c
 
Mollusks, oyster, farmed, cooked 0.211 0.229 0.440 1 <0.050
 c
 
Mollusks, oyster, wild, cooked 0.291 0.260 0.551 1 0.013
 a
 
Mollusks, scallop, mixed species, fried 0.103 0.086 0.180 1 0.050
 a
 











Other Traditional Sources of EPA and DHA  
Source Serving Size  (g) DHA  (g) EPA  (g) DHA + EPA  
Fish broth/Stock 250 mL (1 cup) 0.121 0.086 0.207
 
 
Seaweed, agar, dried 125ml (1/2 cup) = 7.9 g 0 0.007 0.007
 
 
Seaweed, agar, raw 125ml (1/2 cup) = 42.3 g 0 0.003 0.003
 
 
Seaweed, dulse (laver, nori), dried 125ml (1/2 cup) = 7.9 g 0 0.040 0.040
 
 
Seaweed, dulse (laver, nori), raw 125ml (1/2 cup) = 42.3 g 0 0.034 0.034
 
 
Seaweed, irishmoss, raw 125ml (1/2 cup) = 42.3 g 0 0.019 0.019
 
 
Seaweed, kelp (kombu, tangle), raw 125ml (1/2 cup) = 42.3 g  0.002 0.002
 
 





EPA and DHA content:   
Canadian Nutrient File, version 2007b.  http://www.hc-sc.gc.ca/fn-an/nutrition/fiche-nutri-data/index_e.html. 2007 
United States Department of Agriculture.  http://www.health.gov/dietaryguidelines/dga2005/report/HTML/table_g2_adda2.htm. 2004.  
 
Mercury: 
a) Canadian Nutrient File, version 2007b.  http://www.hc-sc.gc.ca/fn-an/nutrition/fiche-nutri-data/index_e.html. 2007.  
b) Sunderland EM. (2007). Mercury exposure from domestic and imported estuarine and marine fish in the U.S. seafood market. 
Environ Health Perspect 115:235-242.   







A: Deck of cards/cheque book 
sized portion = 3oz / 90g 




Laboratory of Nutritional and Nutraceutical Research 
    
 
Traditional Whole Foods (Fish):  Summary Sheet 
 
Cardiovascular benefits associated with two omega-3 fatty acids:  
 Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) 
 
Goal:  1 gram/day of EPA + DHA from fish and shellfish  
 
How to accomplish goal: 
 Substitute fish and shellfish into your regular diet in place of meat, poultry or meat alternatives 
 Do not make other significant changes to your diet for 12 months 
 Select fish with high EPA+DHA and low mercury content (Tier One Fish) most frequently 
 Select types of fish that fit your food budget  
 EPA+DHA intake should average to 1gram/day (intake can be more than 1g on some days and 
less on others)  
 See Tables p. 28-31 for the EPA+DHA/mercury content of various fish 
 
 
Summary of Health Canada Fish Consumption Guidelines with Reference to Mercury 
 Source Max Limit Total Mercury 
in fish  
Health Canada Consumption Limits  
Tier 1 Most retail fish 0.5 ppm 
(0.0000005g  mercury/ g fish) 
No consumption limits 




and orange roughy 
2.0 ppm 
(0.000001g mercury/ g fish) 
·150g/week for adults 
·150g/month: pregnant women, women 
of child-bearing age & breastfeeding 
women 
·125g/month: children between 5 and 11 
yrs 
·75g/month: children between 1 and 4 yrs 
Other Canned albacore 
(white) tuna 
 
NOT light tuna 
0.5 ppm 
(0.0000005g  mercury/ g fish) 
·300g/week (2, 170g cans): pregnant 
women, women of child-bearing age & 
breastfeeding women 
·150 g/week: children between 5 & 11 
yrs 










 There are many nutraceutical products on the market that advertise their omega-3 fatty acid 
content.  However, it is important for you to know that not all of these products contain the same amount 
of EPA and DHA.   
 
Flax Seed Oil 
 As previously described, flax seed oil contains the omega-3 fatty acid alpha linolenic acid (ALA) 
but no EPA or DHA.  Flax seed oil nutraceutical products highlight the importance of reading nutritional 
information labeling as not all products advertised as containing omega-3 fatty acids contain EPA and 
DHA. You are not being asked to consume flax seed oil nutraceuticals in this study. 
 
Essential Oil Blends 
 These products contain fatty acids which are considered essential because they are not 
synthesized by your body and therefore must be obtained through diet or supplements.   
A common essential oil blend is “Omega 3-6-9” which contains fatty acids omega-3, 6 and 9 
(even though omega 9 is not considered essential).  Accordingly, this product contains many fatty acids in 
addition to EPA and DHA and therefore the percent of EPA and DHA is fairly low.  Typically, these 
essential oil blends contain about 72mg EPA and 48 mg DHA per 1200 mg of oil. These nutraceuticals 
are not the most cost effective means to increase your EPA + DHA intake. 
 
Fish Oil Blends 
Fish oil blends, such as salmon oil (blended with other fish oils like sardine and anchovy) are also 
available.  These products supply approximately 180 mg of EPA and 120 mg of DHA per 1000 mg of oil 
and therefore 3-4 capsules would be needed per day to supply approximately 1000 mg of EPA + DHA.  
More concentrated EPA + DHA formulations are available and therefore, these less concentrated products 
are not the most effective means to increase your EPA + DHA intake. 
  
 More concentrated fish oil blends are typically derived from Anchovy, Mackerel and Sardine oils 
and contain approximately 300 mg of EPA and 200 mg of DHA per 1000 mg of oil.  Two of these 
capsules per day will allow you to meet the 1000 mg/day target of EPA + DHA and therefore may be the 
most cost effective means to supply EPA + DHA in nutraceutical form.   
 
 There will be a few varieties of fish oil nutraceuticals that may have higher concentrations of 
DHA relative to EPA by the inclusion of tuna oil.  It is important to examine the cost per gram of EPA + 
DHA of various nutraceutical to determine the most cost effective source.  
 
See chart on page 32 for the most cost effective products to obtain EPA+DHA and where to purchase 
these products. Continue to check your local grocery and drug stores for new nutraceutical products 




 Some individuals experience a fishy taste after consuming fish oil capsules.  It is recommended 
that you consume the fish oil capsules with food to prevent the fishy taste.  Many people find that the 
longer they consume these fish oil capsules, the less noticeable the fishy taste becomes.  Also, when 
consuming more than one fish oil capsule a day, it may help to spread your intake throughout the day as 




 For those who have difficulty swallowing large (1000 mg) capsules, soft chews containing 
EPA+DHA and liquid fish oil formulations are also available.  Unfortunately the soft chews have a much 
lower concentration of EPA+DHA and as a result, fish oil in capsule form is more cost effective.  Some 
liquid fish oil formulations contain a high concentration of EPA+DHA and are a more cost effective 
option. Taking capsules with sufficient liquids may also help swallowing issues.   
 Your goal is to ingest approximately 1000 mg of EPA+DHA per day.  Read the label of the 
nutraceutical product you select in order to determine how much of the product you need to take to meet 
this daily goal.  Your EPA + DHA consumption may be less than 1 g on some days and greater than 1 g 









Costs Associated with Nutraceutical Source of EPA + DHA 
Costs presented above were collected August 2007/January 2008 and may change over time.  These costs do not include any 



















Webber Naturals Omega-3 Super 
Concentrate 1065 mg 600 0.41   0.38 0.33 
Jamieson Omega-3 Complete 1065 mg 600 0.31 0.44 0.35 0.35 
Genuine Health Omega-3 extra strength 1000 mg 600   0.75     
Life Brand Omega-3 Super Concentrate 1000 mg 600     0.31   
Inno-Vite Fish Oil Trio Concentrate 1000 mg 600   0.43     





Swiss Natural Sources omega-3 triple fish 
blend 1000 mg 500 0.60 0.56 0.29 0.27 
Jamieson Omega-3 Select  1000 mg 500 0.27   0.30 0.31 
Compliments Omega-3  1000 mg 500 0.13       
Rexall Naturals Omega-3 1000 mg 500       0.31 
Life Brand Omega-3 1000 mg 500     0.42   





Presidents Choice Mind 1100 mg 
620  
(90 EPA, 530 DHA)  0.27   
Presidents Choice Body 1100 mg 
700 
(400 EPA, 300 DHA)  0.24   
        
Soft Chews 
 
Webber Naturals Omega-3 soft chews 5 g 100     3.20 3.00 
Life Brand Omega-3 soft chews 5 g 100     2.80   
               
Liquid Webber liquid omega-3 super concentrate 
5mL 
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Cardiovascular benefits associated with two omega-3 fatty acids:  
 Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) 
 
Goal:  
 1 gram/day of EPA + DHA from Fish oil capsule (Nutraceutical) Supplementation  
 
How to accomplish goal: 
 Consume enough fish oil capsules to supplement your diet with 1 gram/day of EPA+DHA  
 Do not make other significant changes to your diet for 12 months 
 See Tables p. 32 to help you select fish oil capsules with the highest EPA+DHA content for the 
lowest cost 
Fish oil capsule consumption: 
 Take fish oil capsules with meals 






















FUNCTIONAL FOOD STRATEGY 
 
What are Functional Foods? 
 
According to Health Canada a functional food: 
 resembles to or may be a conventional food 
 is consumed as part of a usual diet 
 has physiological benefits and/or reduces the risk of chronic disease beyond basic nutritional 
functions.   
 
An example of a functional food is omega-3 yogurt.  In this case, EPA and DHA have been purified 
from fish oil and added to regular yogurt.  This process of adding EPA + DHA from fish oil (or from 
algae) is also used in omega-3 juices, bread, milk and soy milk, oil-based spreads, peanut butter and 
cheese.  The fish oil added to these functional foods has been purified to remove any mercury or other 
contaminants.  Another example of omega-3 functional foods are omega-3 eggs.  In this case, chickens or 
cows are fed a special diet to increase the EPA+DHA in their eggs.     
 
How Can I Incorporate Omega-3 Functional Foods into my Diet?  
 
Functional foods are intended to be substituted for their normal counterpart in your diet.  The best 
way to learn about the EPA + DHA content of the foods you purchase is to read the nutritional 
information on the packaging.  Highlighted below are some products available at grocery stores in the 
KW area that contain added EPA + DHA.  Our goal is not to convince you to purchase specific products 




Omega-3 eggs can be an excellent source of EPA + DHA however, it is still important to read 
nutritional labels to get the most EPA + DHA for the lowest cost.  
 
Liquid egg products tend to contain the highest amount of EPA + DHA out of all of the omega-3 
functional foods (up to 0.5 g EPA + DHA per two egg serving).  Another benefit is that some liquid egg 
products contain less dietary cholesterol than regular-shelled eggs.  The Heart and Stroke Foundation of 
Canada recommends that your daily dietary cholesterol intake does not exceed 300mg.  A two egg 
serving of liquid egg products typically contains 80 mg of dietary cholesterol, well within these daily 
cholesterol maximums.  These products taste the same and have the same baking properties as regular 
shelled eggs.  For use, follow instructions on the package. 
Shelled omega-3 eggs typically contain less EPA + DHA per serving than the liquid egg products 
but are preferable for making foods like hard boiled eggs. If a typical egg contains roughly 200 mg of 
cholesterol it may not be advisable to consume two or more shelled eggs every day. However, a two egg 
serving a couple times a week will allow you to keep your dietary cholesterol within recommendations.  
 
Other Omega-3 Functional Foods.  
 
There are various omega-3 yogurt, milk, soy milk, bread, cheese, peanut butter, bread, juice and 
oil-based spread (margarine) products on the market.  Be sure to read nutritional labels to select the 
brand with the most EPA + DHA.  Many products advertise their omega-3 content on the packaging. 
However, if the packaging does not list the amount of EPA + DHA or the ingredient list does not include 




(ALA), usually from flax seed or canola oil.  You should focus on consuming functional foods with added 
EPA and DHA.   
 
 
Product Containing EPA+DHA: 
             
 












Costs Associated with Functional Foods 
 
Functional foods are meant to replace their regular counterparts in your diet.  For instance, 
omega-3 eggs or omega-3 liquid eggs can replace regular eggs in your diet with little additional cost.  The 
researchers have previously assessed the potential additional costs associated with the consumption of 0.6 
g of EPA + DHA per day through functional food strategies.  This strategy does not substantially increase 
daily food cost ($9.87) as compared with a daily diet of similar products with no EPA and DHA ($8.96).  
It is important to note that since this cost analysis was performed, additional EPA + DHA functional 
foods have come on the market and it is becoming easier to add EPA and DHA to your diet in a more 
cost-effective manner.   
 
Not all functional foods are created equally.  The table on page 33 provides detailed information 
about the cost associated with getting 1 g of EPA+ DHA from each of the omega-3 functional foods on 
the market.  Keep reading product labels to watch for new EPA+DHA-containing foods that appear on the 
market.  While the researchers encourage you to substitute as many functional foods as possible into your 
diet, we also encourage you to pick the sources with the highest EPA + DHA content most often to 







Pasteurized orange juice, 
encapsulated fish oil (anchovy 
and sardine oil, fish gelatin, 
sodium polyphosphate, sodium 
ascorbate, soybean oil, canola 
oil, natural flavour, tocopherols, 





Milk, cream, modified milk ingredients (milk and 
whey proteins), blackberries, sugar, modified 
cornstarch, carrageenan, pectin, flax oil, natural 
flavour, rosemary extract, lemon juice 
concentrate, colour and active bacterial cultures 






RECIPES (Functional Foods) 
 
 The recipes shown below are intended to illustrate realistic ways to incorporate EPA + DHA 
functional foods into your typical diet.  Substitute these functional foods into your favourite recipes in 
place of their regular counterparts. 
 
For example, see http://www.eggs.ca/recipes/recipes.asp for more egg recipe ideas! 
 
Western Omelette  
(adapted from http://www.eggs.ca/recipes/Show_recipe.asp?actionID=392&NumPage=3) 
 
INGREDIENTS 
100mL   Naturegg, Breakfree liquid omega-3 eggs (or 2 omega-3 eggs) 
2 tbsp   water 
1 tsp   Becel, Omega-3 margarine with EPA+DHA 
¼ cup   finely chopped lean ham 
2 tbsp   chopped red and green pepper 
1 tbsp   finely chopped onion 
1  shredded or cubed Black Diamond Smart Growth Cheese String 
Salt and pepper to taste 
 
DIRECTIONS 
1.  Beat together eggs and water and season with salt and pepper. 
2.  Heat margarine over medium heat in an 8” (20 cm) non-stick pan. 
3.  Sauté ham, peppers and onion for 2 minutes or until tender. 
4.  Pour in egg and add cheese.  As egg sets, gently lift cooked portion at edges with a spatula to allow 
uncooked egg to flow underneath. 
5.  Once cooked, fold omelette in half with spatula and serve 
 
Makes 1 serving: ~545 mg EPA+DHA 
 
Broccoli Pie   
(adapted from http://www.eggs.ca/recipes/Show_recipe.asp?actionID=392&NumPage=3) 
 
INGREDIENTS 
  Becel, Omega-3 margarine with EPA+DHA  
  Salt and pepper 
½ cup   chopped green onions 
1 clove   garlic, finely chopped 
1 ½ cups cooked chopped broccoli 
½ cup  low fat cottage cheese 
300 mL  Naturegg, Breakfree liquid omega-3 eggs (or 6 omega-3 eggs) 
½ cup  Nielson, Dairy Oh! Milk 
½ cup  variety baking mix (ex: Bisquick) 
1 tbsp each crumbled goat cheese or light cream cheese and grated Parmesan cheese (or try 
shredded Black Diamond, Smart Growth Cheese Strings) 
 
DIRECTIONS (Broccoli Pie) 
1. Grease 9” pie plate and a non-stick skillet with margarine. 




3. Stir in cooked broccoli. 
4. Layer broccoli mixture and cottage cheese in pie plate. 
5. Whisk eggs with milk and baking mix and season with salt and pepper. 
6. Pour egg mixture over broccoli and cottage cheese in pie plate. 
7. Sprinkle top with goat and parmesan cheese.  
8. Bake for 25 minutes at 350 degrees F or until a knife comes out clean. 
 
Makes 4 servings: ~383 mg EPA+DHA per serving  
 
Fudgy Brownies 




1 ¼ cups  all purpose flour 
1 tsp   baking powder 
½ tsp   salt 
¾ cup   Becel, Omega-3 margarine with EPA+DHA 
¾ cup  cocoa powder 
1 cup  each packed brown sugar and white sugar 
200 mL  Naturegg, Breakfree omega-3 liquid eggs 
2 tsp  vanilla extract 
1 cup  chopped walnuts (optional)   
Icing: 
2 tbsp  Becel, Omega-3 margarine with EPA+DHA 
¼ cup  cocoa powder 
½ tsp  vanilla extract 
2 cups  sifted icing sugar 
¼ cup  Nielson, Dairy Oh! Milk 
 
DIRECTIONS 
1. Blend together flour, baking powder and salt and set aside. 
2. Melt margarine in microwave. 
3. Stir cocoa into margarine and beat in brown sugar, white sugar, eggs and vanilla. 
4. Stir in dry ingredients and walnuts. 
5. Grease 9” square pan with Becel, Omega-3 margarine with EPA+DHA. 
6. Spread batter into pan and bake for 40 minutes at 350 degrees F. 
7. To make icing, melt margarine in microwave and stir in cocoa, vanilla, icing sugar and milk.  
8. Beat until smooth. 
9. Allow brownies to cool before spreading on icing. 
 




½ cup  Nielson Dairy Oh! Milk 
100 g  Danone Danino Omega-3 yogurt 
½   banana 







1. Blend in a blender until smooth. 
2. Try adding or substituting in omega-3 ice cream, omega-3 orange juice or frozen fruit and/or ice 
cubes for a frozen smoothie, etc 
3. Try freezing mixture in a popsicle maker for homemade popsicles. 
 
~45mg EPA+DHA / smoothie 
 




2 cups  all-purpose flour 
3/4 cup  sugar 
2 tsp  baking powder 
1/8 tsp  salt 
1 cup  President’s Choice, Oh Mega J orange juice 
4 tbsp  Becel, Omega-3 margarine with EPA+DHA, melted 
50 mL  Naturegg, Breakfree omega-3 liquid eggs 
1 tsp  grated orange peel 
 
DIRECTIONS 
1. Combine flour, sugar, baking powder and salt. 
2. Stir in orange juice, melted margarine, egg and orange peel until all ingredients are just moist. 
3. Spoon batter into muffin cups, filling 2/3 full. 
Bake for 20-25 minutes at 375 degrees F or until wooden toothpick comes out clean from centre.  
 
Makes 9 muffins: ~67mg EPA+DHA per muffin.  
 
Indonesian Chicken (adapted from http://allrecipes.com/Recipe/Erins-Indonesian-
Chicken/Detail.aspx ) 
INGREDIENTS 
 1 cup uncooked long grain brown rice  
 2 cups water  
 1 pound (~450g) fresh green beans, trimmed and snapped  
 2 teaspoons olive oil  
 1 pound (~450 g) skinless, boneless chicken breasts - cut into chunks  
 3/4 cup low-sodium chicken broth  
 1/3 cup Life Brand smooth peanut butter  
 2 teaspoons honey  
 1 tablespoon low sodium soy sauce  
 1 teaspoon red chili paste (optional) 
 2 tablespoons lemon juice  
 3 green onions, thinly sliced  
 2 tablespoons chopped peanuts (optional)  
 
DIRECTIONS 
1. Cook rice in water.  
2. Steam green beans for 10 minutes, or until tender but crisp (or microwave beans).  




4. Mix the chicken broth, peanut butter, honey, soy sauce, chili paste, lemon juice in a saucepan 
over medium heat. Cook and stir 5 minutes, until slightly thickened. Mix in the green beans. 
Serve over rice. Garnish with green onions and peanuts. 
 




Sample Daily Diet 
Meal Food Amount mg 
EPA+DHA 
Breakfast Naturegg, Breakfree omega-3 liquid eggs 100g 500 
 Becel, omega-3 margarine with EPA+DHA 1 tsp 25 
 President’s Choice, Oh Mega J orange juice 1 1/2 cup 75 
 Wonder+, Headstart Bread with DHA 2 pieces 15 
 Life Brand peanut butter with EPA+DHA 2 tbsp 50 
 Banana 1 medium  
Snack Danone, Danino omega-3 yogurt 100g pot 40 
 Apple 1 medium  
Lunch Wonder+, Headstart Bread with DHA 2 pieces 15 
 Becel, omega-3 margarine with EPA+DHA 2 tsp 75 
 Low sodium lean ham slices 1 ounce  
 Black Diamond, Smart Growth Cheese String 1  20 
 Romaine lettuce 2 pieces  
 Tomato 3 slices  
 President’s Choice, Oh Mega J orange juice 1.5 cup 75 
Snack Danone, Danino omega-3 yogurt 100g pot 40 
 Baby carrots 10  
Dinner Skinless chicken breast 3 ounces  
 Mixed green salad 1.5 cups  
 Oil and vinegar salad dressing 1.5 tbsp  
 Brown rice 1 cup  
 Becel, omega-3 margarine with EPA+DHA 1 tsp 25 
 So Good Omega-3 DHA, soymilk 1 1/2 cup 48 















Cost at Various Locations 
      Sobey's  Zehrs Food Basics Shoppers 
Milk Nielson Dairy Oh! 1%, 2% 10 250 mL 6.29/ 4L 5.89/ 4L     
  Nielson Dairy Oh! Homo 10 250 mL 6.89/ 4L 4.59/ 4L     
  Silk Plus Omega-3, soymilk 30 250 mL 4.39/ 1.89L 4.29/ 1.89L     
  So Good Omega-3 DHA, soymilk 32 250 mL     3.77/ 1.89L   
        
Yogurt Danone Danino 40 100 g 3.19/ 4x100g 2.99/ 4x100g 2.97/ 4x100g   
  Danone Danino Go yogurt drink 20 93 g 5.49/ 8x93g 4.99/ 8x93g 4.97/ 8x93g   
                
Margarine Becel Omega-3 Plus Margarine (10g=2tsp) 50 10 g 4.79/ 680g 4.77/ 680g  4.77/ 680g    
                
Juice Tropicana Essentials Omega-3 20 250 mL 4.49/ 1.89L   4.29/ 1.89L    
 * froz.  
 concentrate 
Minute Maid Fruit Solutions Omega-3 















  Lassonde Oasis Blueberry & Concord Grape 20 250 mL  4.29/ 1.89L   3.97/ 1.89L   
  PC Oh Mega J (orange juice) 50 250 mL   3.79/ 1.89L     
                
Eggs Naturegg Breakfree omega-3 (liquid) 250 50 g 3.69/ 500g 3.69/ 500g 2.97/ 500g   
 1 egg = 50 g Naturegg Omega-3 eggs 75 50 g 3.69/ 12x50g 3.79/ 12x50g     
  Naturegg Omega-3 Pro eggs 125 50 g 3.99/ 12x50g 3.89/ 12x50g     
  Complements Omega-3 ~75 50 g 3.59/ 12x50g       
  PC Omega-3  ~75 50 g   3.49/ 12x50g     
  Gray Ridge large eggs 85 50 g     3.17/ 12x50g   
  Gray Ridge x-large eggs (chol=225mg) 102 60 g      3.37/ 12x60g   
                
Peanut 
Butter Life Brand, Smooth Peanut Butter 25 30 g       2.99/ 500g 
                
Cheese 
Black Diamond, Smart Growth Cheese 
Strings 20 21 g 6.49/ 252g 6.29/ 252g     
        
Bread Wonder+, Headstart Bread with DHA 15 75 g $3.19/ 675g $2.99/ 675g   
Costs presented above were collected August 2007/January 2008 and may change over time.  These costs do not include any applicable taxes. 
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Functional Foods Dietary Advice Package 
Summary Sheet 
 
Cardiovascular benefits associated with two omega-3 fatty acids:  
 Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) 
 
Goal:  
 1 gram/day of EPA + DHA from functional foods  
 
How to accomplish goal: 
 Substitute EPA+DHA-enriched functional foods into your regular diet in place of their regular 
counterparts (ex: omega-3 eggs substituted for regular chicken’s eggs) 
 Do not make other significant changes to your diet for 12 months 
 Select functional foods with the highest EPA+DHA content most frequently  
 Select EPA+DHA-enriched functional foods that best fit your food budget  
 See Table p. 33 for the EPA+DHA content of various functional foods 
 Become familiar with reading nutritional labels: ‘omega-3’ doesn’t mean the product contains 
EPA+DHA  
 Omega-3 from flaxseed:  no EPA+DHA 
 Omega-3 from a fish oil or algae source:  look for EPA+DHA content on the label 











  Benefits to the Participant:  
 Receive individual diet counselling  
 Individual dietary assessment (including caloric and nutrient analysis)  
and cardiovascular disease risk factor assessment  
 Learn how to include omega-3 fatty acids into your diet 
 Learn about the potential health benefits of omega-3 fatty acids 
 
Up to $200 participant remuneration 
                 
 
  Participant Procedures: 
 Visit the University of Waterloo 7 times over 1 year 
 Record all food consumed for 3-day intervals on 6 occasions 
 Collect duplicate amounts of food consumed for 3-day interval once 




















For more information, or to volunteer please contact: 
 
The Laboratory of Nutraceutical and Nutritional Research 
Department of Kinesiology  
University of Waterloo 
Phone – (519) 888-4567 ext 37873 
Email – apatters@uwaterloo.ca 
This project has been reviewed and received ethics clearance through the Office of 





Men and Women Aged 35-50 
Needed  
For research on nutritional strategies 




ADVERTISEMENT APPEARING IN KITCHENER-WATERLOO PENNYSAVER: 
 
NUTRITION/ OMEGA-3 fatty acid research at the University of Waterloo. Participants aged 
35-50 needed. Up to $200 remuneration. Participants must collect a diet sample, keep 6 food 
diaries, provide 6 blood samples to certified technicians over 7 visits over 1 year. Call (519)888-
4567 x37873 or email apatters@uwaterloo.ca for details. This project was reviewed and received 




INFORMATION AND CONSENT FORM 
 
Laboratory of Nutritional & Nutraceutical Research 
Department of Kinesiology 
University of Waterloo 
 
Title of Project: Evaluation of the Adherence to Nutraceutical, Functional Food and Whole 
Food Strategies to Increase Omega-3 Fatty Acid Intakes in Men and Women at Risk for 
the Development of Cardiovascular Disease 
 
Principal Investigator: Ken D. Stark 
   University of Waterloo, Department of Kinesiology 
   (519) 888-4567 Ext. 37738 
 
Co-Investigator:  Rhona Hanning 
   University of Waterloo, Department of Health Studies 
   (519) 888-4567 Ext. 35685 
 
Student Investigator:  Ashley Patterson  
   University of Waterloo, Department of Kinesiology 
   (519) 888-4567 Ext. 37873 
 
Online Information: Visit http://www.n3pufa.org or email apatters@uwaterloo.ca 
 
 
Purpose of Study: 
 
Omega-3 fatty acids, particularly the longer chain eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) usually found in fish can help prevent heart disease.  Most 
Canadians do not eat fish and eat low amounts of these important fatty acids. 
 
In the present study, you will receive dietary advice from a dietician or a nutritional science 
graduate student supervised by a licensed dietician about how to increase the amount of EPA and 
DHA in your diet by different strategies.  You will be randomly assigned to advice based either 
on whole foods (foods naturally containing EPA and DHA such as fish), functional foods (new 
manufactured food products with EPA and DHA added), nutraceutical (encapsulated oils with 
EPA and DHA) or a combination of all strategies. We will compare the effectiveness of the 
advice over 1 year by determining how much EPA and DHA you have eaten.  For us to 
determine your EPA and DHA intake, you will be asked to provide blood samples and complete 
dietary records and questionnaires at various time points over one year.  You will also be asked 
to provide a 3-day food sample on one occasion so that omega-3 fatty acids can be directly 
measured as well as look at what other nutrients are associated with increased omega-3 intake.   
 






Procedures Involved in this Study:  
 
As a participant in this study, you will be asked to complete the following:  
 
1. Fast overnight before providing a finger-prick blood sample to determine eligibility for 
this study.  The fast includes no food or drink (water is allowed) 8-12 hours before the 
sample is collected. 
2. Complete a questionnaire about your eating habits and a health screening form during the 
initial screening for study eligibility (2 weeks before study outset).  The 3-day dietary 
record you receive at this time can be completed and returned to the investigators at week 
0.   
3. Have your height, weight, resting heart rate and blood pressure measured on each visit 
following initial eligibility assessment.  
4. You are asked to advise the researchers of any changes to your medications or if you 
begin taking any medications during the study. 
5. Refrain from donating blood or participating in any other study (ex: involving diet 
modification, stress, physical activity, etc) 14 days before Week 0 until week 52. 
6. Fast overnight and then have about 20mL of venous blood taken (see details in 
explanation of procedure and risks). Have your resting heart rate, blood pressure height 
and weight measured on Week 0.   
7. Receive dietary advice to increase omega-3 fatty acid intake on Week 0. 
8. Follow dietary advice provided by the researchers over the subsequent 52 weeks.  Since 
you will be assigned to one of four approaches to increase omega-3 fatty acid intake you 
will be asked to not make diet changes other than those assigned.  
9. After fasting overnight, have venous blood sampling at weeks 4, 8, 12, 24 and 52.  
Completed 3-day dietary records will be collected by the researchers at these times.  
Resting heart rate, blood pressure and weight will also be measured. 
10. Collect duplicates of all food consumed in provided containers over the course of 3 days. 
Please temporarily store the food in a refrigerator or freezer and bring with you on your 
week 4 visit.   
11. Allow your blood to be analyzed for cardiovascular disease risk parameters and other 
biochemical markers including fatty acids, total and HDL cholesterol and glucose.  
 
Further information about each of these tests is presented on the following sheets.  All tests will 
be completed at our laboratory at the University of Waterloo. 
 
Time Commitment:  
 
The maximum time requirement for these tests will be 15-30 min in the laboratory on days when 
venous blood samples and completed dietary records are collected (Weeks 4, 8, 12, 24 and 52).  
The venous blood sample and completed dietary record collection as well as nutritional advice 


















Personal Benefits of Participation: 
 
The purpose is to determine which of four strategies is most effective in increasing omega-3 intake and 
blood levels of omega-3 fatty acids to a desirable level.  You will receive education including background 
information regarding omega-3 fatty acids, what foods contain them and the potential health benefits of 
eating omega-3 fatty acids.  Information on this study, previous studies and omega-3 fatty acids can be 
obtained at http://www.n3pufa.org.  
 
We will provide information regarding your personal omega-3 blood status as well as your blood 
lipid profiles, including cholesterol, in comparison to current health recommendations.  You will 
receive this information at the completion of the study.  You will also be asked to complete 3-
day dietary assessments and food frequency questionnaires.  These assessments, along with 
nutritional advice provided by the researchers, may help you to examine your eating behaviours 
and to assist you in making healthy food choices.   
 
Detailed Explanation of Procedures and Risks: 
 
Three-Day Dietary Records and Food Frequency Questionnaire – You will be asked to complete 
a 3-day dietary record and food frequency questionnaire before returning to the laboratory for 
dietary advice and blood sampling.  Subsequent 3-day dietary records will also be requested at 
weeks 4, 8, 12, 24 and 52.  Forms and detailed instructions are attached.  The dietary record is a 
detailed list of everything you eat and drink for 3 days.  This information will allow us to 
compare your diet to the results of the other tests.  The food frequency questionnaire will pose 49 
questions in a checkbox format about your usual eating patterns over the last 12 months to 
estimate your habitual intake of EPA and DHA fatty acids.  This questionnaire will also assess 
the frequency of meals prepared at home versus purchased prepared meals and/or restaurant 
meals, your involvement in grocery purchases, food selections, as well as food preparation, and 
grocery shopping.  Finally, the questionnaire will pose three sociodemographic-based questions 
including your cultural/racial background, your educational background and your annual 
household income.   
 
Dietary Advice – Dietary advice strategies are assigned randomly.  You will receive individual 
diet counseling by a licensed dietician or a nutrition graduate student supervised by a licensed 
dietician via structured interviews and a take home document about the benefits of omega-3 fatty 
Week 0 





Blood sampling  
Week 12 
Blood sampling  
Week 24 
Blood sampling  
Week 52 





3d Food  
Record 3d Food  
Record 
3d Food  
Record 




3d Food  
Record 
3d Food  
Record 





acids.  Ashley Patterson will contact you at week 1 of the study to answer any questions you may 
have regarding the dietary advice.  Ashley will also contact you on weeks 3 and 7 and 11 to 
answer any questions and confirm scheduling for return visits to the laboratory.  For the visits at 
week 24 and 52, we will contact you 1 month in advance to schedule a visit and then call you the 
week before to remind you. 
 
Venous Blood Sampling – This is similar to blood samples taken by your physician. Venous 
blood will be collected under sterile conditions with an 18-21 gauge needle from a vein in your 
arm and will be collected into sterile glass tubes. For each visit approximately 20 mL (~4 tsp) of 
blood will be collected.  This procedure may result in slight bruising and bleeding.  This can be 
minimized by the application of direct pressure to the point of needle entry into the vein.  The 
use of sterile gauze and alcohol swipes minimizes the risk of infection.  Blood lipids (fats) levels 
including cholesterol and omega-3 fatty acids as well as blood glucose levels will be determined. 
Venous blood sampling will be performed by trained and competent laboratory personnel 
following universal guidelines for handling blood and blood products. 
 
Fingertip Prick Blood Sampling –This sample will be taken during the eligibility assessment to 
determine your baseline omega-3 fatty acid status.  This process involves a small and sterile 
needle pricking the finger and blood being collected on a small strip of paper.  There is a slight 
risk of bruising with this technique.  The use of sterile gauze and alcohol swipes minimizes the 
risk of infection.  Fingertip prick blood sampling will be performed by trained and competent 
laboratory personnel following universal guidelines for handling blood and blood products. 
 
Encapsulated Fish Oil Consumption – Dietary advice strategies are assigned randomly.  Some 
participants will be assigned to the nutraceutical or combined strategy that recommends that 2-3 fish oil 
capsules be eaten daily for the duration of the study.  It is recommended that the capsules be consumed 
with meals throughout the day.  Eating oil capsules may cause nausea and loose stools in some 
participants.  Others may have an increased incidence of "burping" and minor stomach discomfort.  
Participants who have difficulty swallowing pills or capsules may not be able to complete the study. 
 
Three-Day Food Duplicate Collection – You will be asked to collect duplicates of all the meals and 
snacks, including drinks, you consume over the course of three days.  Detailed instructions are listed 
below. You will refrigerate or freeze this food collection at home until you return it to the lab during week 
4.  This food collection will be used to directly analyze the fatty acid content of your diet as well as the 









INSTRUCTIONS FOR THREE-DAY FOOD DUPLICATE COLLECTION 
 
1. Select two weekdays and one weekend day for your food duplicate collection.  (Same three days 
as the food record returned on week 4)   
2. Please do not change your normal diet on collection days.  
3. Please store your food and beverage collection in large plastic containers.  We request that for 
ALL food, drinks and snacks you eat (including condiments, dressings, etc) you place the same 
amount in the plastic containers.  You may omit water in your collection.  
4. Please store your containers in the refrigerator or freezer until you return them to the lab for your 
visit on week 4. 
5. Please take care to be as accurate as possible when collecting food duplicates.  For instance, if 
you do not finish a meal please only add the amount eaten to the plastic container.  Using 
measuring cups, kitchen scales, etc will be helpful.   




Participants are asked to follow their normal diet until dietary advice is given by the researchers.  
Participants are asked to consume only the sources of omega-3 fatty acids advised by the 
researchers and avoid all other sources.  You are asked to advise the researchers of any changes 
to your medications or if you begin taking any medications during the study.  Please refrain from 
donating blood or participating in other experiments (ex: diet modification, stress or physical 
activity studies) during this study.  Participants are asked to fast overnight (water allowed) and 
refrain from drinking alcohol in the 24-hour period immediately prior to testing.   
 
Health Screening Form: 
 
This questionnaire asks some questions about your health status. This information is used to 
guide us with your entry into the study and ensure your suitability for the study. If you have 
kidney problems, diabetes or cardiovascular disease including bleeding disorders, you will not be 
eligible to participate in the study. 
 
Changing Your Mind about Participation: 
 
Your participation is voluntary.  You may withdraw from this study at any time without penalty. 
To do so, indicate this to the researcher or one of the research assistants by saying, "I no longer 
wish to participate in this study".  Once you withdraw, we will ask if you are willing to provide 
more information about what motivated your decision to withdraw.  If you agree to provide more 
information, we will ask you to identify the specific reason or reasons for your decision to 
withdraw.  This can help us to identify problems in the study that we did not anticipate.  You do 
not have to provide any answers regarding your decision to withdraw. 
 
Confidentiality: 
To ensure the confidentiality of individuals’ data, each participant will be identified by an 
identification code known only to the principal investigator and his research assistants.  All data 




data have been entered under an anonymous code and the feedback provided, the paper records 
and code sheet will be confidentially shredded.  
Testing will be performed under private conditions where only laboratory personnel are present.  
No spectators will be allowed during the testing period.  Blood samples will be stored at -80ºC in 
a secure location in the Department of Kinesiology.  After biochemical analyses and data 
interpretation is complete, any remaining blood samples will be disposed in compliance with 




After the study is completed, you will be provided with a feedback sheet that will include your 




You will receive a total of $200 remuneration for completing the study.  Partial payment will be provided 
upon early withdrawal.  The sum will be proportional to the length of time and the number of procedures 
you undertake.  This is broken down into $25 per visit with blood sample collection (6 visits after 
eligibility assessment) and food diary collection and $50 for the food duplicate collection.  This is 





If you have any questions about the study at any time, please contact either Professor Ken Stark 
at his office (519) 888-4567 ext. 37738, Rhona Hanning at extension 35685 or Ashley Patterson 
at extension 37873, or the Lab Assistants at ext. 37873. 
 
Concerns about Your Participation 
 
I would like to assure you that this study has been reviewed and received ethics clearance 
through the Office of Research Ethics. However, the final decision about participation is yours. 
If you have any comments or concerns resulting from your participation in this study, you may 








I agree to take part in a research study being conducted by Professor Ken Stark, Professor Rhona 
Hanning and Ashley Patterson of the Department of Kinesiology, University of Waterloo. 
I have made this decision based on the information I have read in the Information letter. All the 
procedures, any risks and benefits have been explained to me. I have had the opportunity to ask 
any questions and to receive any additional details I wanted about the study.  If I have questions 
later about the study, I can ask one of the researchers (Professor Ken Stark at his office (519) 
888-4567 ext. 37738, Professor Rhona Hanning at extension 35685 or Ashley Patterson at 
extension 37873) or by emailing apatters@uwaterloo.ca. 
 
I understand that I may withdraw from the study at any time without penalty by telling the 
researcher.  
 
This project has been reviewed by, and received ethics clearance through, the Office of Research 
Ethics at the University of Waterloo.  I am aware that I may contact this office (888-4567, ext. 
36005) if I have any concerns or questions resulting from my involvement in this study. 
 
 
Printed Name:   
 
Local Address:   
 
Phone #:     Birth Date:  
 
Signature:   
 
_______________________________ ___________________________________ 












COMPLETING THE DIETARY RECORD 
 
 Record all food and beverages consumed for 3 days (including one weekend day). 
 Do not alter your intake during the recording period. 
 Record if you are taking a vitamin and mineral supplement. 
 Be sure to include beverages (non-alcoholic and alcoholic) and all snack foods. 
 Record what you are eating at the time of the meal and not afterwards. 
 Be sure to include brand names wherever possible. 
 Remember: try to estimate less and measure more.  The use of measuring cups/spoons 
will be helpful. 
 Recipes may be attached.  Please indicate how much of the recipe you ate (ex: 1/5 of a 
casserole recipe). 
 Include the source of the meal (ex: home cooked, Burger King, etc.) in the appropriate 
column. 
 
There is a wrong way and a right way 
  
2 hot dogs 2 enriched white hot dog buns (Wonder®) 
2 (75g each) boiled all beef wieners 
(Shopsy’s®) 
2 tbsp ketchup 
1 tbsp mustard 
1 glass of milk 1 10 fl. oz. glass of 2% milk (Neilson, 
Dairy Oh!®) 
1 large apple 1 Granny Smith apple (diameter 3”) 
1 small salad with ranch dressing 1 small salad: 
1 cup of shredded iceberg lettuce 
¼ cup chopped, raw carrots 
4, ¼” thick slices of tomato  
1” cube low fat cheddar cheese (Kraft®) 
4 tbsp ranch dressing (Hidden Valley®) 
1 yogurt 100g fat free strawberry yogurt, sweetened 






DIETARY ANALYSIS INTAKE FORM 
Day 1  
Date:     Name: 
Please Consult your instruction sheets for directions on how to fill out this form 
List of Foods 
No. Amount Detailed Description of Food Source 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    




DIETARY ANALYSIS INTAKE FORM 
Day 2 
Date:     Name: 
Please Consult your instruction sheets for directions on how to fill out this form 
List of Foods 
No. Amount Detailed Description of Food Source 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    





DIETARY ANALYSIS INTAKE FORM 
Day 3 
Date:     Name: 
Please Consult your instruction sheets for directions on how to fill out this form 
List of Foods 
No. Amount Detailed Description of Food Source 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    





HEALTH SCREENING FORM 
Evaluation of the Adherence to Nutraceutical, Functional Food and  
Whole Food Strategies to Increase Omega-3 Fatty Acid Intakes in Men and Women at Risk 
for the Development of Cardiovascular Disease 
 
Past Health Problems:  
 
Rheumatic Fever (  )  Epilepsy   (  ) 
Heart Murmur (  )  Varicose Veins  (  ) 
High Blood Pressure (  )  Disease of Arteries  (  ) 
High Cholesterol (  )  Emphysema, Pneumonia, 
Congenital Heart Disease (  )   Asthma, Bronchitis (  ) 
Heart Attack (  )  Back Injuries   (  ) 
Heart Operation (  )  Kidney and liver disease (  ) 
Diabetes (diet or insulin) (  )  Heartburn   (  ) 
Ulcers (  )  Bleeding disorders  (  ) 
Bleeding from Intestinal Tract (  )  Lipid Metabolism disorders (  ) 
Enteritis/colitis/diverticulitis       (  )  Other (describe overleaf) (  ) 
       
Present Health: 
 
List current problems:   List medications taken now or in last 3 months: 
1.     1. 
2.     2. 




Irregular Heart Beat (  )  Fatigue  (  ) 
Chest Pain  (  )  Cough Up Blood (  ) 
Short of Breath (  )  Back Pain/Injury (  ) 
Persistent Cough (  )  Leg Pain-Injury (  ) 
Wheezing (asthma) (  )  Dizziness  (  ) 
 
For females: Pregnant ____  Nursing ___ 
 
Are you currently taking any oral contraceptives?  Yes  ( )     No  ( ) 
 
When was the last day of your menses? ____________ 




Never (  ) Ex-smoker (  )  Regular (  ): Average # cigarettes/day ____ 
 
Birth Date (mm/dd/yy): ___________________________ 







Do you take vitamin-mineral or other supplements regularly? Yes (  ) No (  ) 
 If so, please list:  
  
Type (ex: multivitamin)  Brand (ex: Centrum)   Frequency (ex: daily)   Amount (ex: 1, 500mg  






Do you follow a vegetarian, vegan or restricted diet?   Yes (  ) No (  ) 






Do you have any food allergies/intolerances?    Yes (  ) No (  ) 






Current Physical Activity Status: 
 
I consider my physical activity status to be: High (  ), Average (  ), Low (  ). 
 
List the activities that you do on a regular basis: 










The current study has been identified as requiring medical clearance:    





APPENDIX C  
Appendix Table C.1. Fatty acid composition of fish oil capsules for dose-response study
1
 
Fatty Acid Weight % of total fatty acids Concentration (g/capsule) 
Saturated Fatty Acids 29.8 ± 0.7 0.24 ± 0.01 
14:0 7.3 ± 0.1 0.06 ± <0.01 
16:0 15.7 ± 0.4 0.13 ± 0.01 
16:0 dma 0.6 ± <0.1 <0.01 ± <0.01 
17:0 0.7 ± <0.1 0.01 ± <0.01 
18:0 3.6 ± 0.3 0.03 ± <0.01 
18:0 dma 1.5 ± <0.1 0.01 ± <0.01 
20:0 0.2 ± <0.1 <0.01 ± <0.01 
22:0 0.1 ± <0.1 <0.01 ± <0.01 
23:0 <0.1 ± <0.1 <0.01 ± <0.01 
24:0 <0.1 ± <0.1 <0.01 ± <0.01 
Monounsaturated Fatty Acids 24.8 ± 0.3 0.20 ± 0.01 
14:1 <0.1 ± <0.1 <0.01 ± <0.01 
16:1n-7 8.3 ± 0.1 0.07 ± <0.01 
18:1 dma 2.5 ± 0.1 0.02 ± <0.01 
18:1n-7 3.0 ± 0.1 0.02 ± <0.01 
18:1n-9 9.5 ± 0.2 0.08 ± <0.01 
20:1n-9 0.8 ± <0.1 0.01 ± <0.01 
22:1n-9 0.3 ± <0.1 <0.01 ± <0.01 
24:1n-9 0.3 ± <0.1 <0.01 ± <0.01 
n-6 Polyunsaturated Fatty Acids 3.6 ± 0.1 0.03 ± <0.01 
18:2n-6 1.3 ± <0.1 0.01 ± <0.01 
18:3n-6 0.2 ± <0.1 <0.01 ± <0.01 
20:2n-6 0.2 ± <0.1 <0.01 ± <0.01 
20:3n-6 0.1 ± <0.1 <0.01 ± <0.01 
20:4n-6 1.2 ± <0.1 0.01 ± <0.01 
22:2n-6 <0.1 ± <0.1 <0.01 ± <0.01 
22:4n-6 0.1 ± <0.1 <0.01 ± <0.01 
22:5n-6 0.3 ± <0.1 <0.01 ± <0.01 
n-3 Polyunsaturated Fatty Acids 36.4 ± 0.6 0.29 ± 0.01 
18:3n-3 0.7 ± <0.1 0.01 ± <0.01 
18:4n-3 2.4 ± 0.1 0.02 ± <0.01 
20:3n-3 0.1 ± <0.1 <0.01 ± <0.01 
20:4n-3 0.8 ± <0.1 0.01 ± <0.01 
20:5n-3 19.2 ± 0.5 0.15 ± <0.01 
22:5n-3 2.4 ± <0.1 0.02 ± <0.01 
22:6n-3 10.8 ± <0.1 0.09 ± <0.01 
Total 94.6 ± 0.5 0.75 ± 0.02 
1
 Values are means ± sd, (n=3). 





Appendix Figure C.1.  Gas chromatogram of fish oil capsule fatty acid composition.  Analysis on a DB-FFAP 15m capillary column 
with temperature program as follows: initial, 150°C with a 0.25 min hold; ramp: 35°C/min - 200°C, then by 8°C - 225°C with a 3.2 









 Purpose:  To improve how omega-3 fatty acid intakes are measured. 
 
 You may be eligible if you:  
 
 Eat fish less than once a week and do not take fish oil supplements 
 Do not have allergies or sensitivities to fish 
 Do not have diabetes, cardiovascular disease or lipid metabolism disorders 
 
 Participants will be asked to:   
 
 Attend a baseline screening (including a fingertip blood sample) 
 Consume an omega-3 fatty acid dietary supplement daily for 2 months 
Supplements are commercially available and participants will be asked to consume two 
different doses over the 2 month period 
 Fast from food for 8-12 hrs and provide a fingertip blood sample (0.2mL) on 6 visits 
over 2 months  (visits will last up to 20 min each) 
 Fast from food for 8-12 hrs and provide a venous blood sample (20mL) collected by 
certified technician on 3 visits  (visits will last 30-45 minutes each) 
 Record all food consumed for 3 days once and complete an omega-3 fatty acid  
intake questionnaire twice 
 
Participants will receive up to $75 remuneration  
 
 Benefits to the participant:  
 
 Receive individual dietary and heart disease risk factor feedback 

















For more information, or to volunteer please contact: 
 
The Laboratory of Nutraceutical and Nutritional Research 
Department of Kinesiology, University of Waterloo 
Email – apatters@uwaterloo.ca,  Phone – (519) 888-4567 x37873 
This project has been reviewed and received ethics clearance through the Office of Research 





Men and Women Ages 18-35 Needed  




Email Recruitment Script 
 
Mailing Lists Targeted: Applied Health Science and Graduate Student Listservs 
Email Subject Line:  Seeking Participants for a Nutrition Research Study 
 
Email Text:  
The Laboratory of Nutritional and Nutraceutical Research in the Department of Kinesiology is 
looking for male and female participants between the ages of 18 and 35 for a nutrition research 
study.  
 
Study Description:   
Dietary omega-3 fatty acids can help prevent heart disease.  However, many Canadians do not 
eat enough omega-3 fatty acids to meet current recommendations.  The Laboratory of Nutritional 
and Nutritional Research is conducting a research study to improve how omega-3 fatty acid 
intakes are measured.   
 
 You may be eligible if you:  
 Eat fish less than once a week and do not take fish oil supplements 
 Do not have allergies or sensitivities to fish 
 Do not have diabetes, cardiovascular disease or lipid metabolism disorders 
 
Participant will be asked to: 
 Attend a baseline screening (including a fingertip blood sample) 
 Consume an omega-3 fatty acid dietary supplement daily for 2 months 
Supplements are commercially available and participants will be asked to consume two 
different doses over the 2 month period 
 Fast from food for 8-12 hrs and provide a fingertip blood sample (0.2mL) on 6 visits over 
2 months  (visits will last up to 20 min each) 
 Fast from food for 8-12 hrs and provide a venous blood sample (20mL) collected by 
certified technician on 3 visits  (visits will last 30-45 minutes each) 
 Record all food consumed for 3 days once and complete an omega-3 fatty acid intake 
questionnaire twice 
 
Participants will receive up to $75 remuneration  
 
Benefits to the participant:  
 Receive individual dietary and heart disease risk factor feedback 
 Learn about dietary nutrients and related health benefits  
 
For more information or to volunteer please contact: 
The Laboratory of Nutraceutical and Nutritional Research 
Department of Kinesiology, University of Waterloo 
Phone – (519) 888-4567 ext 37873 
Email – apatters@uwaterloo.ca 
This project has been reviewed and received ethics clearance through the Office of Research 




INFORMATION AND CONSENT FORM 
 
Laboratory of Nutritional & Nutraceutical Research 
Department of Kinesiology 
University of Waterloo 
 
Title of Project: Assessment of blood measures of omega-3 highly unsaturated fatty acids in 
response to current intake recommendations in men and women. 
 
Faculty Supervisor: Professor Ken D. Stark 
   University of Waterloo, Department of Kinesiology 
   (519) 888-4567 Ext. 37738 
 
Student Investigators: Ashley Patterson, PhD Student  
   University of Waterloo, Department of Kinesiology 
   (519) 888-4567 Ext. 37873 
   apatters@uwaterloo.ca 
 
   Alan Chalil  
   University of Waterloo, Department of Kinesiology 
   (519) 888-4567 Ext. 37873 
 
Purpose of Study: 
Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
found in seafood, can help prevent heart disease.  It is currently recommended that healthy 
individuals consume 250-500 milligrams (mg) per day of EPA and DHA combined for optimal 
health.  This amount of EPA and DHA is equal to 2 servings of oily fish (120g/4oz each) per 
week.  Many Canadians do not regularly eat seafood or other EPA and DHA sources and do not 
meet these recommendations.   
 
The amount of omega-3 fatty acids in an individual's diet is reflected by the amount of omega-3 
fatty acids in their blood.  The goal of this study is to examine how to use a blood sample to 
measure omega-3 fatty acid intakes in men and women.   
 






Procedures Involved in this Study:  
As a participant in this study, you will be asked to:  
 
Screening Procedures:  
1. Fast overnight before providing a fingertip prick blood sample to determine eligibility for 
this study.  The fast includes no food or drink (water is allowed) for 8-12 hours and no 
alcohol for 24 hours before the sample is collected. 
2. Complete questionnaires about your omega-3 fatty acid intake and a health status during 
 the initial screening for study eligibility. 
 
Study Procedures:  
 
3. During the study, continue to consume your usual diet and do not make changes.  In 
particular, do not eat seafood or enriched foods / dietary supplements containing EPA and 
DHA, other than those provided by the researchers.  An example of an enriched food is 
an omega-3 egg.  
4. Follow your usual physical activity regime during the study and do not make significant 
changes.   
5. Advise the researchers of any changes to your medications or if you begin taking any 
medications during the study. 
6. Refrain from donating blood or participating in any other study (eg: involving diet 
modification, stress or physical activity) upon entry into the study. 
7. Fast overnight and have approximately 20mL (4 tsp) of venous blood taken at baseline 
and at weeks 4 and 8 and a fingertip prick blood sample (0.2 mL) on weeks 1-3 and 5-7 
(see details in explanation of procedure and risks).  
8. At baseline, receive instructions for filling out a 3-day dietary record.  Completed records 
can be returned to the investigators at the week 1 visit.   
9. Have your height, weight, resting heart rate and blood pressure measured at baseline and 
at weeks 4 and 8.  Blood pressure and heart rate will be measured using an automatic 
monitor. 
10. Consume a total of 250 mg/d of EPA+DHA (1000 mg/d of fish oil) in the first 4 weeks 
and 500 mg/d of EPA+DHA (2000 mg/d of fish oil) in the second 4 weeks by consuming 
a daily, commercially available supplement.   
11. Return any unused dietary supplements provided by the researchers at weekly visits. 
12. Repeat the questionnaire measuring omega-3 fatty acid intake at the week 8 visit. 
13. Allow blood samples taken to be analyzed for fatty acid composition.  
 
Further information about each of these tests is presented on the following sheets.  All tests will 
be completed at the Laboratory of Nutritional and Nutraceutical Research at the University of 
Waterloo. 
 
Time Commitment:  
The maximum time requirement for these tests will be 30-45 min on days when venous and 
fingertip prick blood samples are collected (baseline and weeks 4 and 8).  The fingertip prick 







 -Fingertip prick blood sample 
 -Health screening questionnaire 
 -Omega-3 fatty acid intake questionnaire 
 
Eligible participants will be invited to participate in the following: 
 
Baseline 
 -Venous blood sample (20 mL) 
 -Measurement of height, weight, resting heart rate and blood 
   pressure 
 -Instructions for 3-day dietary record 
Week 1 
 -Fingertip prick blood sample (0.2 mL) 
 -Return 3-day dietary record  
Weeks 2-3  
 -Fingertip prick blood sample (0.2 mL) 
Week 4 
 -Venous blood sample (20 mL) 
 -Measurement of height, weight, resting heart rate and blood 
   pressure 
 -Return unused fish oil supplements from first month 
Weeks 5-7  
 -Fingertip prick blood sample (0.2 mL) 
Week 8 
 -Venous blood sample (20 mL) 
 -Omega-3 fatty acid intake questionnaire 
 -Measurement of height, weight, resting heart rate and blood 
   pressure 

















Study Benefits to the Scientific Community & Society:  
 
The results of this study will be useful for establishing blood-based markers of dietary EPA and 
DHA intake.  Such markers could be used to screen for individuals with low EPA and DHA 
intakes and to monitor changes in dietary intake, particularly for individuals at risk for 
cardiovascular disease.  The information will also show whether current intake recommendations 
are sufficient to allow men and women to meet blood targets for preventing cardiovascular 
disease. 
 
Personal Benefits of Participation: 
You will receive educational information including background regarding omega-3 fatty acids, 
dietary sources, recommended intakes and associated health benefits.   
We will provide information regarding your personal omega-3 blood status in comparison to 
current health recommendations.  You will also receive feedback of your overall dietary and 
omega-3 fatty acid intakes.  You will receive this information at the completion of the study.  
During the study, you will also be asked to complete a 3-day dietary assessment and omega-3 
fatty acid intake questionnaires.  These assessments, along with omega-3 recommendations 
provided by the researchers, may help you to examine your eating behaviours and to assist you in 
making healthier food choices.   
 
Detailed Explanation of Procedures and Risks: 
 
Three-Day Dietary Records and Omega-3 Fatty Acid Intake Questionnaire – You will be asked 
to complete a 3-day dietary record and omega-3 fatty acid intake questionnaire at the beginning 
of the study.  A subsequent questionnaire will be requested on week 8.  Forms and detailed 
instructions are attached.  The dietary record is a detailed list of everything you eat and drink for 
3 days.  This information will provide an overview of your daily dietary intake.  The omega-3 
fatty acid intake questionnaire will pose 48 questions in a checkbox format about your usual 
eating patterns over the past months to estimate your usual intake of EPA and DHA.  This 
questionnaire will also assess the frequency of meals prepared at home versus purchased 
prepared meals and/or restaurant meals, your involvement in grocery purchases, food selections, 
as well as food preparation, and grocery shopping.  Finally, the questionnaire will pose three 
sociodemographic-based questions including your cultural/racial background, your educational 
background and your annual household income.   
 
Venous Blood Sampling – This is similar to blood samples taken by your physician. Venous 
blood will be collected under sterile conditions with an 18-21 gauge needle from a vein in your 
arm and will be collected into sterile glass tubes. For each visit approximately 20mL or 4tsp of 
blood will be collected.  This procedure may result in slight bruising and bleeding.  This can be 
minimized by the application of direct pressure to the point of needle entry into the vein.  The 
use of sterile gauze and alcohol swipes minimizes the risk of infection.  Blood fatty acid levels 
will be determined. Venous blood sampling will be performed by trained and competent 
laboratory personnel following universal guidelines for handling blood and blood products. 
 
Fingertip Prick Blood Sampling –This sample will be taken during the eligibility assessment to 




involves a small and sterile needle pricking the finger and blood being collected on a small strip 
of paper.  There is a slight risk of bruising with this technique.  The use of sterile gauze and 
alcohol swipes minimizes the risk of infection.  Fingertip prick blood sampling will be 
performed by trained and competent laboratory personnel following universal guidelines for 
handling blood and blood products. 
 
Encapsulated Fish Oil Consumption – You are asked to consume 250mg/day of EPA+DHA 
during the first month and 500mg/day of EPA+DHA during the second month by consuming a 
fish oil supplement.  It is recommended that the fish oil capsules be consumed with meals.  In 
addition to fish oil, the supplements are composed of a softgel capsule (gelatin, glycerin and 
water) and a low amount of vitamin E (less than 4.5 mg/capsule).  Health Canada considers this 
level of supplementation safe for healthy adults.   
Some individuals may experience nausea and loose stools after consuming the capsules.  Others 
may have an increased incidence of "burping" and minor stomach discomfort.  Participants who 




Participants are asked to follow their normal diet and in particular, refrain from eating seafood or 
enriched foods / dietary supplements containing EPA and DHA, other than those provided by the 
researchers, upon entry into the study.  An example of an enriched food is an omega-3 egg.    
You are asked to advise the researchers of any changes to your medications or if you begin 
taking any medications during the study.  Please refrain from donating blood or participating in 
other experiments (ex: diet modification, stress or physical activity studies) during this study.  
Participants are asked to fast overnight (water allowed) and refrain from drinking alcohol in the 
24-hour period immediately prior to testing.  Please return any unused dietary supplements 
provided by the researchers at week 4 and 8 visits. 
 
Health Screening Form: 
 
This questionnaire poses some questions about your health status. This information is used to 
guide us with your entry into the study and ensure your eligibility for the study. If you have 
diabetes or cardiovascular disease including bleeding disorders or lipid metabolism disorders, 
you will not be eligible to participate in the study. 
 
Changing Your Mind about Participation: 
 
Your participation is voluntary.  You may withdraw from this study at any time without penalty. 
To do so, indicate this to the researcher or one of the research assistants by saying, "I no longer 
wish to participate in this study".  Once you withdraw, we will ask if you are willing to provide 
more information about what motivated your decision to withdraw.  If you agree to provide more 
information, we will ask you to identify the specific reason or reasons for your decision to 
withdraw.  This can help us to identify problems in the study that we did not anticipate.  You do 






Confidentiality and Security of Data: 
 
To ensure the confidentiality of individuals’ data, each participant will be identified by an 
identification code known only to the principal investigator and his research assistants.  All data 
including questionnaires will be entered and blood samples will be stored under this code.  Once 
data have been entered under an anonymous code and the feedback provided, the paper records 
and code sheet will be confidentially shredded.  
Testing will be performed under private conditions where only laboratory personnel are present.  
Blood samples will be stored at -80ºC in a secure location in the Department of Kinesiology.  
After biochemical analyses and data interpretation is complete, any remaining blood samples 







After the study is completed, you will be provided with a feedback sheet that will include your 




You will receive a total of $75 remuneration for completing the study.  Partial payment will be 
provided upon early withdrawal.  The sum will be proportional to the number of procedures you 





If you have any questions about the study at any time, please contact either Professor Ken Stark 
at his office (519) 888-4567 ext. 37738 or Ashley Patterson at extension 37873. 
 
Concerns about Your Participation 
 
I would like to assure you that this study has been reviewed and received ethics clearance 
through the Office of Research Ethics. However, the final decision about participation is yours. 
If you have any comments or concerns resulting from your participation in this study, you may 







I agree to take part in a research study being conducted by Professor Ken Stark and Ashley 
Patterson and Alan Chalil of the Department of Kinesiology, University of Waterloo. 
I have made this decision based on the information I have read in the Information letter. All the 
procedures, any risks and benefits have been explained to me. I have had the opportunity to ask 
any questions and to receive any additional details I wanted about the study.  If I have questions 
later about the study, I can ask one of the researchers (Professor Ken Stark at his office (519) 
888-4567 ext. 37738 or Ashley Patterson at extension 37873) or by emailing 
apatters@uwaterloo.ca. 
I am aware that I may withdraw from the study at any time without penalty by telling the 
researcher.  
This project has been reviewed by, and received ethics clearance through, the Office of Research 
Ethics at the University of Waterloo.  I am aware that I may contact Dr. Susan Sykes, Director of 
the Office of Research Ethics at (519) 888-4567 ext. 36005, ssykes@uwaterloo.ca, if I have any 
concerns or questions resulting from my involvement in this study. 
 
Printed Name:   
 
Local Address:   
 
Phone #:     Birth Date:  
 
With full knowledge of all foregoing, I agree, of my own free will, to participate in this study. 
 
Signature:   
 
_______________________________ ___________________________________ 






COMPLETING THE DIETARY RECORD 
 
What to include:  
 
 Record ALL food and beverages consumed for 2 weekdays and 1 weekend day: 
 Foods and beverages (non-alcoholic and alcoholic) 
 Snack foods 
 Condiments, spreads and sauces  
 Oils and seasonings used for cooking 
 Vitamin, mineral or other dietary supplements 
 
 Include as much detail as possible: 
 Indicate the source of the meal (eg: home cooked, Burger King, etc.) or brand of 
purchased foods (eg: Wonder® bread) in the appropriate column. 
 Be descriptive and include relevant cooking methods. 
(eg: write ‘90g, lean ground beef, pan fried in 1 tsp olive oil’ instead of just ‘beef’) 
 
Measuring the correct amount:  
 
 Use measuring cups and spoons or record amounts from food package labels (eg: label 
indicates 1 hamburger bun weighs 45g).  
 Indicate whether the measurement is in cooked or uncooked form (eg: 1 cup uncooked 
macaroni versus 1 cup cooked) 
 Recipes may be included for mixed foods (eg: baked goods, casseroles). Indicate total 
recipe yield and how much you ate (eg: recipe makes 6 portions, ate 1 portion). 










 Do not alter your intake during the recording period.   
 Record at the time of the meal instead of recalling intake afterwards. 
 You are welcome to include package labels with your diet record. 
 
 
Deck of cards sized 
portion = 3oz / 90g 




The following diet record needs more detail and is an example of what NOT to do:  
# Measured Amount Detailed Description of Food Source/Brand 
1 1 Multi-vitamin Drug Store 
2 1 bowl Oatmeal Homemade 
3 1 Banana  
4 1 Egg  
5 1 small Toss salad Homemade 
6 1 glass Milk  
7 1 Steak  
8 1 Dinner roll  
 
Instead, please include following details:  
# Measured Amount Detailed Description of Food Source/Brand 
1 1 capsule Centrum Forte multi-vitamin Centrum® 
2 ½ cup, uncooked Original Quick Oats Quaker® 
 ½ cup  Water (to prepare oatmeal) tap 
 1 tbsp (level) Packed brown sugar Redpath® 
3 1 7” long banana  
4 1 Omega-3 egg, pan fried President’s Choice® 
 1 tsp Extra virgin olive oil  Bertolli® 
5 1 cup Shredded iceberg lettuce Dole® 
 4 slices (¼” thick) Tomato  
 1 tbsp Ranch salad dressing  Kraft® 
6 320 mL 2% milk Nielson® 
7 5 oz Rib eye steak, trim fat removed, broiled Grocery deli counter 
 2 tbsp Original barbecue sauce Kraft® 
 1 dash Table salt Windsor® 
8 1 (28g) White dinner roll Wonder® 
 1 tsp Salt-free margarine Becel® 
 
Recipe Example:  
# Measured 
Amount 
Detailed Description of Food Source/Brand 
1 ate 1/4 of recipe 
below: 
Stir Fry recipe:  Home made 
2 4 (4 oz ea) Boneless, skinless chicken breasts, pan fried Maple Leaf® 
3 1 tbsp 100% Canola oil Canola Harvest® 
4 1 cup Diced green pepper  
5 1, 7oz can Whole kernel sweet corn niblets Green Giant® 
6 2 tbsp Low sodium soy sauce Kikkoman® 
7 4 cups cooked  
(1 cup uncooked) 
Enriched, long grain, white rice Uncle Ben’s® 






DIETARY ANALYSIS INTAKE FORM 
Day 1  
Date:      
Please consult your instruction sheets for directions 
# Measured 
Amount 
Detailed Description of Food Source/Brand 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    






DIETARY ANALYSIS INTAKE FORM 
Day 2 
Date:      
Please consult your instruction sheets for directions 
# Measured 
Amount 
Detailed Description of Food Source/Brand 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    






DIETARY ANALYSIS INTAKE FORM 
Day 3 
Date:     
Please consult your instruction sheets for directions 
# Measured 
Amount 
Detailed Description of Food Source/Brand 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    






HEALTH SCREENING FORM 
 Comprehensive assessment of blood fatty acid response to sustained and variable 
supplementation with a low dose of omega-3 highly unsaturated fatty acids 
 
Past Health Problems:  
 
Rheumatic Fever (  )  Epilepsy   (  ) 
Heart Murmur (  )  Varicose Veins  (  ) 
High Blood Pressure (  )  Disease of Arteries  (  ) 
High Cholesterol (  )  Emphysema, Pneumonia, 
Congenital Heart Disease (  )   Asthma, Bronchitis (  ) 
Heart Attack (  )  Back Injuries   (  ) 
Heart Operation (  )  Kidney and liver disease (  ) 
Diabetes (diet or insulin) (  )  Heartburn   (  ) 
Ulcers (  )  Bleeding disorders  (  ) 
Bleeding from Intestinal Tract (  )  Lipid Metabolism disorders (  ) 
Enteritis/colitis/diverticulitis       (  )  Other (describe overleaf) (  ) 
       
Present Health: 
 
List current problems:   List medications taken now or in last 3 months: 
1.     1. 
2.     2. 




Irregular Heart Beat (  )  Fatigue  (  ) 
Chest Pain  (  )  Cough Up Blood (  ) 
Short of Breath (  )  Back Pain/Injury (  ) 
Persistent Cough (  )  Leg Pain-Injury (  ) 
Wheezing (asthma) (  )  Dizziness  (  ) 
 
Birth Date (mm/dd/yy): ___________________________ 
 
Smoking: 
Never (  ) Ex-smoker (  )  Regular (  ): Average # cigarettes/day ____ 
 
  





Alcohol Intake:  
 
A standard drink is:  
 -1 can/bottle of beer (355 ml/12 oz) 
 -1 glass of wine (150 ml/5 oz) 
 -1 shot of 40% hard liquor or spirits (44 ml/1.5 oz) 
 
How often do you have 10 or more standard drinks on 1 occasion? 
 (   ) Never 
 (   ) Less than Monthly 
 (   ) Monthly 
 (   ) Weekly 
 (   ) Daily or Almost Daily 
 
Dietary Supplements: 
Do you take vitamin-mineral or other supplements regularly? Yes (  ) No (  ) 
 









(eg: 1,  500mg 
capsule) 
    
    
    
    
    
 
The supplements contain the following ingredients: 
 -fish oils (anchovy, mackerel, sardine and salmon) 
 -gelatin 
 -glycerin 
 -purified water 
 -vitamin E 
 
Do you have any allergies or sensitivities these ingredients? Yes (  ) No (  ) 
 
 
Do you follow a vegetarian, vegan or restricted diet?   Yes (  )     No (  ) 










Have you made any major changes to your diet over the past year?  Yes (  ) No (  ) 









Have you lost or gained weight in the past year?   Yes (  ) No (  ) 









Current Physical Activity Status: 
I consider my physical activity status to be: High (  ), Average (  ), Low (  ). 
 
List the physical activities that you do on a regular basis:   
Type (eg: jogging) Frequency (eg: 3x/week) Duration (eg:30 min) 
   
   
   
   
   
 
 








    
   Laboratory of Nutritional and Nutraceutical Research 
    
Food Frequency Questionnaire 
 
INSTRUCTIONS:  Please answer the following background questions and subsequent 44 questions 
about your usual eating habits over the past 12 months.  
 
Date you answered this questionnaire: ______________________ 
 
Age:
(  ) Under 19 years (  ) 30-34 years  (  ) 45-49 years  (  ) 60-64 years 
(  ) 19-24 years  (  ) 35-39 years  (  ) 50-54 years  (  ) 65 years and over 
(  ) 25-29 years  (  ) 40-44 years  (  ) 55-59 years 
  




1.  With which of the following racial/cultural  
groups do you most closely associate yourself? 
 
(  ) Caucasian 
(  ) Chinese 
(  ) South Asian (eg: East Indian, Pakistani, 
      Sri Lankan) 
(  ) African 
(  ) Filipino 
(  ) Latin American 
(  ) Southeast Asian (eg: Cambodian, Indonesian,   
      Laotian, Vietnamese) 
(  ) Arab 
(  ) West Asian (eg: Afghan, Iranian) 
(  ) Japanese 
(  ) Korean 
(  ) Aboriginal  








2. What is the highest level of education you have 
attained? 
 
(  ) Some High School 
(  ) High School Diploma 
(  ) Diploma/Certificate from trade, technical or   
     vocational school or business college 
(  ) Diploma/Certificate from community college,  
     CEGEP or nursing school 
(  ) Bachelor’s undergraduate degree or teacher’s  
     college 
(  ) Master’s degree 
(  ) Degree in Medicine, Dentistry, Veterinary  
     Medicine, Optometry or Law 
(  ) Earned doctorate (eg: PhD) 
(  ) Other: 
_________________________________ 
 
3.  What is your annual household income? 
 
(  ) less than $25,000 
(  ) $25,000 - $49,999 
(  ) $50,000 - $74,999 
(  ) $75,000 - $99,999 




4.  What type of milk do you usually use? 
 
(  ) I do not drink milk 
(  ) Regular cow’s milk (non-omega-3) 
(  ) Regular soy milk (non-omega-3) 
(  ) Nielson, Dairy Oh! 1% or 2% milk 
(  ) Nielson, Dairy Oh! homogenized milk 
 
 
(  ) Parmalat, Smart Growth 2% milk 
(  ) Parmalat, Smart Growth homogenized milk  
(  ) Silk Plus, Omega-3 DHA soy milk 
(  ) So Good, Omega-3 DHA soy milk 
(  ) Other Omega-3 enriched milk 
     Please specify Brand:    




5. How much omega-3 milk do you usually use per 
day (including milk added to tea, coffee, cereal, 
etc.)?  
 
(  ) None 
(  ) 1 tablespoon 
(  ) 2 tablespoons 
(  ) ¼ cup (62.5 mL) 
(  ) ½ cup (125 mL) 
(  ) 1 cup (250 mL) 
(  ) between 1-2 cups (250-500 mL) 
(  ) between  2-3 cups (500-750 mL) 
(  ) 3 cups (750 mL) or more 
 
6. What kinds of margarine/spread do you usually 
use? (eg: On bread, vegetables, in cooking and 
baking, etc.) 
 
(  ) I don’t use any margarine/spread 
(  ) Regular margarine (non-omega-3) 
(  ) Becel, Omega-3 Plus Margarine 
(  ) Other Omega-3 enriched margarine 
     Please specify brand:          
     __________________________________ 
 
7. How much omega-3 margarine/spread do you 
usually use per day?  
 
(  ) None 
(  ) 1-2 teaspoons 
(  ) 1 tablespoon 
(  ) 2 tablespoons 
(  ) 3 tablespoons 
(  ) 4 tablespoons 
(  ) 5-7 tablespoons 
(  ) 8 or more tablespoons 
 
8. What kinds of eggs do you usually eat (include 
eggs in baked goods/cooking)? 
 
(  ) Naturegg Breakfree omega-3 Pro liquid eggs 
(  ) Naturegg Omega-3 eggs (in shell) 
(  ) Naturegg Omega-3 Pro eggs (in shell) 
(  ) Complements Omega-3 eggs  
(  ) President’s Choice Omega-3 eggs 
(  ) Gold Egg Omega-3 eggs 
(  ) Gold Egg Omega Choice eggs 
(  ) Conestoga Farms Free Run Omega-3 eggs 
(  ) Burnbrae Farms Free Run Omega-3 eggs 
(  ) Irresistables Omega-3 eggs 
(  ) Regular Chicken eggs 
(  ) Organic eggs 
(  ) Other Omega-3 enriched eggs 
     Please specify brand:  
      _____________________________________ 
 
9. On average, how many eggs do you usually 
eat per week (including eggs in baked 
goods/cooking)?   
 
(  ) I don’t eat eggs 
(  ) Less than 1 egg   
(  ) 1 to 2 eggs            
(  ) 3 to 5 eggs           
(  ) 6 or more eggs  
 
10. What kind of juice do you usually drink? 
 
(  ) I don’t drink juice 
(  ) Regular juice (non-omega-3) 
(  ) President’s Choice, Oh Mega J orange juice 
(  ) Lassonde Oasis, omega-3 concord   
     blueberry-grape juice 
(  ) Lassonde Oasis, omega-3 strawberry kiwi  
     juice 
(  ) Lassonde Oasis, omega-3 orange juice 
(  ) Other Omega-3 enriched juice 
     Please specify brand:  
     ___________________________________ 
  
11. How much omega-3 juice do you usually 
drink per day?  
 
(  ) None 
(  ) less than one cup (<250 mL) 
(  ) 1 cup (250 mL) 
(  ) between 1-2 cups (250-500 mL) 
(  ) between 2-3 cups (500-750 mL) 
(  ) 3 cups (750 mL) or more 
 
12. What kind of yogurt do you usually eat? 
 
(  ) I don’t eat yogurt 
(  ) Regular yogurt (non-omega-3) 
(  ) President's Choice Blue Menu strawberry  
     yogurt smoothie 
(  ) Li'l Ones omega-3 yogurt  
(  ) Other Omega-3 enriched yogurt 
     Please specify brand:  
    ____________________________________ 
 
13. How much omega-3 yogurt do you usually 
eat per week?   
 
(  ) none 
(  ) less than 1 single serve container 
(  ) 1, single serve container 
(  ) 2-3, single serve containers 
(  ) 4-5, single serve containers 
(  ) 6-7, single serve containers 





14.  What kind of sliced or brick cheese do you 
usually eat? 
 
(  ) I don't eat sliced or brick cheese 
(  ) Regular sliced or brick cheese (non-omega-3) 
(  ) Silani omega-3 mozzarella or provolone 
(  ) Silani omega-3 feta 
(  ) Other omega-3 sliced or brick cheese 
      Please specify brand:  
      _____________________________________ 
 
15.  How many slices (15g / size of 2 dice) of 
omega-3 sliced or brick cheese do you usually 
eat? Include cheese in sandwiches. 
 
(  ) None 
(  ) Less than 1 slice per month 
(  ) 1-3 slices per month 
(  ) 1 slices per week 
(  ) 2-3 slices per week 
(  ) 4-6 slices per week 
(  ) 1 slice per day 
(  ) 2 or more slices per day 
 
17. What kind of soft or grated cheese do you 
usually eat? 
 
(  ) I don't eat soft or grated cheeses 
(  ) Regular soft or grated cheese (not omega-3) 
(  ) Silani omega-3 grated parmesan 
(  ) Silani omega-3 ricotta 
(  ) Silani omega-3 mascarpone 
(  ) Other omega-3 soft or grated cheese 
      Please specify brand:  
      _____________________________________ 
 
18. How much omega-3 soft or grated cheese do 
you usually eat per week? 
 
(  ) None 
(  ) Less than 1 tablespoon  
(  ) 1-3 tablespoons 
(  ) 1/4-1/2  cup 
(  ) 1/2-1 cup 
(  ) 1-2 cups 
(  ) 3 or more cups  
 
19. What kind of string cheese do you usually eat?  
 
(  ) I don’t eat string cheese 
(  ) Regular string cheese (non-omega-3) 
(  ) Black Diamond, Smart Growth Cheese 
     Strings with DHA 
(  ) Other omega-3 enriched string cheese 
     Please specify brand: 
     ______________________________________      
17. How many omega-3 string cheese portions 
do you usually eat per week? 
 
(  ) None 
(  ) less than 1oz ( less than 1 string cheese  
     portion) 
(  ) 1 oz (1 string cheese portion) 
(  ) 2-3 oz (2-3 string cheese portions) 
(  ) 4-5 oz (4-5 string cheese portions) 
(  ) 6-7 oz (6-7 string cheese portions) 
(  ) 8 or more oz (8+ string cheese portions) 
 
20.  What kind of nut butter (eg: peanut) do you 
usually eat? 
 
(  ) I don’t eat nut butter 
(  ) Regular nut butter (non-omega-3) 
(  ) Life Brand, Omega-3 Peanut Butter 
(  ) Other omega-3 enriched nut butter 
     Please specify brand:  
     ___________________________________ 
 
21.  How much omega-3 nut butter do you eat 
per week? 
 
(  ) None 
(  ) less than 1 tablespoon (tbsp) 
(  ) 1 tbsp 
(  ) 2-3 tbsp 
(  ) 4-5 tbsp 
(  ) 6-7 tbsp 
(  ) 8 or more tbsp 
 
22.  What kind of biscuits do you usually eat? 
 
(  ) None 
(  ) Regular biscuits (non-omega-3) 
(  ) President's Choice, Blue Menu Blueberry   
      Lemon with Flaxseeds whole grain biscuits 
(  ) Other omega-3 enriched biscuits 
      Please specify brand:  
     ___________________________________ 
 
23.  How many omega-3 biscuits do you usually 
eat? 
 
(  ) None 
(  ) Less than 1 cookie per month 
(  ) 1-3 cookies per month 
(  ) 1 cookie per week 
(  ) 2-3 cookies per week 
(  ) 4-6 cookies per week 
(  ) 1 cookie per day 






24.  On average, how often do you eat fish paste? 
(eg: Surimi) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Specify the type of fish paste, brand and amount 
usually eaten (number of teaspoons) 
Type of fish paste Brand  #tsp 
________________________________________ 
 
25.  On average, how often do you eat seaweed? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of seaweed and amount 
eaten on a typical occasion  
Type of seaweed  Amount 
________________________________________ 
 
26.  On average, how often do you eat seafood-
containing sauce? (eg: fish sauce, oyster sauce)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
Please specify the type of seafood sauce, 
brand and amount usually eaten (# tsp) 




27. On average, how often do you eat fish-
based broth (eg: fish broth-based soup)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the brand (or ‘homemade’) and 
amount of fish broth usually eaten (eg: 1 cup) 







28.  How much of a fish oil supplement do you 
usually take per day (eg: capsules, chews, 
gummies, oil, powder) 
 
(  ) None 
(  ) Amount: 
_____________________________________ 
 
Please Specify brand, product name and type 
of supplement  
(eg: Jamieson, Omega-3 Complete, capsules) 









29.  When you eat meat or poultry, what size serving do you usually eat? 
 
 
(  ) Less than A   (  ) B    (  ) C 
(  ) A    (  ) Between B and C  (  ) More than C 
(  ) Between A and B 
 
 
30. On average, how often do you eat chicken or 
turkey?  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the types of chicken/turkey eaten 
most frequently and whether the skin is eaten  




31. On average, how often do you eat duck or 
goose? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of duck/goose eaten most 
frequently and whether the skin in eaten. (eg: 





32. How often do you usually eat beef? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of beef most often eaten 
(eg: Rump steak): 
_______________________________________ 
 
33. On average, how often do you eat lamb? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of lamb most often eaten 










A: Deck of cards sized 
portion = 3oz / 90g 




34. On average, how often do you eat veal? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of veal most often eaten  
(eg: Veal steak): 
________________________________________ 
 
35. On average, how often do you eat pork? (do 
not include ham or bacon) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of pork most often eaten 
(eg: Pork chop): 
________________________________________ 
 
36. On average, how often do you eat bacon?  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the number of slices of bacon 













37. On average, how often do you eat ham (not 
deli/sandwich meat)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the number of slices of ham 
usually eaten on each occasion: 
_______________________________________ 
 
38. On average, how often do you usually eat 
sliced deli meat (eg: luncheon meats or salami)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type (eg: lean turkey breast), 
brand and the number of slices of sliced deli 
meat most often eaten: 




39. On average, how often do you eat sausages? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type (eg: Beef, pork, turkey) 
and number of sausages usually eaten on each 
occasion: 










40. On average, how often do you eat canned 
fish? (eg: canned tuna, salmon, sardines, etc.) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify up to 4 types of canned fish that 
you regularly eat, including the brand and the 
amount typically eaten. (eg: White tuna in water, 
Goldseal, ½ 120g tin) 
 






41. On average, how often do you eat fresh or 
frozen fish? (Include fish meals at home, at a 
restaurant and take out).  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 









Please specify up to 4 types of fresh or frozen 
fish that you regularly eat and the amount 
typically eaten. Include the brand for frozen fish.  
(eg: frozen Wild Atlantic Salmon, Highliner, 150g) 
 






42. How often do you eat fresh, frozen or canned 
shellfish? (eg: shrimp, oysters, scallops, crab, 
calamari, lobster, etc).  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type and amount of shellfish 
eaten on a typical occasion: 





43. Are there any other meat, poultry or fish 
products that you eat regularly?  
 
Please specify the type, amount and how 
often other meat or fish products are eaten 
 





44.  Have you changed your diet in any significant way over the past year?  
  
(  ) Yes 
(  ) No 
 










Appendix Table C.2. Whole blood fatty acid composition in the dose-response study (n=20) 
 
Week 0 Week 4 Week 8 
  Males Females Males Females Males Females 
14:0 0.75 ± 0.17 0.79 ± 0.24 0.81 ± 0.25 0.73 ± 0.20 0.80 ± 0.24 0.70 ± 0.09 
16:0 21.28 ± 0.96 20.92 ± 1.45 21.13 ± 1.32 20.44 ± 1.72 20.68 ± 1.18 20.21 ± 1.10 
16:0 dma
2
 1.08 ± 0.37 0.83 ± 0.07 0.86 ± 0.28 0.83 ± 0.13 1.02 ± 0.15 0.86 ± 0.11 
17:0 0.31 ± 0.06 0.30 ± 0.04 0.31 ± 0.04 0.30 ± 0.02 0.31 ± 0.05 0.27 ± 0.08 
18:0
1,3
 11.59 ± 1.30
a,b
 12.43 ± 0.96
a
 11.62 ± 1.52
a,b
 10.79 ± 0.62
b
 11.02 ± 0.83
a,b





 1.17 ± 0.13 0.97 ± 0.10 1.07 ± 0.47 0.98 ± 0.12 1.32 ± 0.22 1.08 ± 0.14 
20:0 0.27 ± 0.05 0.30 ± 0.05 0.29 ± 0.05 0.29 ± 0.05 0.30 ± 0.06 0.38 ± 0.21 
22:0 0.77 ± 0.13 0.79 ± 0.14 0.82 ± 0.24 0.88 ± 0.20 0.84 ± 0.10 0.85 ± 0.09 
23:0 0.19 ± 0.02 0.19 ± 0.03 0.18 ± 0.05 0.21 ± 0.05 0.20 ± 0.03 0.21 ± 0.02 
24:0 1.54 ± 0.24 1.50 ± 0.21 1.75 ± 0.84 1.69 ± 0.37 1.68 ± 0.16 1.74 ± 0.22 
SFAs 39.23 ± 1.62 39.32 ± 2.07 39.14 ± 3.02 37.45 ± 1.11 38.78 ± 1.34 38.18 ± 2.26 
14:1 0.03 ± 0.02 0.03 ± 0.02 0.04 ± 0.03 0.04 ± 0.02 0.05 ± 0.03 0.03 ± 0.01 
16:1n-7 1.05 ± 0.48 0.85 ± 0.24 1.01 ± 0.40 0.87 ± 0.25 1.12 ± 0.40 0.87 ± 0.25 
18:1 dma 0.31 ± 0.05 0.28 ± 0.06 0.28 ± 0.11 0.28 ± 0.04 0.35 ± 0.07 0.31 ± 0.05 
18:1n-7 1.52 ± 0.08 1.49 ± 0.17 1.47 ± 0.11 1.44 ± 0.17 1.48 ± 0.14 1.43 ± 0.19 
18:1n-9 14.54 ± 1.33 14.41 ± 1.92 14.71 ± 2.18 14.89 ± 1.57 14.98 ± 1.42 14.31 ± 1.59 
20:1n-9
1
 0.22 ± 0.03 0.25 ± 0.05 0.21 ± 0.03 0.22 ± 0.03 0.21 ± 0.02 0.22 ± 0.04 
22:1n-9
1,3
 0.28 ± 0.04
a,c
 0.34 ± 0.06
a
 0.16 ± 0.07
b
 0.19 ± 0.05
b,d
 0.24 ± 0.06
c,d
 0.22 ± 0.05
b,c
 
24:1n-9 1.71 ± 0.21 1.69 ± 0.17 1.83 ± 0.62 1.92 ± 0.38 1.90 ± 0.29 2.00 ± 0.33 
MUFAs 19.67 ± 1.65 19.36 ± 2.27 19.70 ± 1.85 19.86 ± 1.92 20.33 ± 1.55 19.39 ± 2.16 
18:2n-6
2
 17.67 ± 1.86 19.37 ± 1.87 17.83 ± 3.71 21.73 ± 1.82 17.95 ± 1.58 19.76 ± 1.01 
18:3n-6
1
 0.20 ± 0.05 0.16 ± 0.05 0.24 ± 0.13 0.21 ± 0.09 0.26 ± 0.09 0.19 ± 0.07 
20:2n-6
1,2,3
 0.25 ± 0.03
a
 0.27 ± 0.05
a
 0.26 ± 0.10
a
 0.39 ± 0.14
b
 0.27 ± 0.03
a





 1.80 ± 0.53 1.72 ± 0.28 1.68 ± 0.48 1.48 ± 0.24 1.64 ± 0.40 1.55 ± 0.18 
20:4n-6
1
 11.33 ± 1.49 10.38 ± 1.54 10.37 ± 1.32 9.41 ± 0.92 10.20 ± 1.39 9.60 ± 0.69 
22:2n-6 0.05 ± 0.01 0.06 ± 0.02 0.05 ± 0.01 0.05 ± 0.02 0.05 ± 0.01 0.06 ± 0.01 
22:4n-6
1






 0.38 ± 0.04 0.36 ± 0.06 0.36 ± 0.08 0.33 ± 0.04 0.33 ± 0.03 0.31 ± 0.06 
n-6 33.37 ± 1.87 33.82 ± 2.05 32.40 ± 3.10 34.90 ± 1.89 32.13 ± 2.07 33.08 ± 1.44 
18:3n-3 0.43 ± 0.14 0.44 ± 0.19 0.41 ± 0.15 0.46 ± 0.17 0.47 ± 0.12 0.42 ± 0.11 
20:3n-3 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 
20:5n-3
1,3
 0.55 ± 0.15
a
 0.38 ± 0.06
a
 0.78 ± 0.13
b
 0.77 ± 0.07
b
 1.19 ± 0.17
c





 1.53 ± 0.18 1.18 ± 0.18 1.59 ± 0.31 1.11 ± 0.14 1.66 ± 0.20 1.42 ± 0.16 
22:6n-3
1,2
 2.38 ± 0.37 2.73 ± 0.14 2.55 ± 0.46 2.76 ± 0.29 2.97 ± 0.32 3.57 ± 0.46 
n-3
1,3
 4.92 ± 0.48
a
 4.76 ± 0.30
a
 5.36 ± 0.58
b
 5.13 ± 0.41
a
 6.31 ± 0.42
a
 6.77 ± 0.68
b
 
PUFAs 38.29 ± 1.84 38.59 ± 1.95 37.76 ± 2.85 40.03 ± 1.90 38.44 ± 2.28 39.84 ± 1.71 
HUFAs
1,2
 19.68 ± 1.58 18.30 ± 1.73 18.98 ± 2.10 17.18 ± 1.14 19.45 ± 1.63 19.12 ± 0.92 
EPA+DHA
1,2,3
 2.93 ± 0.46
a
 3.11 ± 0.13
a,b
 3.33 ± 0.44
b
 3.53 ± 0.26
b
 4.16 ± 0.36
c





 6.85 ± 0.78
a
 7.14 ± 0.75
a
 6.12 ± 0.92
b
 6.84 ± 0.71
a,b
 5.10 ± 0.35
c





 22.80 ± 1.97
a
 23.87 ± 2.84
a,b
 26.10 ± 1.80
b,c
 27.21 ± 2.03
c,d
 30.10 ± 1.43
d,e





   4.51 ± 1.12
a
 7.36 ± 1.50
c
 3.41 ± 1.03
b
 3.63 ± 0.60
a,b
 2.53 ± 0.44
b





 1.57 ± 0.29 2.37 ± 0.38 1.63 ± 0.27 2.50 ± 0.34 1.80 ± 0.21 2.53 ± 0.30 
 n-3 HUFA
1,3
 4.49 ± 0.54
a
 4.33 ± 0.22
a
 4.95 ± 0.67
a
 4.67 ± 0.34
a
 5.84 ± 0.46
b





 15.19 ± 1.29 13.97 ± 1.82 14.02 ± 1.56 12.51 ± 1.02 13.60 ± 1.26 12.78 ± 0.77 
Total [FA]
1
 164.16 ± 30.91 139.20 ± 27.95 208.18 ± 44.89 182.75 ± 39.69 203.64 ± 31.25 211.39 ± 33.96 
Values are means  ± standard deviation.  Values are wt% of total fatty acids with the exception of total fatty acid concentration expressed as 
fatty acids (ug)/100uL whole blood. 
SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, HUFA: highly unsaturated fatty acids, 
HUFA Score: % n-3 HUFA in total HUFA, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, [FA]: fatty acid concentration 






 by the linear mixed models procedure (LMM) with time, sex and interaction as factors.  
Different letters represent a significant sex x time interaction by Bonferroni's post-hoc test, following a significant F-value by the LLM 






Appendix Table C.3. Erythrocyte fatty acid composition in the dose-response study (n=20) 
 
Week 0 Week 4 Week 8 
  Males Females Males Females Males Females 
14:0
1,3
 0.50 ± 0.09
a
 0.69 ± 0.11
b,c
 0.79 ± 0.09
b
 0.71 ± 0.18
b,c
 0.50 ± 0.11
a
 0.58 ± 0.10
a,c
 
16:0 21.37 ± 0.67 21.74 ± 0.83 21.23 ± 0.89 21.09 ± 1.08 20.55 ± 1.20 21.48 ± 0.88 
16:0 dma
1
 1.78 ± 0.60 1.66 ± 0.10 1.33 ± 0.15 1.22 ± 0.48 1.69 ± 0.23 1.47 ± 0.18 
17:0 0.33 ± 0.03 0.32 ± 0.03 0.31 ± 0.03 0.30 ± 0.03 0.32 ± 0.04 0.32 ± 0.03 
18:0
1
 13.27 ± 0.69 12.53 ± 0.68 12.87 ± 1.00 13.32 ± 0.91 13.65 ± 0.62 13.79 ± 1.29 
18:0 dma
1
 2.70 ± 0.93 2.33 ± 0.22 1.70 ± 0.25 1.64 ± 0.73 2.22 ± 0.61 2.03 ± 0.39 
20:0
1
 0.28 ± 0.05 0.31 ± 0.04 0.29 ± 0.04 0.31 ± 0.03 0.33 ± 0.04 0.33 ± 0.05 
22:0 1.14 ± 0.17 1.12 ± 0.13 1.15 ± 0.20 1.14 ± 0.15 1.15 ± 0.21 1.11 ± 0.13 
23:0
1
 0.19 ± 0.02 0.18 ± 0.03 0.17 ± 0.03 0.16 ± 0.03 0.19 ± 0.03 0.18 ± 0.03 
24:0 3.06 ± 0.44 3.22 ± 0.44 3.13 ± 0.65 3.26 ± 0.44 3.18 ± 0.36 3.21 ± 0.40 
SFAs
1
 44.87 ± 1.48 44.36 ± 0.70 43.18 ± 1.96 43.38 ± 1.28 44.05 ± 1.02 44.72 ± 1.14 
14:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.02 ± 0.04 0.01 ± 0.01 
16:1n-7 0.30 ± 0.13 0.25 ± 0.06 0.35 ± 0.24 0.24 ± 0.04 0.27 ± 0.08 0.24 ± 0.05 
18:1 dma
1
 0.67 ± 0.25 0.64 ± 0.11 0.44 ± 0.09 0.46 ± 0.19 0.59 ± 0.16 0.60 ± 0.13 
18:1n-7
1
 1.28 ± 0.10 1.26 ± 0.11 1.23 ± 0.14 1.18 ± 0.12 1.20 ± 0.12 1.17 ± 0.11 
18:1n-9
1
 12.21 ± 0.95 12.28 ± 1.03 12.30 ± 1.05 11.87 ± 1.00 11.63 ± 1.14 11.74 ± 0.77 
20:1n-9
2
 0.24 ± 0.03 0.27 ± 0.04 0.23 ± 0.03 0.27 ± 0.04 0.23 ± 0.04 0.25 ± 0.02 
22:1n-9
1
 0.13 ± 0.02 0.14 ± 0.02 0.12 ± 0.03 0.10 ± 0.01 0.16 ± 0.06 0.16 ± 0.08 
24:1n-9 3.10 ± 0.43 3.37 ± 0.46 3.20 ± 0.52 3.38 ± 0.27 3.25 ± 0.52 3.31 ± 0.41 
MUFAs
1
 17.93 ± 1.04 18.22 ± 1.57 17.89 ± 0.90 17.50 ± 1.28 17.37 ± 1.37 17.48 ± 1.07 
18:2n-6 9.97 ± 1.04 10.49 ± 1.07 10.49 ± 2.74 10.18 ± 0.92 9.29 ± 0.70 9.85 ± 0.82 
18:3n-6
2
 0.05 ± 0.02 0.04 ± 0.01 0.06 ± 0.06 0.03 ± 0.01 0.05 ± 0.02 0.03 ± 0.01 
20:2n-6 0.23 ± 0.03 0.26 ± 0.05 0.23 ± 0.04 0.26 ± 0.06 0.26 ± 0.05 0.26 ± 0.05 
20:3n-6
1
 1.61 ± 0.46 1.51 ± 0.22 1.54 ± 0.44 1.45 ± 0.23 1.45 ± 0.44 1.34 ± 0.17 
20:4n-6
1






 0.06 ± 0.02 0.08 ± 0.01 0.06 ± 0.02 0.08 ± 0.01 0.06 ± 0.03 0.07 ± 0.02 
22:4n-6
1
 3.12 ± 0.63 3.27 ± 0.36 2.82 ± 0.72 3.07 ± 0.31 2.79 ± 0.75 2.75 ± 0.33 
22:5n-6
1
 0.56 ± 0.06 0.56 ± 0.08 0.51 ± 0.07 0.52 ± 0.06 0.49 ± 0.09 0.45 ± 0.07 
n-6
1
 29.28 ± 1.19 29.31 ± 0.87 28.53 ± 1.93 28.44 ± 0.61 27.18 ± 1.38 27.04 ± 1.11 
18:3n-3
1
 0.15 ± 0.04 0.15 ± 0.05 0.17 ± 0.08 0.17 ± 0.03 0.20 ± 0.04 0.21 ± 0.04 
20:3n-3 0.02 ± 0.00 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 
20:5n-3
1,3
 0.51 ± 0.14
a,b
 0.38 ± 0.04
a
 0.68 ± 0.15
c
 0.62 ± 0.05
b,c
 1.00 ± 0.14
a





 2.27 ± 0.21 1.85 ± 0.20 2.30 ± 0.33 1.98 ± 0.24 2.60 ± 0.33 2.19 ± 0.19 
22:6n-3
1,2
 3.05 ± 0.47 3.71 ± 0.43 3.17 ± 0.41 3.89 ± 0.46 3.69 ± 0.35 4.22 ± 0.59 
n-3
1
 5.99 ± 0.49 6.11 ± 0.51 6.34 ± 0.50 6.68 ± 0.61 7.52 ± 0.45 7.67 ± 0.78 
PUFAs 35.27 ± 1.16 35.42 ± 1.12 34.87 ± 1.79 35.12 ± 0.85 34.70 ± 1.67 34.70 ± 1.49 
HUFAs 24.82 ± 1.01 24.40 ± 1.03 23.86 ± 1.48 24.40 ± 0.82 24.84 ± 1.68 24.28 ± 1.12 
EPA+DHA
1,2
 3.56 ± 0.53 4.09 ± 0.43 3.85 ± 0.45 4.51 ± 0.46 4.69 ± 0.37 5.25 ± 0.63 
n-6:n-3
1
 4.92 ± 0.49 4.83 ± 0.39 4.54 ± 0.56 4.29 ± 0.40 3.62 ± 0.20 3.56 ± 0.37 
HUFA Score
1
 23.56 ± 1.81 24.47 ± 2.28 25.87 ± 1.84 26.71 ± 2.43 29.49 ± 1.41 30.68 ± 2.63 
DHA:EPA
1,2,3
 6.24 ± 1.36
a
 9.93 ± 1.51
d
 4.86 ± 1.08
b,d
 6.35 ± 0.83
a,b
 3.75 ± 0.63
c





 1.36 ± 0.29
a
 2.03 ± 0.33
a
 1.41 ± 0.28
a
 1.99 ± 0.30
b
 1.44 ± 0.24
b





 5.85 ± 0.50 5.96 ± 0.48 6.17 ± 0.53 6.52 ± 0.59 7.32 ± 0.46 7.46 ± 0.78 
n-6 HUFA
1,3
 18.98 ± 0.92 18.44 ± 1.16 17.69 ± 1.26 17.88 ± 0.92 17.52 ± 1.38 16.82 ± 0.90 
Total [FA] 190.08 ± 14.07 184.15 ± 12.16 188.18 ± 10.84 200.63 ± 33.05 189.10 ± 17.22 191.95 ± 12.19 
Values are means  ± standard deviation.  Values are wt% of total fatty acids with the exception of total fatty acid concentration expressed as fatty 
acids (ug)/100mg erythrocytes. 
SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, HUFA: highly unsaturated fatty acids, HUFA 
Score: % n-3 HUFA in total HUFA, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, [FA]: fatty acid concentration 






 by the linear mixed models procedure (LMM) with time, sex and interaction as factors.  





Appendix Table C.4. Plasma phospholipid fatty acid composition in the dose-response study (n=20) 
 
Week 0 Week 4 Week 8 
  Males Females Males Females Males Females 
14:0
1
 0.50 ± 0.08 0.49 ± 0.12 0.52 ± 0.15 0.54 ± 0.16 0.52 ± 0.13 0.70 ± 0.17 
16:0
3
 25.41 ± 1.26 24.77 ± 1.27 25.43 ± 1.35 23.78 ± 2.58 24.68 ± 1.93 26.07 ± 2.12 
16:0dma 0.48 ± 0.13 0.37 ± 0.19 0.37 ± 0.25 0.38 ± 0.27 0.43 ± 0.21 0.37 ± 0.24 
18:0 14.44 ± 0.96 14.95 ± 0.98 15.38 ± 2.81 14.75 ± 3.39 14.42 ± 2.66 15.37 ± 3.95 
18:0dma 0.27 ± 0.05 0.18 ± 0.10 0.21 ± 0.16 0.22 ± 0.16 0.29 ± 0.13 0.27 ± 0.07 
20:0
1
 0.50 ± 0.08 0.52 ± 0.08 0.47 ± 0.08 0.47 ± 0.07 0.39 ± 0.05 0.45 ± 0.07 
22:0
1
 1.29 ± 0.21 1.41 ± 0.31 1.13 ± 0.29 1.08 ± 0.35 0.85 ± 0.17 0.95 ± 0.21 
23:0
1,3
 0.57 ± 0.11 0.53 ± 0.11 0.46 ± 0.11 0.38 ± 0.11 0.32 ± 0.05 0.38 ± 0.07 
24:0
1
 1.18 ± 0.21 1.28 ± 0.31 1.07 ± 0.23 0.95 ± 0.33 0.79 ± 0.18 0.89 ± 0.19 
SFAs 44.98 ± 1.00 44.79 ± 1.39 45.47 ± 3.44 43.19 ± 6.51 43.02 ± 4.03 46.00 ± 4.48 
14:1 0.01 ± 0.01 0.01 ± 0.01 0.02 ± 0.02 0.01 ± 0.01 0.01 ± 0.00 0.02 ± 0.02 
16:1n-7
3
 0.42 ± 0.19
a
 0.38 ± 0.07 0.54 ± 0.14
b
 0.37 ± 0.06 0.45 ± 0.14
a,b
 0.38 ± 0.10 
18:1dma 0.13 ± 0.04 0.11 ± 0.05 0.10 ± 0.07 0.10 ± 0.06 0.12 ± 0.04 0.13 ± 0.03 
18:1n-7 1.65 ± 0.11 1.62 ± 0.21 1.61 ± 0.21 1.61 ± 0.37 1.63 ± 0.28 1.60 ± 0.22 
18:1n-9
1,3
 8.59 ± 1.18
a
 9.08 ± 1.32 9.38 ± 2.06
a
 13.31 ± 6.82 13.59 ± 3.95
b
 10.93 ± 5.28 
20:1n-9
3
 0.17 ± 0.03 0.23 ± 0.04 0.17 ± 0.03 0.26 ± 0.14 0.24 ± 0.08 0.20 ± 0.05 
22:1n-9 0.32 ± 0.14 0.30 ± 0.09 0.28 ± 0.10 0.38 ± 0.29 0.39 ± 0.16 0.36 ± 0.06 
24:1n-9
1
 2.12 ± 0.36 2.18 ± 0.49 1.72 ± 0.51 1.51 ± 0.63 1.17 ± 0.25 1.38 ± 0.32 
MUFAs
1,3
 13.41 ± 1.13 13.92 ± 1.77 13.84 ± 2.29 17.56 ± 7.08 17.65 ± 4.33 15.02 ± 5.21 
18:2n-6 18.62 ± 2.36 20.15 ± 1.17 18.15 ± 2.56 19.86 ± 2.14 17.83 ± 1.54 18.71 ± 1.99 
18:3n-6 0.11 ± 0.04 0.08 ± 0.05 0.10 ± 0.05 0.08 ± 0.06 0.09 ± 0.05 0.10 ± 0.06 
202:n-6
1
 0.34 ± 0.05 0.38 ± 0.09 0.30 ± 0.04 0.28 ± 0.08 0.24 ± 0.04 0.28 ± 0.05 
20:3n-6
1
 3.32 ± 0.87 3.05 ± 0.47 2.93 ± 0.91 2.23 ± 0.59 2.54 ± 0.69 2.42 ± 0.52 
20:4n-6
1
 11.78 ± 2.00 10.34 ± 2.04 9.56 ± 1.80 7.88 ± 1.52 8.48 ± 1.47 8.07 ± 1.54 
22:2n-6
3






 0.46 ± 0.07 0.41 ± 0.05 0.35 ± 0.06 0.27 ± 0.06 0.25 ± 0.04 0.23 ± 0.04 
22:5n-6
1
 0.32 ± 0.05 0.33 ± 0.06 0.23 ± 0.05 0.20 ± 0.05 0.15 ± 0.03 0.18 ± 0.04 
n-6
1
 34.99 ± 1.82 34.78 ± 1.72 31.65 ± 3.03 30.86 ± 1.90 29.64 ± 2.07 30.02 ± 2.87 
18:3n-3
1,3
 0.28 ± 0.20
a
 0.27 ± 0.16
a
 0.28 ± 0.34
a
 0.95 ± 1.09
a,b
 1.12 ± 0.71
b





 0.05 ± 0.02 0.05 ± 0.02 0.03 ± 0.02 0.04 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 
20:5n-3
1,2
 0.73 ± 0.23 0.48 ± 0.11 1.08 ± 0.16 0.91 ± 0.17 1.58 ± 0.30 1.62 ± 0.23 
22:5n-3
2
 1.10 ± 0.21 0.79 ± 0.17 1.09 ± 0.18 0.73 ± 0.20 1.09 ± 0.16 0.95 ± 0.14 
22:6n-3
2,3
 2.95 ± 0.48
a
 3.36 ± 0.45
a,b
 3.09 ± 0.59
a
 2.96 ± 0.63
a
 2.92 ± 0.27
a





 5.12 ± 0.66 4.94 ± 0.60 5.57 ± 0.53 5.58 ± 0.63 6.74 ± 0.54 6.73 ± 0.84 
PUFAs
1
 40.11 ± 1.80 39.72 ± 2.07 37.23 ± 3.30 36.44 ± 1.92 36.37 ± 1.73 36.74 ± 3.54 
HUFAs
1,2,3
 20.71 ± 2.11
a
 18.81 ± 2.50
a,c
 18.37 ± 2.05
b,c
 15.21 ± 2.66
a,c
 17.04 ± 1.40
b





 3.68 ± 0.62
a
 3.84 ± 0.52
a,b
 4.17 ± 0.59
b
 3.86 ± 0.72
a,b
 4.50 ± 0.42
a,b





 6.94 ± 0.95 7.10 ± 0.69 5.71 ± 0.59 5.61 ± 0.79 4.44 ± 0.62 4.49 ± 0.40 
HUFA Score
1,2
 23.29 ± 2.44 25.01 ± 2.74 28.79 ± 1.62 30.49 ± 2.20 33.10 ± 2.54 37.41 ± 3.61 
DHA:EPA
1,2,3
 4.31 ± 1.16
a
 7.28 ± 1.85
a,b,c
 2.95 ± 0.84
c
 3.32 ± 0.70
d
 1.91 ± 0.37
a,b





 2.72 ± 0.50 4.39 ± 0.79 2.87 ± 0.57 4.23 ± 1.09 2.74 ± 0.56 4.10 ± 0.68 
n-3 HUFA
1,3
 4.83 ± 0.79
a,b
 4.68 ± 0.64
a,b
 5.29 ± 0.68
a,c
 4.63 ± 0.83
a,b
 5.62 ± 0.38
b





 15.87 ± 1.57 14.13 ± 2.15 13.07 ± 1.46 10.58 ± 1.93 11.42 ± 1.27 10.89 ± 1.97 
Total [FA]
1,3
 105.49 ± 22.60
a,b
 104.69 ± 17.97
a,b
 109.21 ± 21.76
c
 132.07 ± 23.03
a
 141.66 ± 29.27
b,c
 110.48 ± 5.75
a,b
 
Values are means  ± standard deviation.  Values are wt% of total fatty acids with the exception of total fatty acid concentration expressed as 
fatty acids (ug)/100uL plasma. 
SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, HUFA: highly unsaturated fatty acids, 
HUFA Score: % n-3 HUFA in total HUFA, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, [FA]: fatty acid concentration. 






 by the linear mixed models procedure (LMM) with time, sex and interaction as factors.  







Appendix Table C.5.  Subgroup whole blood fatty acid composition in the dose-
response study (n=5) 
  Week 0 Week 4 Week 8 Week 12 
14:0 0.77 ± 0.24 0.76 ± 0.36 0.75 ± 0.17 0.50 ± 0.11 
16:0
1
 20.97 ± 1.27
a
 20.49 ± 1.61
a
 20.64 ± 1.42
a
 18.55 ± 0.44
b
 
16:0 dma 1.21 ± 0.54 0.86 ± 0.26 1.02 ± 0.18 1.14 ± 0.14 
17:0 0.31 ± 0.03 0.32 ± 0.04 0.32 ± 0.04 0.32 ± 0.05 
18:0 11.70 ± 1.34 11.05 ± 0.76 11.63 ± 1.49 10.21 ± 0.65 
18:0 dma
1
 1.17 ± 0.10
a
 1.09 ± 0.45
a
 1.34 ± 0.24
a
 0.43 ± 0.06
b
 
20:0 0.28 ± 0.06 0.27 ± 0.03 0.41 ± 0.30 0.25 ± 0.04 
22:0 0.79 ± 0.14 0.71 ± 0.12 0.87 ± 0.14 0.72 ± 0.12 
23:0
1
 0.20 ± 0.01
a,b
 0.16 ± 0.03
a
 0.23 ± 0.03
b





 1.45 ± 0.08
a,b
 1.32 ± 0.16
a,b
 1.61 ± 0.17
a





 39.15 ± 1.63
a
 37.35 ± 2.19
a,b
 39.53 ± 2.50
a
 33.86 ± 1.20
b
 
14:1 0.04 ± 0.04 0.05 ± 0.04 0.03 ± 0.02 0.03 ± 0.01 
16:1n-7 0.98 ± 0.67 0.99 ± 0.36 0.98 ± 0.59 0.84 ± 0.24 
18:1 dma
1
 0.32 ± 0.06
a
 0.31 ± 0.14
a,b
 0.37 ± 0.07
a
 0.17 ± 0.04
b
 
18:1n-7 1.53 ± 0.07 1.49 ± 0.19 1.42 ± 0.24 1.50 ± 0.19 
18:1n-9 14.51 ± 1.14 15.41 ± 0.27 14.26 ± 1.85 15.28 ± 1.51 
20:1n-9 0.22 ± 0.03 0.20 ± 0.04 0.19 ± 0.04 0.19 ± 0.03 
22:1n-9
1
 0.27 ± 0.04
a
 0.14 ± 0.02
b
 0.25 ± 0.09
a
 0.24 ± 0.04
a
 
24:1n-9 1.75 ± 0.25 1.54 ± 0.19 1.96 ± 0.42 1.50 ± 0.28 
MUFAs
1
 19.63 ± 1.63
a,b
 20.12 ± 0.49
a
 19.47 ± 2.58
b





 16.89 ± 1.64
a
 19.51 ± 2.40
a
 18.10 ± 1.35
a
 22.43 ± 3.16
b
 
18:3n-6 0.20 ± 0.08 0.31 ± 0.16 0.29 ± 0.11 0.23 ± 0.05 
20:2n-6
1
 0.23 ± 0.03
a,b
 0.21 ± 0.03
a
 0.27 ± 0.03
b





 1.62 ± 0.40
a
 1.45 ± 0.24
a,b
 1.47 ± 0.24
a,b





 12.41 ± 1.46
a
 10.80 ± 0.92
b
 10.33 ± 0.98
b
 10.07 ± 0.46
b
 
22:2n-6 0.05 ± 0.01 0.05 ± 0.01 0.06 ± 0.02 0.05 ± 0.02 
22:4n-6
1
 1.87 ± 0.50
a
 1.61 ± 0.50
a,b
 1.51 ± 0.49
b





 0.39 ± 0.04
a
 0.33 ± 0.04
a
 0.32 ± 0.07
a
 0.23 ± 0.04
b
 
n-6 33.65 ± 2.97 34.27 ± 3.30 32.34 ± 2.13 35.58 ± 2.62 
18:3n-3 0.36 ± 0.03 0.40 ± 0.10 0.41 ± 0.09 0.47 ± 0.07 
20:3n-3 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 
20:5n-3
1
 0.49 ± 0.09
a
 0.79 ± 0.10
a
 1.25 ± 0.14
b
 1.81 ± 0.28
c
 
22:5n-3 1.42 ± 0.18 1.40 ± 0.18 1.54 ± 0.27 1.54 ± 0.31 
22:6n-3
1
 2.38 ± 0.09
a
 2.47 ± 0.15
a
 2.87 ± 0.27
b





 4.69 ± 0.11
a
 5.09 ± 0.17
a
 6.09 ± 0.42
b





 38.34 ± 2.94
a
 39.35 ± 3.35
a,b
 38.43 ± 2.43
a
 42.68 ± 2.04
b,c
 






 2.88 ± 0.16
a
 3.26 ± 0.17
a
 4.12 ± 0.22
b





 7.18 ± 0.72
a
 6.74 ± 0.63
a
 5.32 ± 0.29
b





 21.11 ± 1.79
a
 24.91 ± 1.55
b
 29.47 ± 1.19
c





 4.96 ± 0.79
a
 3.20 ± 0.51
b
 2.34 ± 0.47
b,c





 1.70 ± 0.25
a
 1.79 ± 0.28
a
 1.90 ± 0.30
a





 4.33 ± 0.13
a
 4.69 ± 0.13
a
 5.68 ± 0.39
b





 16.28 ± 1.49
a
 14.18 ± 1.00
b
 13.62 ± 1.30
b
 12.66 ± 0.77
b
 
Total [FA] 173.38 ± 35.96 210.90 ± 32.91 209.85 ± 52.47 217.96 ± 42.15 
Values are means  ± standard deviation.  Values are wt% of total fatty acids with the exception of total 
fatty acid concentration expressed as fatty acids (ug)/100uL whole blood. 
SFA; saturated fatty acids, MUFA; monounsaturated fatty acids, PUFA; polyunsaturated fatty acids, 
HUFA; highly unsaturated fatty acids, HUFA Score; %n-3 HUFA in total HUFA, FA: fatty acids 
Significant main effect of time
1
 by the linear mixed models procedure (p < 0.05). 
Different letters represent a significant difference between time points by Bonferroni's post-hoc test, 
following a significant F-value by the linear mixed models procedure. 
 




Appendix Table C.6.  Subgroup erythrocyte fatty acid composition in the dose-response 
study (n=5) 
  Week 0 Week 4 Week 8 Week 12 
14:0
1
 0.53 ± 0.08
a
 0.78 ± 0.10
b
 0.55 ± 0.05
a
 0.43 ± 0.04
a
 
16:0 20.97 ± 1.27
a
 20.49 ± 1.61
a
 20.64 ± 1.42
a
 18.55 ± 0.44
b
 
16:0 dma 1.21 ± 0.54 0.86 ± 0.26 1.02 ± 0.18 1.14 ± 0.14 
17:0 0.31 ± 0.03 0.32 ± 0.04 0.32 ± 0.04 0.32 ± 0.05 
18:0 11.70 ± 1.34 11.05 ± 0.76 11.63 ± 1.49 10.21 ± 0.65 
18:0 dma
1
 1.17 ± 0.10
a
 1.09 ± 0.45
a
 1.34 ± 0.24
a
 0.43 ± 0.06
b
 
20:0 0.28 ± 0.06 0.27 ± 0.03 0.41 ± 0.30 0.25 ± 0.04 
22:0 0.79 ± 0.14 0.71 ± 0.12 0.87 ± 0.14 0.72 ± 0.12 
23:0
1
 0.20 ± 0.01
a,b
 0.16 ± 0.03
a
 0.23 ± 0.03
b





 1.45 ± 0.08
a,b
 1.32 ± 0.16
a,b
 1.61 ± 0.17
a





 39.15 ± 1.63
a
 37.35 ± 2.19
a,b
 39.53 ± 2.50
a
 33.86 ± 1.20
b
 
14:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
16:1n-7 0.98 ± 0.67 0.99 ± 0.36 0.98 ± 0.59 0.84 ± 0.24 
18:1 dma
1
 0.32 ± 0.06
a
 0.31 ± 0.14
a,b
 0.37 ± 0.07
a
 0.17 ± 0.04
b
 
18:1n-7 1.53 ± 0.07 1.49 ± 0.19 1.42 ± 0.24 1.50 ± 0.19 
18:1n-9 14.51 ± 1.14 15.41 ± 0.27 14.26 ± 1.85 15.28 ± 1.51 
20:1n-9 0.22 ± 0.03 0.20 ± 0.04 0.19 ± 0.04 0.19 ± 0.03 
22:1n-9
1
 0.27 ± 0.04
a
 0.14 ± 0.02
b
 0.25 ± 0.09
a
 0.24 ± 0.04
a
 
24:1n-9 1.75 ± 0.25 1.54 ± 0.19 1.96 ± 0.42 1.50 ± 0.28 
MUFA
1
 19.63 ± 1.63
a,b
 20.12 ± 0.49
a
 19.47 ± 2.58
b





 16.89 ± 1.64
a
 19.51 ± 2.40
a
 18.10 ± 1.35
a
 22.43 ± 3.16
b
 
18:3n-6 0.20 ± 0.08 0.31 ± 0.16 0.29 ± 0.11 0.23 ± 0.05 
20:2n-6
1
 0.23 ± 0.03
a,b
 0.21 ± 0.03
a
 0.27 ± 0.03
b





 1.62 ± 0.40
a
 1.45 ± 0.24
a,b
 1.47 ± 0.24
a,b





 12.41 ± 1.46
a
 10.80 ± 0.92
b
 10.33 ± 0.98
b
 10.07 ± 0.46
b
 
22:2n-6 0.05 ± 0.01 0.05 ± 0.01 0.06 ± 0.02 0.05 ± 0.02 
22:4n-6
1
 1.87 ± 0.50
a
 1.61 ± 0.50
a,b
 1.51 ± 0.49
b





 0.39 ± 0.04
a
 0.33 ± 0.04
a
 0.32 ± 0.07
a
 0.23 ± 0.04
b
 
n-6 PUFA 33.65 ± 2.97 34.27 ± 3.30 32.34 ± 2.13 35.58 ± 2.62 
18:3n-3 0.36 ± 0.03 0.40 ± 0.10 0.41 ± 0.09 0.47 ± 0.07 
20:3n-3 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 
20:5n-3
1
 0.49 ± 0.09
a
 0.79 ± 0.10
b
 1.25 ± 0.14
c
 1.81 ± 0.28
d
 
22:5n-3 1.42 ± 0.18 1.40 ± 0.18 1.54 ± 0.27 1.54 ± 0.31 
22:6n-3
1
 2.38 ± 0.09
a
 2.47 ± 0.15
a
 2.87 ± 0.27
b





 4.69 ± 0.11
a
 5.09 ± 0.17
a
 6.09 ± 0.42
b





 38.34 ± 2.94
a
 39.35 ± 3.35
a,b
 38.43 ± 2.43
a
 42.68 ± 2.04
b,c
 






 2.88 ± 0.16
a
 3.26 ± 0.17
a
 4.12 ± 0.22
b





 7.18 ± 0.72
a
 6.74 ± 0.63
a
 5.32 ± 0.29
b





 21.11 ± 1.79
a
 24.91 ± 1.55
b
 29.47 ± 1.19
c





 4.96 ± 0.79
a
 3.20 ± 0.51
b
 2.34 ± 0.47
b,c





 1.70 ± 0.25
a
 1.79 ± 0.28
a
 1.90 ± 0.30
a





 4.33 ± 0.13
a
 4.69 ± 0.13
a
 5.68 ± 0.39
b





 16.28 ± 1.49
a
 14.18 ± 1.00
b
 13.62 ± 1.30
b





 173.38 ± 35.96
a
 210.90 ± 32.91
a,b
 209.85 ± 52.47
a,b
 217.96 ± 42.15
b
 
Values are means  ± standard deviation.  Values are wt% of total fatty acids with the exception of total fatty 
acid concentration expressed as fatty acids (ug)/100mg erythrocytes. 
SFA; saturated fatty acids, MUFA; monounsaturated fatty acids, PUFA; polyunsaturated fatty acids, HUFA; 
highly unsaturated fatty acids, HUFA Score; %n-3 HUFA in total HUFA, FA: fatty acids. 
Significant main effect of time
1
 by the linear mixed models procedure (p < 0.05). 
Different letters represent a significant difference between time points by Bonferroni's post-hoc test, 
following a significant F-value by the linear mixed models procedure. 
 





Appendix Table C.7.  Subgroup plasma phospholipid fatty acid composition in the dose-
response study (n=5) 
  Week 0 Week 4 Week 8 Week 12 
14:0 0.52 ± 0.11 0.50 ± 0.17 0.53 ± 0.14 0.67 ± 0.07 
16:0 25.27 ± 1.23 23.47 ± 1.47 24.24 ± 2.26 25.71 ± 0.72 
16:0 dma
1
 0.44 ± 0.18
a,b
 0.33 ± 0.30
a
 0.50 ± 0.15
a,b
 0.73 ± 0.10
b
 
18:0 14.82 ± 0.38 14.41 ± 1.34 16.40 ± 5.08 17.86 ± 2.22 
18:0 dma
1
 0.26 ± 0.06 0.18 ± 0.16 0.33 ± 0.14 0.44 ± 0.04 
20:0 0.52 ± 0.10 0.47 ± 0.08 0.40 ± 0.09 0.49 ± 0.07 
22:0
1
 1.31 ± 0.31
a
 1.18 ± 0.33
a,b
 0.77 ± 0.13
b





 0.60 ± 0.12
a
 0.50 ± 0.13
a,b
 0.33 ± 0.07
b





 1.16 ± 0.27
a
 1.09 ± 0.24
a,b
 0.71 ± 0.15
b
 0.94 ± 0.10
a,b
 
SFAs 45.29 ± 1.13 42.51 ± 2.99 44.52 ± 7.22 48.66 ± 2.90 
14:1 0.01 ± 0.00 0.01 ± 0.01 0.01 ± 0.00 0.02 ± 0.02 
16:1n-7 0.43 ± 0.28 0.45 ± 0.16 0.39 ± 0.20 0.31 ± 0.03 
18:1 dma
1
 0.11 ± 0.03
a
 0.09 ± 0.08
a
 0.13 ± 0.02
a,b
 0.21 ± 0.03
b
 
18:1n-7 1.66 ± 0.04 1.77 ± 0.18 1.56 ± 0.33 1.55 ± 0.21 
18:1n-9 9.00 ± 1.48 11.65 ± 4.96 13.59 ± 5.23 7.14 ± 1.08 
20:1n-9 0.18 ± 0.05 0.22 ± 0.07 0.23 ± 0.10 0.15 ± 0.02 
22:1n-9 0.32 ± 0.21 0.25 ± 0.05 0.41 ± 0.16 0.36 ± 0.11 
24:1n-9
1
 2.25 ± 0.47
a
 1.91 ± 0.67
a,b
 1.14 ± 0.23
b
 1.51 ± 0.26
a,b
 
MUFAs 13.97 ± 1.18 16.35 ± 4.36 17.50 ± 5.79 11.25 ± 1.04 
18:2n-6 17.30 ± 1.94 17.81 ± 1.94 17.07 ± 1.46 17.60 ± 2.40 
18:3n-6 0.13 ± 0.06 0.10 ± 0.08 0.09 ± 0.06 0.14 ± 0.02 
20:2n-6
1
 0.30 ± 0.04
a
 0.26 ± 0.05
a,b
 0.22 ± 0.04
b





 2.86 ± 0.71
a
 2.50 ± 0.57
a,b
 2.13 ± 0.47
a,b





 12.75 ± 2.03
a
 10.53 ± 1.40
a,b
 8.20 ± 0.58
b
 9.56 ± 0.96
b
 
22:2n-6 0.05 ± 0.03 0.03 ± 0.02 0.03 ± 0.01 0.04 ± 0.02 
22:4n-6
1
 0.45 ± 0.02
a
 0.33 ± 0.05
b
 0.22 ± 0.02
c





 0.36 ± 0.05
a
 0.23 ± 0.04
b
 0.14 ± 0.04
c





 34.21 ± 1.63
a
 31.80 ± 1.80
a,b
 28.11 ± 1.71
c
 29.91 ± 2.11
b,c
 
18:3n-3 0.33 ± 0.27 0.51 ± 0.81 1.18 ± 0.87 0.17 ± 0.04 
20:3n-3 0.05 ± 0.02 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 
20:5n-3
1
 0.64 ± 0.15
a
 1.03 ± 0.14
a,b
 1.63 ± 0.26
b,c
 2.10 ± 0.45
c
 
22:5n-3 1.02 ± 0.14 1.07 ± 0.18 1.11 ± 0.17 1.03 ± 0.08 
22:6n-3
1
 2.73 ± 0.47
a
 3.37 ± 0.51
a,b
 2.86 ± 0.30
a





 4.77 ± 0.40
a
 6.02 ± 0.20
b
 6.80 ± 0.87
b,c





 38.98 ± 1.64
a
 37.81 ± 1.67
a,b
 34.91 ± 2.15
b





 20.87 ± 2.14
a
 19.09 ± 2.22
a,b
 16.32 ± 1.02
b





 3.37 ± 0.43
a
 4.40 ± 0.57
a
 4.49 ± 0.47
a








 7.21 ± 0.68
a
 5.30 ± 0.44
b
 4.19 ± 0.58
c





 21.28 ± 1.37
a
 28.79 ± 1.17
b
 34.42 ± 1.63
c





 4.53 ± 1.48
a
 3.30 ± 0.59
a,b
 1.77 ± 0.27
b





 2.70 ± 0.49 3.18 ± 0.26 2.63 ± 0.51 3.95 ± 0.31 
n-3 HUFA
1
 4.44 ± 0.52
a
 5.50 ± 0.73
a
 5.63 ± 0.57
a





 16.43 ± 1.72
a
 13.58 ± 1.54
b
 10.70 ± 0.53
c
 11.90 ± 1.06
b,c
 
Total [FA] 114.82 ± 34.41 113.72 ± 45.28 143.15 ± 43.42 128.90 ± 35.30 
Values are means  ± standard deviation.  Values are wt% of total fatty acids with the exception of total fatty acid 
concentration expressed as fatty acids (ug)/100uL plasma. 
SFA; saturated fatty acids, MUFA; monounsaturated fatty acids, PUFA; polyunsaturated fatty acids, HUFA; 
highly unsaturated fatty acids, HUFA Score; %n-3 HUFA in total HUFA, FA: fatty acids. 
Significant main effect of time
1
 by the linear mixed models procedure (p < 0.05). 
Different letters represent a significant difference between time points by Bonferroni's post-hoc test, following a 







Appendix Figure C.2.  Gas chromatogram of whole blood fatty acid composition.  Analysis on a DB-FFAP 15m capillary column 
with temperature program as follows: initial, 150°C with a 0.25 min hold; ramp: 35°C/min - 200°C, then by 8°C - 225°C with a 3.2 
min hold, then by 80°C/min - 245°C with a 15 min hold.  BHT: butylated hydroxytoluene, DMA: dimethyl acetal, ISTD: internal 
standard. 
